

# ASTCT Consensus Grading for Cytokine Release Syndrome Associated with Immune Effector Cells

Biology of Blood and Marrow Transplantation  
25, 625-638

DOI: [10.1016/j.bbmt.2018.12.758](https://doi.org/10.1016/j.bbmt.2018.12.758)

Citation Report

#	ARTICLE	IF	CITATIONS
1	CAR-T “ and a side order of IgG, to go? ” Immunoglobulin replacement in patients receiving CAR-T cell therapy. Blood Reviews, 2019, 38, 100596.	5.7	109
2	Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy. British Journal of Haematology, 2019, 187, e35-e38.	2.5	35
3	&lt;p&gt;Evaluating tisagenlecleucel and its potential in the treatment of relapsed or refractory diffuse large B cell lymphoma: evidence to date&lt;/p&gt;. OncoTargets and Therapy, 2019, Volume 12, 4543-4554.	2.0	6
4	Chimeric Antigen Receptor T Cell-Related Neurotoxicity: Mechanisms, Clinical Presentation, and Approach to Treatment. Current Treatment Options in Neurology, 2019, 21, 40.	1.8	65
5	At the end of the beginning: immunotherapies as living drugs. Nature Immunology, 2019, 20, 955-962.	14.5	4
6	Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies. Immunotherapy, 2019, 11, 851-857.	2.0	48
7	Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood, 2019, 134, 860-866.	1.4	178
8	Cellular therapy: Immuneâ€related complications. Immunological Reviews, 2019, 290, 114-126.	6.0	55
9	Updates on CAR Tâ€cell therapy in Bâ€cell malignancies. Immunological Reviews, 2019, 290, 39-59.	6.0	61
10	Fludarabine and Total-Body Irradiation Conditioning before Ablative Haploidentical Transplantation: Long-Term Safety and Efficacy. Biology of Blood and Marrow Transplantation, 2019, 25, 2211-2216.	2.0	13
11	CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma. Blood, 2019, 134, 626-635.	1.4	59
12	Utilization of Chimeric Antigen Receptor T-cell Therapy in Adults. Seminars in Oncology Nursing, 2019, 35, 150930.	1.5	4
13	Elevated serum interleukinâ€2 after gluten correlates with symptoms and is a potential diagnostic biomarker for coeliac disease. Alimentary Pharmacology and Therapeutics, 2019, 50, 901-910.	3.7	51
14	Driving the CAR to the Bone Marrow Transplant Program. Current Hematologic Malignancy Reports, 2019, 14, 561-569.	2.3	10
15	Dual T Cell Depletion with Anti-Thymocyte Globulin and Post-Transplant Cyclophosphamide Results in Low Rates of Cytokine Release Syndrome in Peripheral Blood Haplo-Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, e387-e388.	2.0	4
16	CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives. Leukemia, 2019, 33, 2767-2778.	7.2	47
17	Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, 2305-2321.	2.0	132
18	Management Principles Associated With Cytokine Release Syndrome. Seminars in Oncology Nursing, 2019, 35, 150931.	1.5	6

#	ARTICLE	IF	CITATIONS
19	Clinical lessons learned from the first leg of the CAR T cell journey. <i>Nature Medicine</i> , 2019, 25, 1341-1355.	30.7	400
20	Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin's Lymphoma. <i>Molecular Therapy - Oncolytics</i> , 2019, 15, 60-68.	4.4	101
23	Utilization of CAR T Cell Therapy in Pediatric Patients. <i>Seminars in Oncology Nursing</i> , 2019, 35, 150929.	1.5	3
24	Clinical chimeric antigen receptor T cell therapy: a new and promising treatment modality for glioblastoma. <i>Clinical and Translational Immunology</i> , 2019, 8, e1050.	3.8	33
25	Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 813-822.	3.0	221
26	A review of chimeric antigen receptor T-cells in lymphoma. <i>Expert Review of Hematology</i> , 2019, 12, 551-561.	2.2	11
27	Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma. <i>Leukemia</i> , 2019, 33, 2540-2544.	7.2	26
28	NextGen cell-based immunotherapies in cancer and other immune disorders. <i>Current Opinion in Immunology</i> , 2019, 59, 79-87.	5.5	15
29	Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy. <i>Annals of Neurology</i> , 2019, 86, 42-54.	5.3	124
30	Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL) – an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). <i>Bone Marrow Transplantation</i> , 2019, 54, 1868-1880.	2.4	86
31	Can Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Predict Chimeric Antigen Receptor T Cell Adverse Effects?. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e187-e188.	2.0	1
32	Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations. <i>Clinical and Translational Immunology</i> , 2019, 8, e1049.	3.8	205
33	Mechanisms of resistance to CAR T cell therapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 372-385.	27.6	518
34	&lt;p&gt;Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy&lt;/p&gt;. <i>Therapeutics and Clinical Risk Management</i> , 2019, Volume 15, 323-335.	2.0	110
35	Comments Regarding “ASBMT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells”. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e209-e210.	2.0	4
36	Chimeric Antigen Receptor T Cells: A Race to Revolutionize Cancer Therapy. <i>Transfusion Medicine and Hemotherapy</i> , 2019, 46, 15-24.	1.6	107
37	Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy. <i>Expert Review of Hematology</i> , 2019, 12, 195-205.	2.2	63
38	Anti-CD19 CAR T cell therapy for lymphoma – off to the races!. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 279-280.	27.6	9

#	ARTICLE	IF	CITATIONS
39	Driving CAR T cell translation forward. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	61
40	Early and late hematologic toxicity following CD19 CAR-T cells. <i>Bone Marrow Transplantation</i> , 2019, 54, 1643-1650.	2.4	254
41	Toxicities of CD19 CAR-T cell immunotherapy. <i>American Journal of Hematology</i> , 2019, 94, S42-S49.	4.1	102
43	Cytokine release syndrome: a primer for generalists. <i>Adverse Drug Reaction Bulletin</i> , 2019, 319, 1235-1238.	0.5	0
44	Clinical care of chimeric antigen receptor T-cell patients and managing immune-related adverse effects in the ambulatory and hospitalized setting: a review. <i>Future Oncology</i> , 2019, 15, 4235-4246.	2.4	5
45	Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy. <i>Blood</i> , 2019, 134, 2149-2158.	1.4	194
46	The CNS can be a safe space for CARs. <i>Blood</i> , 2019, 134, 845-846.	1.4	3
47	Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy. <i>Blood Advances</i> , 2019, 3, 3062-3069.	5.2	74
48	Teaming up for CAR-T cell therapy. <i>Haematologica</i> , 2019, 104, 2335-2336.	3.5	7
49	Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. <i>Blood</i> , 2019, 134, 2361-2368.	1.4	190
50	The earlier the better: timely mitigation of CRS. <i>Blood</i> , 2019, 134, 2119-2120.	1.4	8
51	Trispecific antibodies offer a third way forward for anticancer immunotherapy. <i>Nature</i> , 2019, 575, 450-451.	27.8	27
52	Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network. <i>Haematologica</i> , 2019, 104, 2358-2360.	3.5	18
53	Unexpected neurologic complications following a novel lymphoma treatment â€œexpectedâ€™ to give rise to neurologic toxicity. <i>BMJ Case Reports</i> , 2019, 12, e229946.	0.5	6
55	Hematopoietic-cell transplantation for lymphoma in the era of genetically engineered cellular therapy: it's not quite time to scrap the old vehicle for the new car. <i>Current Opinion in Hematology</i> , 2019, 26, 288-293.	2.5	0
56	EEG Correlates of Delirium in Children and Young Adults With CD19-Directed CAR T Cell Treatment-Related Neurotoxicity. <i>Journal of Clinical Neurophysiology</i> , 2021, 38, 135-142.	1.7	15
57	Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart. <i>Journal of the American College of Cardiology</i> , 2019, 74, 3153-3163.	2.8	78
58	Adult Acute Lymphoblastic Leukemia: Treatment and Management Updates. <i>Seminars in Oncology Nursing</i> , 2019, 35, 150951.	1.5	12

#	ARTICLE	IF	CITATIONS
59	&lt;p&gt;Cytokine Release Syndrome: Current Perspectives&lt;/p&gt;. ImmunoTargets and Therapy, 2019, Volume 8, 43-52.	5.8	116
60	Immunotherapy in pediatric acute lymphoblastic leukemia. Cancer and Metastasis Reviews, 2019, 38, 595-610.	5.9	65
62	T-cell receptor and chimeric antigen receptor in solid cancers: current landscape, preclinical data and insight into future developments. Current Opinion in Oncology, 2019, 31, 430-438.	2.4	6
63	EHA Guidance Document The process of CAR&T cell therapy in Europe. HemaSphere, 2019, 3, e280.	2.7	7
64	Next Generation of Cancer Treatments: Chimeric Antigen Receptor T-Cell Therapy and Its Related Toxicities: A Review for Perioperative Physicians. Anesthesia and Analgesia, 2019, 129, 434-441.	2.2	11
65	Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, e76-e85.	2.0	85
66	Harmonizing Immune Effector Toxicity Reporting. Biology of Blood and Marrow Transplantation, 2019, 25, e121-e122.	2.0	4
67	Cytokine release syndrome and neurologic toxicities associated with chimeric antigen receptor T-cell therapy: A comprehensive review of emerging grading models. Hematology/ Oncology and Stem Cell Therapy, 2020, 13, 1-6.	0.9	12
68	Adverse Events of Novel Therapies for Hematologic Malignancies: What Emergency Physicians Should&Know. Annals of Emergency Medicine, 2020, 75, 264-286.	0.6	3
69	Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy. Biology of Blood and Marrow Transplantation, 2020, 26, 34-43.	2.0	93
70	CAR T&Cell Therapy in Hematologic Malignancies: A Voyage in Progress. Clinical Pharmacology and Therapeutics, 2020, 107, 112-122.	4.7	111
71	Central nervous system emergencies in haematological malignancies. British Journal of Haematology, 2020, 189, 1028-1037.	2.5	0
72	The treatment of adolescents and young adults with acute lymphoblastic leukemia. Leukemia and Lymphoma, 2020, 61, 18-26.	1.3	5
73	Late Events After CD-19 CAR-T Treatment. Biology of Blood and Marrow Transplantation, 2020, 26, e1-e2.	2.0	2
74	Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma. JAMA Oncology, 2020, 6, 281.	7.1	36
75	How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma. Clinical Cancer Research, 2020, 26, 1541-1554.	7.0	79
76	Serum cytokines elevated during gluten-mediated cytokine release in coeliac disease. Clinical and Experimental Immunology, 2019, 199, 68-78.	2.6	36
77	Horses for courses: an approach to the qualification of clinical trial sites and investigators in ATMPs. Drug Discovery Today, 2020, 25, 265-268.	6.4	7

#	ARTICLE	IF	CITATIONS
79	Using CD19 chimeric antigen receptorâ€”T cell therapy in a 4â€”monthâ€”old patient with infantile acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28155.	1.5	4
80	Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis. <i>Journal of Hematology and Oncology</i> , 2020, 13, 1.	17.0	244
81	Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement. <i>Lancet Haematology</i> , the, 2020, 7, e61-e72.	4.6	56
82	Application of Genetic Engineering in Biotherapeutics Development. <i>Journal of Pharmaceutical Innovation</i> , 2020, 15, 232-254.	2.4	4
83	Engineering strategies to overcome the current roadblocks in CAR T cell therapy. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 147-167.	27.6	786
84	Cellular Immunotherapy for Refractory Diffuse Large B Cell Lymphoma in the Chimeric Antigen Receptor-Engineered T Cell Era: Still a Role for Allogeneic Transplantation?. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e77-e85.	2.0	41
85	Myeloid cell and cytokine interactions with chimeric antigen receptor-T-cell therapy: implication for future therapies. <i>Current Opinion in Hematology</i> , 2020, 27, 41-48.	2.5	14
87	Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer. <i>Critical Care Medicine</i> , 2020, 48, 10-21.	0.9	42
88	Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT). <i>Leukemia and Lymphoma</i> , 2020, 61, 940-943.	1.3	75
89	Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?. <i>Leukemia</i> , 2020, 34, 21-34.	7.2	117
90	Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). <i>Haematologica</i> , 2020, 105, 297-316.	3.5	230
91	Refining patient selection for CAR T-cell therapy in aggressive large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 799-807.	1.3	10
92	What a headache! Double-hit lymphoma with CNS recurrence â€” Role of chimeric antigen receptor (CAR) T-cell therapy. <i>Leukemia and Lymphoma</i> , 2020, 61, 757-762.	1.3	4
93	Role of CAR-T cell therapy in B-cell acute lymphoblastic leukemia. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 36-42.	0.5	3
94	The future of cellular immunotherapy for childhood leukemia. <i>Current Opinion in Pediatrics</i> , 2020, 32, 13-25.	2.0	13
95	B cell maturation antigenâ€”specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A metaâ€”analysis. <i>European Journal of Haematology</i> , 2020, 104, 318-327.	2.2	41
96	Management of Cytokine Release Syndrome. , 2020, , 45-64.		1
97	Neurotoxicities After CAR T-Cell Immunotherapy. , 2020, , 83-105.		7

#	ARTICLE	IF	CITATIONS
98	Regulatory Issues in Gene-Modified Immune Effector Cell Therapy. , 2020, , 209-222.		2
99	Advances in chimeric antigen receptor T cells. Current Opinion in Hematology, 2020, 27, 368-377.	2.5	24
100	Chimeric antigen receptor T-cell therapy for acute lymphocytic leukaemia: where are we in 2020?. Lancet Haematology,the, 2020, 7, e778-e779.	4.6	3
101	Tocilizumab for severe COVID-19 related illness â€“ A community academic medical center experience. Cytokine: X, 2020, 2, 100035.	1.4	7
102	Neurological complications of chimeric antigen receptor T cells and immune-checkpoint inhibitors: ongoing challenges in daily practice. Current Opinion in Oncology, 2020, 32, 603-612.	2.4	5
103	CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?. Molecular Therapy, 2020, 28, 2320-2339.	8.2	194
104	Chimeric antigen receptor T cell therapy for pediatric and young adult B cell acute lymphoblastic leukemia. Expert Review of Clinical Immunology, 2020, 16, 1029-1042.	3.0	8
105	Transfusion reactions in pediatric and adolescent young adult haematology oncology and immune effector cell patients. EclinicalMedicine, 2020, 26, 100514.	7.1	5
106	Chimeric Antigen Receptor T-Cells in B-Acute Lymphoblastic Leukemia: State of the Art and Future Directions. Frontiers in Oncology, 2020, 10, 1594.	2.8	46
107	Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study. Lancet Rheumatology, The, 2020, 2, e754-e763.	3.9	237
108	A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy. Neurologic Clinics, 2020, 38, 953-963.	1.8	14
109	Real world experience of approved chimeric antigen receptor T-cell therapies outside of clinical trials. Current Research in Translational Medicine, 2020, 68, 159-170.	1.8	24
110	The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia. , 2020, 8, e000810.		5
111	Severe delayed pulmonary toxicity following PDâ€“1â€“specific CARâ€“T cell therapy for nonâ€“small cell lung cancer. Clinical and Translational Immunology, 2020, 9, e1154.	3.8	12
112	Assessment of CAR T Cell Frequencies in Axicabtagene Ciloleucel and Tisagenlecleucel Patients Using Duplex Quantitative PCR. Cancers, 2020, 12, 2820.	3.7	13
113	Reply to Letter to the Editor: Therapeutic plasma exchange resolving COVID-19 related ARDS. Journal of the Formosan Medical Association, 2020, 119, 1890-1892.	1.7	1
114	In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19. PLoS ONE, 2020, 15, e0240400.	2.5	54
115	Tisagenlecleucel in Children and Young Adults: Reverse Translational Research by Using Real-World Safety Data. Pharmaceuticals, 2020, 13, 258.	3.8	6



#	ARTICLE	IF	CITATIONS
116	Cardiovascular Events Associated with Chimeric Antigen Receptor T Cell Therapy: Cross-Sectional FDA Adverse Events Reporting System Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2211-2216.	2.0	40
117	Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 4898-4911.	5.2	238
118	Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. <i>Cytotherapy</i> , 2020, 22, 755-761.	0.7	33
119	Central nervous system injury from novel cancer immunotherapies. <i>Current Opinion in Neurology</i> , 2020, 33, 723-735.	3.6	9
120	A Systematic Review of the Clinical Efficacy of Treatments in Relapsed or Refractory Diffuse Large B Cell Lymphoma. <i>Advances in Therapy</i> , 2020, 37, 4877-4893.	2.9	8
121	Successful application of anti-CD19 CAR-T therapy with IL-6 knocking down to patients with central nervous system B-cell acute lymphocytic leukemia. <i>Translational Oncology</i> , 2020, 13, 100838.	3.7	15
122	Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. <i>Nature Medicine</i> , 2020, 26, 1878-1887.	30.7	321
123	Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. <i>Nature Medicine</i> , 2020, 26, 1569-1575.	30.7	266
124	Immune escape: A critical hallmark in solid tumors. <i>Life Sciences</i> , 2020, 258, 118110.	4.3	91
125	Emerging trends in COVID-19 treatment: learning from inflammatory conditions associated with cellular therapies. <i>Cytotherapy</i> , 2020, 22, 474-481.	0.7	29
126	Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma. <i>Haematologica</i> , 2020, 106, 255-258.	3.5	38
127	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. , 2020, 8, e000734.		27
128	Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel. <i>Clinical Cancer Research</i> , 2020, 26, 4823-4831.	7.0	47
129	A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. <i>Journal of Hematology and Oncology</i> , 2020, 13, 94.	17.0	107
130	Macrophage, the potential key mediator in CAR-T related CRS. <i>Experimental Hematology and Oncology</i> , 2020, 9, 15.	5.0	54
131	Long: molecular tracking of CML with bilineal inv(16) myeloid and del(9) lymphoid blast crisis and durable response to CD19-directed CAR-T therapy. <i>Leukemia</i> , 2020, 34, 3050-3054.	7.2	3
132	Encephalopathy in COVID-19 Presenting With Acute Aphasia Mimicking Stroke. <i>Frontiers in Neurology</i> , 2020, 11, 587226.	2.4	19
133	Gene Modified CAR-T Cellular Therapy for Hematologic Malignancies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8655.	4.1	13



#	ARTICLE	IF	CITATIONS
134	Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function. <i>Advances in Chronic Kidney Disease</i> , 2020, 27, 434-441.	1.4	5
135	Influence of patient characteristics on chimeric antigen receptor T cell therapy in B-cell acute lymphoblastic leukemia. <i>Nature Communications</i> , 2020, 11, 5928.	12.8	34
136	Complications after CD19+ CAR T-Cell Therapy. <i>Cancers</i> , 2020, 12, 3445.	3.7	32
137	Antitumor activity without on-target off-tumor toxicity of GD2- chimeric antigen receptor T cells in patients with neuroblastoma. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	108
138	Patient factors influencing acute gluten reactions and cytokine release in treated coeliac disease. <i>BMC Medicine</i> , 2020, 18, 362.	5.5	22
139	Current Immunotherapy Approaches in Non-Hodgkin Lymphomas. <i>Vaccines</i> , 2020, 8, 708.	4.4	13
140	Autologous non-human primate model for safety assessment of piggyBac transposon-mediated chimeric antigen receptor T cells on granulocyte-macrophage colony-stimulating factor receptor. <i>Clinical and Translational Immunology</i> , 2020, 9, e1207.	3.8	6
141	A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma. <i>Frontiers of Medicine</i> , 2020, 14, 711-725.	3.4	8
142	Cytokine Storm. <i>New England Journal of Medicine</i> , 2020, 383, 2255-2273.	27.0	1,911
143	Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome. <i>Blood Advances</i> , 2020, 4, 4648-4652.	5.2	53
144	Immunotherapy with cells (article not eligible for CME credit). <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 590-597.	2.5	1
145	CD33 directed bispecific antibodies in acute myeloid leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101224.	1.7	17
146	Cancer Immunotherapy Using Chimeric Antigen Receptor Expressing T-Cells: Present and Future Needs of Clinical Cancer Centers. <i>Frontiers in Immunology</i> , 2020, 11, 565236.	4.8	9
147	Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy. <i>JAMA Neurology</i> , 2020, 77, 1536.	9.0	68
148	CAR T-cell therapy-related neurotoxicity in paediatric acute lymphocytic leukaemia. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28635.	1.5	3
149	Potential strategies for combating COVID-19. <i>Archives of Virology</i> , 2020, 165, 2419-2438.	2.1	12
150	Cytokines Are at the Heart of It. <i>JACC: CardioOncology</i> , 2020, 2, 204-206.	4.0	5
151	Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3794-3804.	1.6	235

#	ARTICLE	IF	CITATIONS
152	Acute life-threatening toxicity from CAR T-cell therapy. Intensive Care Medicine, 2020, 46, 1723-1726.	8.2	14
153	Debate: Transplant Is Still Necessary in the Era of Targeted Cellular Therapy for Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 713-719.	0.4	9
154	High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. Blood Advances, 2020, 4, 3268-3276.	5.2	134
155	Identification of Neurotoxicity after Chimeric Antigen Receptor (CAR) T Cell Infusion without Deterioration in the Immune Effector Cell-Associated Encephalopathy (ICE) Score. Biology of Blood and Marrow Transplantation, 2020, 26, e271-e274.	2.0	13
156	CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions. Frontiers in Oncology, 2020, 10, 1243.	2.8	63
157	The Great War of Today: Modifications of CAR-T Cells to Effectively Combat Malignancies. Cancers, 2020, 12, 2030.	3.7	19
158	Efficacy and Safety of CD28- or 4-1BB-Based CD19 CAR-T Cells in B Cell Acute Lymphoblastic Leukemia. Molecular Therapy - Oncolytics, 2020, 18, 272-281.	4.4	68
159	The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma. Signal Transduction and Targeted Therapy, 2020, 5, 134.	17.1	84
160	Phase 2 study of pembrolizumab for measurable residual disease in adults with acute lymphoblastic leukemia. Blood Advances, 2020, 4, 3239-3245.	5.2	19
161	Engineering CAR-T Cells for Next-Generation Cancer Therapy. Cancer Cell, 2020, 38, 473-488.	16.8	342
162	The clinical outcomes of fresh versus cryopreserved CD19-directed chimeric antigen receptor T cells in non-Hodgkin lymphoma patients. Cryobiology, 2020, 96, 106-113.	0.7	7
163	G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphoma. Bone Marrow Transplantation, 2020, 55, 2347-2349.	2.4	40
164	Arming cytotoxic lymphocytes for cancer immunotherapy by means of the NKG2D/NKG2D-ligand system. Expert Opinion on Biological Therapy, 2020, 20, 1491-1501.	3.1	10
165	Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. Haematologica, 2021, 106, 2667-2672.	3.5	92
166	Commercial <sc>anti-CD19 CAR</sc> T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center. American Journal of Hematology, 2020, 95, 1324-1333.	4.1	89
167	Chimeric Antigen Receptor T Cell Therapy in Patients with Multiply Relapsed or Refractory Extramedullary Leukemia. Biology of Blood and Marrow Transplantation, 2020, 26, e280-e285.	2.0	35
168	Chimeric Antigen Receptor, Teamwork, Education, Assessment, and Management (CAR-TEAM): A Simulation-Based Inter-professional Education (IPE) Intervention for Management of CAR Toxicities. Frontiers in Oncology, 2020, 10, 1227.	2.8	1
169	COVID-19-Associated Encephalopathy and Cytokine-Mediated Neuroinflammation. Annals of Neurology, 2020, 88, 860-861.	5.3	56

#	ARTICLE	IF	CITATIONS
170	Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Advances, 2020, 4, 3776-3787.	5.2	162
171	Chimeric Antigen Receptor T Cells: Clinical Applications, Advances and Challenges. , 2020, , 319-333.		1
172	Overcoming key challenges in cancer immunotherapy with engineered T cells. Current Opinion in Oncology, 2020, 32, 398-407.	2.4	9
173	Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children. Blood Advances, 2020, 4, 5174-5183.	5.2	30
175	How I treat adverse effects of CAR-T cell therapy. ESMO Open, 2020, 4, e000746.	4.5	19
176	Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. Journal of Allergy and Clinical Immunology, 2020, 146, 940-948.	2.9	78
177	Multifocal Necrotizing Leukoencephalopathy With Preferential Microglia Toxicity in a Patient Treated With Chimeric Antigen Receptor T-Cells and Review of the Literature. Journal of Neuropathology and Experimental Neurology, 2020, 79, 1115-1121.	1.7	7
178	Radiographic and clinical neurologic manifestations of COVID-19 related hypoxemia. Journal of the Neurological Sciences, 2020, 418, 117119.	0.6	27
179	Cellular immunotherapy in breast cancer: The quest for consistent biomarkers. Cancer Treatment Reviews, 2020, 90, 102089.	7.7	27
180	Emerging immunotherapies in multiple myeloma. BMJ, The, 2020, 370, m3176.	6.0	62
181	Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. Blood Advances, 2020, 4, 3943-3951.	5.2	69
182	Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes. Frontiers in Immunology, 2020, 11, 1985.	4.8	7
183	Clinical development of cell therapies for cancer: The regulators' perspective. European Journal of Cancer, 2020, 138, 41-53.	2.8	9
184	Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies. Annals of Hematology, 2020, 99, 2215-2229.	1.8	29
185	Immunotherapy in Pediatric B-Cell Acute Lymphoblastic Leukemia: Advances and Ongoing Challenges. Paediatric Drugs, 2020, 22, 485-499.	3.1	21
186	Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies. Frontiers in Immunology, 2020, 11, 1973.	4.8	148
187	Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS-CoV-2. Clinical and Translational Science, 2021, 14, 2146-2151.	3.1	15
188	Modulating TNF activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia. , 2020, 8, e001229.		29

#	ARTICLE	IF	CITATIONS
189	Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies. , 2020, 8, e001159.		55
190	CAR T Cell Therapy for Pediatric Brain Tumors. <i>Frontiers in Oncology</i> , 2020, 10, 1582.	2.8	37
191	Neurological adverse events following CAR T-cell therapy: a real-world analysis. <i>Immunotherapy</i> , 2020, 12, 1077-1082.	2.0	10
192	New targets and technologies for CAR-T cells. <i>Current Opinion in Oncology</i> , 2020, 32, 510-517.	2.4	12
193	An IMiD-inducible degron provides reversible regulation for chimeric antigen receptor expression and activity. <i>Cell Chemical Biology</i> , 2021, 28, 802-812.e6.	5.2	25
194	Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies. <i>Frontiers in Immunology</i> , 2020, 11, 620312.	4.8	21
195	Practical aspects of building a new immunotherapy program: the future of cell therapy. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 579-584.	2.5	2
196	Precision Tools in Immuno-Oncology: Synthetic Gene Circuits for Cancer Immunotherapy. <i>Vaccines</i> , 2020, 8, 732.	4.4	4
197	Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 1185-1204.	3.0	23
198	Challenges and strategies of clinical application of CAR-T therapy in the treatment of tumors—a narrative review. <i>Annals of Translational Medicine</i> , 2020, 8, 1093-1093.	1.7	8
199	CD123 bi-specific antibodies in development in AML: What do we know so far?. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101219.	1.7	12
200	Description of neurotoxicity in a series of patients treated with CAR T-cell therapy. <i>Scientific Reports</i> , 2020, 10, 18997.	3.3	59
201	Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. <i>Blood Advances</i> , 2020, 4, 5414-5424.	5.2	263
202	Highways to hell: Mechanism-based management of cytokine storm syndromes. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 949-959.	2.9	39
203	Preclinical development of a humanized chimeric antigen receptor against B cell maturation antigen for multiple myeloma. <i>Haematologica</i> , 2020, 106, 173-184.	3.5	25
204	Overcoming Heterogeneity of Antigen Expression for Effective CAR T Cell Targeting of Cancers. <i>Cancers</i> , 2020, 12, 1075.	3.7	57
205	Biomarkers in individualized management of chimeric antigen receptor T cell therapy. <i>Biomarker Research</i> , 2020, 8, 13.	6.8	23
207	Advances in CAR T Therapy for Hematologic Malignancies. <i>Pharmacotherapy</i> , 2020, 40, 741-755.	2.6	11

#	ARTICLE	IF	CITATIONS
208	Chimeric antigen receptor therapy in hematological malignancies: antigenic targets and their clinical research progress. <i>Annals of Hematology</i> , 2020, 99, 1681-1699.	1.8	5
209	Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant. <i>Bone Marrow Transplantation</i> , 2020, 55, 2160-2169.	2.4	11
210	Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. <i>Journal of Clinical Oncology</i> , 2020, 38, 3119-3128.	1.6	481
211	Management of Chimeric Antigen Receptor (CAR) T-Cell Toxicities: A Review and Guideline for Emergency Providers. <i>Journal of Emergency Medicine</i> , 2020, 59, 61-74.	0.7	5
212	Continuous renal replacement therapy in cytokine release syndrome following immunotherapy or cellular therapies?. , 2020, 8, e000742.		15
213	A Cross-Reactive Small Protein Binding Domain Provides a Model to Study Off-Tumor CAR-T Cell Toxicity. <i>Molecular Therapy - Oncolytics</i> , 2020, 17, 278-292.	4.4	9
214	Feasibility and Safety of CD19 Chimeric Antigen Receptor T Cell Treatment for B Cell Lymphoma Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1575-1580.	2.0	20
215	Intrathecal chemotherapy for management of steroid-refractory CAR T-cell-associated neurotoxicity syndrome. <i>Blood Advances</i> , 2020, 4, 2119-2122.	5.2	32
216	Updates in Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Lymphoma and Leukemia from the Annual Meeting of American Society of Hematology 2019. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 152, 103007.	4.4	0
217	Value and affordability of CAR T-cell therapy in the United States. <i>Bone Marrow Transplantation</i> , 2020, 55, 1706-1715.	2.4	66
218	Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features. <i>Blood Advances</i> , 2020, 4, 2325-2338.	5.2	122
219	Chimeric Antigen Receptor T Cell Therapy Comes to Clinical Practice. <i>Current Oncology</i> , 2020, 27, 115-123.	2.2	26
220	CAR T-cell immunotherapy of B-cell malignancy: the story so far. , 2020, 8, 251513552092716.	2.3	30
221	The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice. <i>Frontiers in Immunology</i> , 2020, 11, 888.	4.8	45
222	A New Era in Endothelial Injury Syndromes: Toxicity of CAR-T Cells and the Role of Immunity. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3886.	4.1	23
223	Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies. , 2020, 8, e000621.		29
224	CAR T-Cell Therapy for B-Cell non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Clinical Trials and Real-World Experiences. <i>Frontiers in Oncology</i> , 2020, 10, 849.	2.8	62
225	Neurotoxicity—CAR T-cell therapy: what the neurologist needs to know. <i>Practical Neurology</i> , 2020, 20, 285-293.	1.1	30

#	ARTICLE	IF	CITATIONS
226	Digital-Droplet PCR for Quantification of CD19-Directed CAR T-Cells. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 84.	3.5	26
227	Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019. <i>Immunotherapy</i> , 2020, 12, 1121-1126.	2.0	18
228	IL6 Fuels Durable Memory for Th17 Cell-Mediated Responses to Tumors. <i>Cancer Research</i> , 2020, 80, 3920-3932.	0.9	16
229	Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B cell lymphoma. <i>Blood</i> , 2020, 136, 1632-1644.	1.4	119
230	Neurologic Toxicities of Cancer Immunotherapies: a Review. <i>Current Neurology and Neuroscience Reports</i> , 2020, 20, 27.	4.2	17
231	Cardiovascular Effects of CAR T Cell Therapy. <i>JACC: CardioOncology</i> , 2020, 2, 193-203.	4.0	84
232	CAR T Cell Therapy-Related Cardiovascular Outcomes and Management. <i>JACC: CardioOncology</i> , 2020, 2, 97-109.	4.0	73
233	Chimeric antigen receptor T-cell therapies: Optimising the dose. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1678-1689.	2.4	25
234	Immune-Based Approaches for the Treatment of Pediatric Malignancies. <i>Annual Review of Cancer Biology</i> , 2020, 4, 353-370.	4.5	7
235	Psychosocial care for children receiving chimeric antigen receptor (CAR) T-cell therapy. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28249.	1.5	8
236	Potentials, challenges and future of chimeric antigen receptor T-cell therapy in non-Hodgkin lymphomas. <i>Acta Oncologica</i> , 2020, 59, 766-774.	1.8	9
237	You Have Got a Fast CAR: Chimeric Antigen Receptor NK Cells in Cancer Therapy. <i>Cancers</i> , 2020, 12, 706.	3.7	73
238	Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa105.	0.9	255
239	Acute lymphoblastic leukaemia. <i>Lancet, The</i> , 2020, 395, 1146-1162.	13.7	343
240	T cell-engaging therapies – BiTEs and beyond. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 418-434.	27.6	296
241	Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS/VOD after haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2020, 190, 822-836.	2.5	53
242	Recognizing and Grading CAR T-Cell Toxicities: An Advanced Practitioner Perspective. <i>Frontiers in Oncology</i> , 2020, 10, 885.	2.8	20
243	Neurological Complications of CAR T Cell Therapy. <i>Current Oncology Reports</i> , 2020, 22, 83.	4.0	16

#	ARTICLE	IF	CITATIONS
244	Advances in Supportive Care for Acute Lymphoblastic Leukemia. Current Hematologic Malignancy Reports, 2020, 15, 276-293.	2.3	8
245	Immune and Cell Therapy in Non-Hodgkin Lymphoma. Cancer Journal (Sudbury, Mass ), 2020, 26, 269-277.	2.0	4
246	DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality. Blood Advances, 2020, 4, 3024-3033.	5.2	75
247	Cellular Therapy in Follicular Lymphoma. Hematology/Oncology Clinics of North America, 2020, 34, 701-714.	2.2	1
248	Infections associated with the new ã~nibs and mabsâ€™™ and cellular therapies. Current Opinion in Infectious Diseases, 2020, 33, 281-289.	3.1	10
249	Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab. Journal of Autoimmunity, 2020, 114, 102512.	6.5	59
250	Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a U.S. Hospitalâ€™™s Perspective. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 971-980.	0.9	7
251	How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood, 2020, 136, 925-935.	1.4	158
252	Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. Blood Advances, 2020, 4, 2871-2883.	5.2	134
253	Cytokine release syndrome after allogeneic stem cell transplantation with posttransplant cyclophosphamide. Hematological Oncology, 2020, 38, 597-603.	1.7	14
254	Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid Tumors. Oncoimmunology, 2020, 9, 1777064.	4.6	25
255	Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. Current Treatment Options in Oncology, 2020, 21, 16.	3.0	19
256	Chimeric antigen receptor Tâ€™™cell therapy in patients with neurologic comorbidities. Pediatric Blood and Cancer, 2020, 67, e28199.	1.5	12
257	Toxicities of novel therapies for hematologic malignancies. Expert Review of Hematology, 2020, 13, 241-257.	2.2	2
258	Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data. Pharmaceuticals, 2020, 12, 194.	4.5	40
259	Ensuring center quality, proper patient selection and fair access to chimeric antigen receptor T-cell therapy: position statement of the Austrian CAR-T Cell Network. Memo - Magazine of European Medical Oncology, 2020, 13, 27-31.	0.5	5
260	Summary of a workshop on preclinical and translational safety assessment of CD3 bispecifics. Journal of Immunotoxicology, 2020, 17, 67-85.	1.7	30
261	Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract. Cytotherapy, 2020, 22, 166-171.	0.7	27



#	ARTICLE	IF	CITATIONS
262	Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy. Expert Opinion on Biological Therapy, 2020, 20, 653-664.	3.1	39
263	Advances in the development of chimeric antigen receptor-T-cell therapy in B-cell acute lymphoblastic leukemia. Chinese Medical Journal, 2020, 133, 474-482.	2.3	9
264	Controlling Cytokine Release Syndrome to Harness the Full Potential of CAR-Based Cellular Therapy. Frontiers in Oncology, 2020, 9, 1529.	2.8	23
265	Adoptive Cell Therapy: A Novel and Potential Immunotherapy for Glioblastoma. Frontiers in Oncology, 2020, 10, 59.	2.8	24
266	Harnessing T Cells to Target Pediatric Acute Myeloid Leukemia: CARs, BiTEs, and Beyond. Children, 2020, 7, 14.	1.5	13
267	Extracorporeal cytokine removal in severe CAR-T cell associated cytokine release syndrome. Journal of Critical Care, 2020, 57, 124-129.	2.2	25
268	Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery. Biology of Blood and Marrow Transplantation, 2020, 26, 1071-1076.	2.0	63
269	CAR T-Cell-Associated Neurotoxicity. Critical Care Nursing Quarterly, 2020, 43, 191-204.	0.8	28
270	CAR T cells: continuation in a revolution of immunotherapy. Lancet Oncology, The, 2020, 21, e168-e178.	10.7	204
271	Complications neurologiques des immunothérapies anti-cancéreuses: une pathologie émergente. Pratique Neurologique - FMC, 2020, 11, 60-68.	0.1	0
272	Digital PCR Assays for Precise Quantification of CD19-CAR-T Cells after Treatment with Axicabtagene Ciloleucel. Molecular Therapy - Methods and Clinical Development, 2020, 16, 172-178.	4.1	46
273	A review of cancer immunotherapy toxicity. Ca-A Cancer Journal for Clinicians, 2020, 70, 86-104.	329.8	753
274	Remission of acute myeloid leukemia with t(8;21) following CD19 CAR T-cells. Leukemia, 2020, 34, 1939-1942.	7.2	12
275	Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer. Journal of Clinical Medicine, 2020, 9, 182.	2.4	49
276	Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia. Therapeutic Advances in Hematology, 2020, 11, 204062071989989.	2.5	31
277	Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. Nature Medicine, 2020, 26, 270-280.	30.7	182
278	Fatal Mycobacterium abscessus in a recipient of axicabtagene ciloleucel CAR-T: beware of T cells. Bone Marrow Transplantation, 2020, 55, 1464-1465.	2.4	1
279	Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. New England Journal of Medicine, 2020, 382, 545-553.	27.0	1,252

#	ARTICLE	IF	CITATIONS
280	Chimeric Antigen Receptor T Cell Therapy: A Novel Modality for Immune Modulation. Chonnam Medical Journal, 2020, 56, 6.	0.9	1
281	C-reactive protein: not always a reliable marker of ongoing cytokine release syndrome in CAR-T therapy following IL-6 blockade. Leukemia and Lymphoma, 2020, 61, 2280-2282.	1.3	0
282	The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptorâ€T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma. Cytotherapy, 2020, 22, 214-226.	0.7	29
283	Severe dysautonomia as a manifestation of neurotoxicity after <scp>CARâ€T</scp> cell therapy for diffuse large <scp>Bâ€cell</scp> lymphoma. American Journal of Hematology, 2020, 95, E146-E148.	4.1	4
284	Bâ€cell maturation antigenâ€specific chimeric antigen receptor T cells for multiple myeloma: Clinical experience and future perspectives. International Journal of Cancer, 2020, 147, 2029-2041.	5.1	10
286	CAR T-cell therapy in diffuse large B-cell lymphoma. Memo - Magazine of European Medical Oncology, 2020, 13, 32-35.	0.5	2
288	Extracorporeal cytokine adsorption for treating severe refractory cytokine release syndrome (CRS). Bone Marrow Transplantation, 2020, 55, 2052-2055.	2.4	5
289	Car-T Treatment for Hematological Malignancies. Journal of Investigative Medicine, 2020, 68, 956-964.	1.6	20
290	Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence. International Journal of Molecular Sciences, 2020, 21, 2856.	4.1	31
291	CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial. Journal of Clinical Oncology, 2020, 38, 1938-1950.	1.6	273
292	The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities. Journal of Critical Care, 2020, 58, 58-64.	2.2	31
293	Dissecting the Tumorâ€Immune Landscape in Chimeric Antigen Receptor T-cell Therapy: Key Challenges and Opportunities for a Systems Immunology Approach. Clinical Cancer Research, 2020, 26, 3505-3513.	7.0	18
295	Exploring the Dilemma of Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy: To Transplant or Not?. Biology of Blood and Marrow Transplantation, 2020, 26, e183-e191.	2.0	25
296	Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE). BMJ Open, 2020, 10, e034629.	1.9	26
297	Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2020, 38, 2862-2871.	1.6	102
298	Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. Blood Advances, 2020, 4, 676-686.	5.2	101
299	Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial. Blood Advances, 2020, 4, 1432-1439.	5.2	54
300	Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial. Blood Advances, 2020, 4, 1440-1447.	5.2	29

#	ARTICLE	IF	CITATIONS
301	Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. <i>Journal of Hematology and Oncology</i> , 2020, 13, 30.	17.0	187
302	Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2020, 13, 29.	17.0	146
303	Chimeric antigen receptor T-cell therapy toxicities. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2414-2424.	2.4	19
304	Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes. <i>Blood Reviews</i> , 2021, 45, 100707.	5.7	137
305	Clinical Perspective: Treatment of Aggressive B Cell Lymphomas with FDA-Approved CAR-T Cell Therapies. <i>Molecular Therapy</i> , 2021, 29, 433-441.	8.2	22
306	Kinetics of humoral deficiency in CART19-treated children and young adults with acute lymphoblastic leukaemia. <i>Bone Marrow Transplantation</i> , 2021, 56, 376-386.	2.4	11
307	Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes. <i>Neuro-Oncology</i> , 2021, 23, 112-121.	1.2	53
308	Acute leucoencephalomyelopathy and quadriparesis after CAR T-cell therapy. <i>Haematologica</i> , 2021, 106, 1504-1506.	3.5	14
309	Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges. <i>Bone Marrow Transplantation</i> , 2021, 56, 9-19.	2.4	22
310	Toward Better Understanding and Management of CAR-T Cell-associated Toxicity. <i>Annual Review of Medicine</i> , 2021, 72, 365-382.	12.2	34
311	Tisagenlecleucel in Acute Lymphoblastic Leukemia: A Review of the Literature and Practical Considerations. <i>Annals of Pharmacotherapy</i> , 2021, 55, 466-479.	1.9	6
312	Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 683-685.	2.4	7
313	Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma. <i>Annals of Pharmacotherapy</i> , 2021, 55, 390-405.	1.9	13
314	The Evolving Management of Peritoneal Surface Malignancies. <i>Current Problems in Surgery</i> , 2021, 58, 100860.	1.1	2
315	Nanotechnology-Based CAR-T Strategies for Improving Efficacy and Safety of Tumor Immunotherapy. <i>Advanced Functional Materials</i> , 2021, 31, .	14.9	13
316	CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 473-484.	7.0	68
317	Pharmacology of Chimeric Antigen Receptor-Modified T Cells. <i>Annual Review of Pharmacology and Toxicology</i> , 2021, 61, 805-829.	9.4	7
318	Safety of Axicabtagene Ciloleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 238-245.	0.4	7

#	ARTICLE	IF	CITATIONS
319	Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant. <i>Leukemia</i> , 2021, 35, 1563-1570.	7.2	49
320	Filgrastim associations with <scp>CAR</scp> T-cell therapy. <i>International Journal of Cancer</i> , 2021, 148, 1192-1196.	5.1	21
321	Acute Leukemias. <i>Hematologic Malignancies</i> , 2021, , .	0.2	2
322	Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL. <i>Bone Marrow Transplantation</i> , 2021, 56, 552-566.	2.4	113
323	Evaluation and management of chimeric antigen receptor (CAR) T-cell-associated neurotoxicity. <i>Neuro-Oncology Practice</i> , 2021, 8, 259-265.	1.6	3
324	Rapid single-molecule digital detection of protein biomarkers for continuous monitoring of systemic immune disorders. <i>Blood</i> , 2021, 137, 1591-1602.	1.4	21
325	Toxicities Associated with Immunotherapy and Approach to Cardiotoxicity with Novel Cancer Therapies. <i>Critical Care Clinics</i> , 2021, 37, 47-67.	2.6	5
326	CARâ€” TREK through the lymphoma universe, to boldly go where no other therapy has gone before. <i>British Journal of Haematology</i> , 2021, 193, 449-465.	2.5	17
327	Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative diseaseâ€”a single center case series. <i>Bone Marrow Transplantation</i> , 2021, 56, 1031-1037.	2.4	25
328	Eradication of T-ALL Cells by CD7-targeted Universal CAR-T Cells and Initial Test of Ruxolitinib-based CRS Management. <i>Clinical Cancer Research</i> , 2021, 27, 1242-1246.	7.0	62
329	18F-FDG PET/CT of off-target lymphoid organs in CD19-targeting chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma. <i>Annals of Nuclear Medicine</i> , 2021, 35, 132-138.	2.2	17
330	Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 1134-1143.	2.4	17
331	Ruxolitinib mitigates steroidâ€”refractory CRS during CAR T therapy. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 1089-1099.	3.6	37
332	CAR T Cell and BiTE Therapyâ€”New Therapies, New Risks?. <i>Current Cardiovascular Risk Reports</i> , 2021, 15, 1.	2.0	1
333	Considerations when treating high-grade pediatric glioma patients with immunotherapy. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 205-219.	2.8	5
334	Blinatumomab use in pediatric ALL: Taking a BiTE out of preparation, administration and toxicity challenges. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 376-388.	0.9	6
335	CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CARâ€”refractory large B-cell lymphoma. <i>Blood</i> , 2021, 137, 2321-2325.	1.4	51
336	Cytokine release syndrome and complete remission of extra medullary acute lymphoblastic leukemia of the breast with CARâ€” and radiation therapy. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28839.	1.5	3

#	ARTICLE	IF	CITATIONS
337	C-reactive protein and ferritin levels and length of intensive care unit stay in patients with B-cell lymphomas treated with axicabtagene ciloleucel. Hematology/ Oncology and Stem Cell Therapy, 2021, 14, 141-146.	0.9	5
338	Safety of CAR T-cell therapy in kidney transplant recipients. Blood, 2021, 137, 2558-2562.	1.4	33
339	Inflammatory Leptomeningeal Cytokines Mediate COVID-19 Neurologic Symptoms in Cancer Patients. Cancer Cell, 2021, 39, 276-283.e3.	16.8	54
340	Liquid biopsy for disease monitoring after anti-CD19 chimeric antigen receptor T cell in diffuse large B-cell lymphoma. EJHaem, 2021, 2, 112-114.	1.0	1
341	Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Annals of Oncology, 2021, 32, 34-48.	1.2	231
342	Characterizing inclusion and exclusion criteria in clinical trials for chimeric antigen receptor (CAR) T-cell therapy among adults with hematologic malignancies. Journal of Geriatric Oncology, 2021, 12, 235-238.	1.0	9
343	Comparison of myeloablative and reduced intensity conditioning regimens in haploidentical peripheral blood stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 741-744.	2.4	3
344	T cell immunobiology and cytokine storm of COVID-19. Scandinavian Journal of Immunology, 2021, 93, e12989.	2.7	77
345	Neurological updates: neurological complications of CAR-T therapy. Journal of Neurology, 2021, 268, 1544-1554.	3.6	37
346	Cytokine syndromes associated with hematopoietic cellular therapy. Advances in Cell and Gene Therapy, 2021, 4, .	0.9	1
347	Humanized anti-CD19 chimeric antigen receptor T cell therapy is safe and effective in lymphoma and leukemia patients with chronic and resolved hepatitis B virus infection. Hematological Oncology, 2021, 39, 75-86.	1.7	15
348	CAR T cell therapies for patients with multiple myeloma. Nature Reviews Clinical Oncology, 2021, 18, 71-84.	27.6	156
349	Cytokine release syndrome-associated encephalopathy in patients with COVID-19. European Journal of Neurology, 2021, 28, 248-258.	3.3	114
350	Neurologic Complications of Chemotherapy and Radiation Therapy. , 2021, , 521-537.		0
351	CAR T Toxicity Management: Cytokine Release Syndrome and Neurotoxicity. , 2021, , 915-928.		0
352	How we treat mature B-cell neoplasms (indolent B-cell lymphomas). Journal of Hematology and Oncology, 2021, 14, 5.	17.0	16
353	Toxicities of Novel Antineoplastic Therapies. , 2021, , 711-738.		1
354	Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes. Journal of Clinical Investigation, 2021, 131, .	8.2	54

#	ARTICLE	IF	CITATIONS
355	Toxicity and effectiveness of CD19 CAR T therapy in children with high-burden central nervous system refractory B-ALL. Cancer Immunology, Immunotherapy, 2021, 70, 1979-1993.	4.2	15
357	Myeloablative haploidentical t��cell replete hematopoietic cell transplantation with post��transplant cyclophosphamide in high��risk hematological malignancies: Bending the learning curve in a middle��income setting. Advances in Cell and Gene Therapy, 2021, 4, e106.	0.9	0
358	Adverse Effects of Biological Therapies on the Nervous System. , 2021, , 145-154.		0
359	Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy. Blood Advances, 2021, 5, 593-601.	5.2	28
360	Immunotherapy-Associated Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy: Diagnostic and Management Challenges and Strategies. Current Cardiology Reports, 2021, 23, 11.	2.9	35
361	Neurologic complications associated with CAR T-cell therapy. , 2021, , 381-388.		0
362	Neurologic Manifestations of Hematologic Disorders. , 2021, , 441-474.		0
363	Neurologic Complications of Transplantation and Immunosuppressive Agents. , 2021, , 785-801.		0
364	Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis. International Journal of Medical Sciences, 2021, 18, 1786-1797.	2.5	20
365	Have CD19-directed immunotherapy and haploidentical hematopoietic cell transplantation transformed pediatric B-cell acute lymphoblastic leukemia into a chronic disease?. Oncoimmunology, 2021, 10, 1956125.	4.6	0
366	Successful Treatment of Pediatric Refractory Burkitt Lymphoma PTLN after Liver Transplantation using Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy. Cell Transplantation, 2021, 30, 096368972199664.	2.5	22
367	A Phase I Study of a Novel Fully Human BCMA-Targeting CAR (CT103A) in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2021, 137, 2890-2901.	1.4	100
368	Schwere <i>Candida-glabrata</i>-Pankolitis und letale <i>Aspergillus-fumigatus</i>-Lungeninfektion vor dem Hintergrund einer Knochenmarkaplasie nach CD19-spezifischer CAR T-Zell-Therapie â�� ein Fallbericht. Karger Kompass Onkologie, 2021, 8, 159-165.	0.0	0
369	Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy â�� a case report. BMC Infectious Diseases, 2021, 21, 121.	2.9	33
370	Care of the Critically Ill Pediatric Hematopoietic Cell Transplant Patient. , 2021, , 1207-1241.		0
372	Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma. Blood Advances, 2021, 5, 143-155.	5.2	92
373	The dual role of Natural Killer cells during tumor progression and angiogenesis: Implications for tumor microenvironment-targeted immunotherapies. , 2021, , 305-347.		0
374	The role of axicabtagene ciloleucel as a treatment option for patients with follicular/marginal zone lymphoma. Therapeutic Advances in Hematology, 2021, 12, 204062072110177.	2.5	3

#	ARTICLE	IF	CITATIONS
376	Immune-Related Adverse Events with Other Cancer Immunotherapies. , 2021, , 255-269.		1
377	CAR-T Therapy, the End of a Chapter or the Beginning of a New One?. Cancers, 2021, 13, 853.	3.7	5
378	Acute patient-reported outcomes in B-cell malignancies treated with axicabtagene ciloleucel. Cancer Medicine, 2021, 10, 1936-1943.	2.8	13
379	Tocilizumab Use in Children with Cytokine Release Syndrome. Indian Pediatrics, 2021, 58, 186-187.	0.4	0
380	Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment. Frontiers in Immunology, 2021, 12, 611366.	4.8	41
381	Real Impact of Novel Immunotherapy Drugs in Cancer. The Experience of 10 Last Years. Toxins, 2021, 13, 149.	3.4	6
382	Selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies. Current Hematologic Malignancy Reports, 2021, 16, 32-39.	2.3	6
383	Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies. BMC Cancer, 2021, 21, 198.	2.6	7
385	CAR-T and checkpoint inhibitors: toxicities and antidotes in the emergency department. Clinical Toxicology, 2021, 59, 376-385.	1.9	4
386	Human Herpesvirus 6 Encephalitis Following Axicabtagene Ciloleucel Treatment for Refractory Diffuse Large B Cell Lymphoma. HemaSphere, 2021, 5, e535.	2.7	7
387	Utility of a safety switch to abrogate CD19.CAR T-cell-associated neurotoxicity. Blood, 2021, 137, 3306-3309.	1.4	26
388	How I Manage: Pathophysiology and Management of Toxicity of Chimeric Antigen Receptor T-Cell Therapies. Journal of Clinical Oncology, 2021, 39, 456-466.	1.6	21
389	Reducing the risk of medication errors in cancer settings. Cancer Nursing Practice, 2021, 20, 23-29.	0.0	1
390	Case Report: Reversible Neurotoxicity and a Clinical Response Induced by BCMA-Directed Chimeric Antigen Receptor T Cells Against Multiple Myeloma With Central Nervous System Involvement. Frontiers in Immunology, 2021, 12, 552429.	4.8	10
391	Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. Nature Reviews Clinical Oncology, 2021, 18, 435-453.	27.6	31
392	Is There Still a Role for Allogeneic Transplantation in the Management of Lymphoma?. Journal of Clinical Oncology, 2021, 39, 487-498.	1.6	27
394	Characteristics and risk factors of infections following CD28-based CD19 CAR-T cells. Leukemia and Lymphoma, 2021, 62, 1692-1701.	1.3	22
395	A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia. International Journal of Molecular Sciences, 2021, 22, 2150.	4.1	60



#	ARTICLE	IF	CITATIONS
397	Chimeric antigen receptorâ€ natural killer cells: novel insight into immunotherapy for solid tumors (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 21, 340.	1.8	7
398	Regulatory challenges and considerations for the clinical application of CAR T cell therapy. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 549-552.	3.1	1
399	La terapia con c�lulas CAR-T. <i>Medicina Cl�nica</i> , 2021, 156, 123-125.	0.6	0
400	Clinicopathologic Findings in Fatal Neurotoxicity After Adoptive Immunotherapy With CD19-Directed CAR T-Cells. <i>HemaSphere</i> , 2021, 5, e533.	2.7	8
401	Grade 3â€4 cytokine release syndrome is associated with poor survival in haploidentical peripheral blood stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2021, 62, 1982-1989.	1.3	5
402	Challenges and Clinical Strategies of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview and Developments. <i>Frontiers in Immunology</i> , 2020, 11, 569117.	4.8	26
403	Bloodless chimeric antigen receptor (CAR) T-cell therapy in Jehovahâ€™s Witnesses. <i>Leukemia and Lymphoma</i> , 2021, 62, 1497-1501.	1.3	1
404	Chimeric Antigen Receptor T-Cell Therapy in the Management of Relapsed Non-Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 476-486.	1.6	8
405	CAR-T cell therapy. <i>Medicina Cl�nica (English Edition)</i> , 2021, 156, 123-125.	0.2	0
406	New Era of Immunotherapy in Pediatric Brain Tumors: Chimeric Antigen Receptor T-Cell Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2404.	4.1	4
407	Interleukin-6 Trajectory and Secondary Infections in Mechanically Ventilated Patients With Coronavirus Disease 2019 Acute Respiratory Distress Syndrome Treated With Interleukin-6 Receptor Blocker. , 2021, 3, e0343.		8
408	Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature. <i>Leukemia and Lymphoma</i> , 2021, 62, 1765-1769.	1.3	25
409	Chimeric Antigen Receptor T-Cell Therapy. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2021, 42, 089-092.	0.2	0
410	Interleukin-6 blocking agents for treating COVID-19: a living systematic review. <i>The Cochrane Library</i> , 2021, 2021, CD013881.	2.8	106
411	Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. <i>Leukemia</i> , 2021, 35, 2672-2683.	7.2	45
412	Cardiotoxicity Associated with Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Recognition, Risk Factors, and Management. <i>Diseases (Basel, Switzerland)</i> , 2021, 9, 20.	2.5	19
413	The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 233-240.	1.2	24
414	Adoptive Cellular Therapy for Solid Tumors. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, 57-65.	3.8	10

#	ARTICLE	IF	CITATIONS
415	Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial. Journal of Clinical Oncology, 2021, 39, 920-930.	1.6	110
416	Recurrent Status Epilepticus in the Setting of Chimeric Antigen Receptor (CAR)-T Cell Therapy. Neurohospitalist, The, 2022, 12, 194187442110009.	0.8	2
417	Immune Effector Cell Associated Neurotoxicity (ICANS) in Pediatric and Young Adult Patients Following Chimeric Antigen Receptor (CAR) T-Cell Therapy: Can We Optimize Early Diagnosis?. Frontiers in Oncology, 2021, 11, 634445.	2.8	23
418	Cytokine Release Syndrome Biology and Management. Cancer Journal (Sudbury, Mass ), 2021, 27, 119-125.	2.0	25
419	Retargeting of NK-92 Cells against High-Risk Rhabdomyosarcomas by Means of an ERBB2 (HER2/Neu)-Specific Chimeric Antigen Receptor. Cancers, 2021, 13, 1443.	3.7	7
420	2020 White Paper on Recent Issues in Bioanalysis: BAV Guidance, CLSI H62, Biotherapeutics Stability, Parallelism Testing, CyTOF and Regulatory Feedback (Part 2A) – Recommendations on Tj ETQq1 1 0.784314 rgBT /Overlook	1.5	16
421	Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection?. Lancet Haematology,the, 2021, 8, e216-e228.	4.6	41
422	Cell-Based Delivery Systems: Emerging Carriers for Immunotherapy. Advanced Functional Materials, 2021, 31, 2100088.	14.9	60
423	Cellular Therapy in Pediatric Hematologic Malignancies. Clinics in Laboratory Medicine, 2021, 41, 121-132.	1.4	2
425	Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma. Transplantation and Cellular Therapy, 2021, 27, 477.e1-477.e7.	1.2	12
426	A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and Lymphoma. OncoTargets and Therapy, 2021, Volume 14, 2185-2201.	2.0	9
427	Novel Treatments for Mantle Cell Lymphoma: From Targeted Therapies to CAR T Cells. Drugs, 2021, 81, 669-684.	10.9	2
428	Chimeric Antigen Receptor T Cells for Multiple Myeloma. Cancer Journal (Sudbury, Mass ), 2021, 27, 112-118.	2.0	4
429	Chimeric Antigen Receptor T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia. Cancer Journal (Sudbury, Mass ), 2021, 27, 98-106.	2.0	2
430	Biomarkers for Predicting Cytokine Release Syndrome following CD19-Targeted CAR T Cell Therapy. Journal of Immunology, 2021, 206, 1561-1568.	0.8	36
431	When and How to Treat Relapsed Multiple Myeloma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, 358-375.	3.8	9
432	Early Evaluation of Immunotherapy Response in Lymphoma Patients by 18F-FDG PET/CT: A Literature Overview. Journal of Personalized Medicine, 2021, 11, 217.	2.5	17
433	Neurotoxicity Biology and Management. Cancer Journal (Sudbury, Mass ), 2021, 27, 126-133.	2.0	7

#	ARTICLE	IF	CITATIONS
434	Improving and Maintaining Responses in Pediatric B-Cell Acute Lymphoblastic Leukemia Chimeric Antigen Receptor T Cell Therapy. <i>Cancer Journal</i> (Sudbury, Mass ), 2021, 27, 151-158.	2.0	0
435	CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities. <i>Cellular Oncology</i> (Dordrecht), 2021, 44, 495-523.	4.4	32
436	Brain dysfunction in COVID-19 and CAR-T therapy: cytokine storm-associated encephalopathy. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 968-979.	3.7	52
437	Impact of hypoalbuminemia on the prognosis of relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel. <i>European Journal of Haematology</i> , 2021, 107, 48-53.	2.2	3
438	A new decade: novel immunotherapies on the horizon for relapsed/refractory multiple myeloma. <i>Expert Review of Hematology</i> , 2021, 14, 377-389.	2.2	6
439	Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas. <i>Journal of Personalized Medicine</i> , 2021, 11, 355.	2.5	41
440	CRISPR-edited CART with GM-CSF knockout and auto secretion of IL6 and IL1 blockers in patients with hematologic malignancy. <i>Cell Discovery</i> , 2021, 7, 27.	6.7	20
441	Chimeric Antigen Receptor-Modified T Cells and T Cell-Engaging Bispecific Antibodies: Different Tools for the Same Job. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 218-233.	2.3	4
442	Paraneoplastic Neurological Syndromes and Beyond Emerging With the Introduction of Immune Checkpoint Inhibitor Cancer Immunotherapy. <i>Frontiers in Neurology</i> , 2021, 12, 642800.	2.4	26
443	Reactions Related to CAR-T Cell Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 663201.	4.8	54
444	Activity of blinatumomab in lymphoblastic leukemia with impaired T-cell immunity due to congenital immunodeficiency. <i>Blood Advances</i> , 2021, 5, 2153-2155.	5.2	8
445	CAR-T cell therapy: current limitations and potential strategies. <i>Blood Cancer Journal</i> , 2021, 11, 69.	6.2	871
446	A Review of Cancer Immunotherapy Toxicity II: Adoptive Cellular Therapies, Kinase Inhibitors, Monoclonal Antibodies, and Oncolytic Viruses. <i>Journal of Medical Toxicology</i> , 2022, 18, 43-55.	1.5	18
447	Evaluation of mid-term (6-12 months) neurotoxicity in B-cell lymphoma patients treated with CAR T cells: a prospective cohort study. <i>Neuro-Oncology</i> , 2021, 23, 1569-1575.	1.2	20
448	European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma. <i>Haematologica</i> , 2021, 106, 2054-2065.	3.5	27
449	Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia. , 2021, 9, e002056.		52
450	IL-6 modulation for COVID-19: the right patients at the right time?. , 2021, 9, e002285.		32
451	Chimeric Antigen Receptor T-Cell Emergencies: Inpatient Administration, Assessment, and Management. <i>Seminars in Oncology Nursing</i> , 2021, 37, 151134.	1.5	3

#	ARTICLE	IF	CITATIONS
452	Neurological update: COVID-19. <i>Journal of Neurology</i> , 2021, 268, 4379-4387.	3.6	25
454	Consolidative Hematopoietic Stem Cell Transplantation After CD19 CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: A Systematic Review and Meta-analysis. <i>Frontiers in Oncology</i> , 2021, 11, 651944.	2.8	11
455	Cognitive and behavioral manifestations in SARS-CoV-2 infection: not specific or distinctive features?. <i>Neurological Sciences</i> , 2021, 42, 2273-2281.	1.9	14
456	Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas. <i>Future Oncology</i> , 2021, 17, 1269-1283.	2.4	20
457	Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy. <i>Blood</i> , 2021, 138, 531-543.	1.4	42
458	Using JAK inhibitor to treat cytokine release syndrome developed after chimeric antigen receptor T cell therapy for patients with refractory acute lymphoblastic leukemia. <i>Medicine (United States)</i> , 2021, 100, e25786.	1.0	10
459	Determinants of in-hospital mortality in COVID-19; a prospective cohort study from Pakistan. <i>PLoS ONE</i> , 2021, 16, e0251754.	2.5	29
460	Advanced Flow Cytometry Assays for Immune Monitoring of CAR-T Cell Applications. <i>Frontiers in Immunology</i> , 2021, 12, 658314.	4.8	28
461	Cardiovascular Toxicities of CAR T-cell Therapy. <i>Current Oncology Reports</i> , 2021, 23, 78.	4.0	10
462	Neurological complications of cancer immunotherapy (CAR T cells). <i>Journal of the Neurological Sciences</i> , 2021, 424, 117405.	0.6	10
463	Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2021, 35, 3383-3393.	7.2	77
464	The use of intrathecal chemotherapy and dexamethasone for secondary prevention of blinatumomab-related neurotoxicity. <i>Current Research in Translational Medicine</i> , 2021, 69, 103285.	1.8	7
466	An owner's manual for CD19 CAR-T cell therapy in managing pediatric and young adult B-cell acute lymphoblastic leukemia. <i>Blood Reviews</i> , 2021, 50, 100848.	5.7	4
467	Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma. <i>Cancer Medicine</i> , 2021, 10, 3214-3223.	2.8	73
470	Proven and unproven cell therapies – what we have learned so far?. <i>ISBT Science Series</i> , 2021, 16, 213-218.	1.1	2
471	What the Cardiologist Needs to Know About Cancer Immunotherapies and Complications. <i>Current Treatment Options in Oncology</i> , 2021, 22, 53.	3.0	2
472	Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed/refractory multiple myeloma: a case report and review of the literature. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 39-44.	4.2	18
473	Single-cell Analysis Technologies for Immuno-oncology Research: from Mechanistic Delineation to Biomarker Discovery. <i>Genomics, Proteomics and Bioinformatics</i> , 2021, 19, 191-207.	6.9	5

#	ARTICLE	IF	CITATIONS
474	CAR T-Cells for CNS Lymphoma: Driving into New Terrain?. <i>Cancers</i> , 2021, 13, 2503.	3.7	15
475	CAR T cells “the future for cancer therapy. <i>Medicine</i> , 2021, 49, 322-324.	0.4	0
476	Place des CAR T cells dans les leucémies aiguës pédiatriques. <i>Perfectionnement En Pédiatrie</i> , 2021, 4, E7-E8.	0.0	0
477	Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies. <i>Circulation Research</i> , 2021, 128, 1780-1801.	4.5	48
478	Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study. <i>Lancet Haematology</i> , 2021, 8, e355-e364.	4.6	43
479	Immune Cells and Immunotherapy for Cardiac Injury and Repair. <i>Circulation Research</i> , 2021, 128, 1766-1779.	4.5	93
480	Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 511-521.	10.7	174
481	CD19-targeted chimeric antigen receptor-modified T cells induce remission in patients with relapsed acute B lymphoblastic leukemia after umbilical cord blood transplantation. <i>Chinese Medical Journal</i> , 2021, Publish Ahead of Print, .	2.3	4
482	Ibrutinib improves the efficacy of anti-CD19 CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma. <i>Cancer Science</i> , 2021, 112, 2642-2651.	3.9	23
483	Graft-versus-host disease risk after chimeric antigen receptor T-cell therapy: the diametric opposition of T cells. <i>British Journal of Haematology</i> , 2021, 195, 660-668.	2.5	37
484	Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. <i>Nature Reviews Immunology</i> , 2022, 22, 85-96.	22.7	315
485	Mass Cytometry: a robust platform for the comprehensive immunomonitoring of CAR T-cell therapies. <i>British Journal of Haematology</i> , 2021, 194, 788-792.	2.5	5
486	A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma. <i>Frontiers in Oncology</i> , 2021, 11, 664421.	2.8	20
487	Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL. <i>Journal of Clinical Oncology</i> , 2021, 39, 1650-1659.	1.6	173
488	Prevalence and factors associated with anxiety and depressive symptoms among patients hospitalized with hematological malignancies after chimeric antigen receptor T-cell (CAR-T) therapy: A cross-sectional study. <i>Journal of Affective Disorders</i> , 2021, 286, 33-39.	4.1	6
489	The Potential Role of the Intestinal Microenvironment and Individual Microbes in the Immunobiology of Chimeric Antigen Receptor T-Cell Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 670286.	4.8	16
490	Neurological Immunotoxicity from Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6716.	4.1	9
491	CAR T-cell therapy for multiple myeloma: state of the art and prospects. <i>Lancet Haematology</i> , 2021, 8, e446-e461.	4.6	75

#	ARTICLE	IF	CITATIONS
492	Adverse events reported to the U.S. Food and Drug Administration Adverse Event Reporting System for tisagenlecleucel. American Journal of Hematology, 2021, 96, 1087-1100.	4.1	3
493	Anti-cytokine effects of chalcon analogues in experimental "cytokine storm" in rats. Meditsinskii Akademicheskii Zhurnal, 2021, 21, 31-38.	0.2	1
494	Next-Generation Implementation of Chimeric Antigen Receptor T-Cell Therapy Using Digital Health. JCO Clinical Cancer Informatics, 2021, 5, 668-678.	2.1	20
495	Neurological complications of cancer immunotherapy. Cancer Treatment Reviews, 2021, 97, 102189.	7.7	34
496	CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Blood, 2021, 138, 2499-2513.	1.4	160
497	Anti-CD19 chimeric antigen receptor T-cell therapy in B-cell lymphomas: current status and future directions. International Journal of Hematologic Oncology, 2021, 10, IJH33.	1.6	11
498	Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL. Frontiers in Oncology, 2021, 11, 640166.	2.8	12
499	Cytokine Release Syndrome By T-cell-Redirecting Therapies: Can We Predict and Modulate Patient Risk?. Clinical Cancer Research, 2021, 27, 6083-6094.	7.0	9
500	Novel Use of Extracorporeal Blood Purification for Treatment of Severe, Refractory Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy—A Case Report. , 2021, 3, e0472.		0
501	An Analysis of Cardiac Disorders Associated With Chimeric Antigen Receptor T Cell Therapy in 126 Patients: A Single-Centre Retrospective Study. Frontiers in Oncology, 2021, 11, 691064.	2.8	15
502	CAR T-Cell Therapy: An Update for Radiologists. American Journal of Roentgenology, 2021, 217, 1461-1474.	2.2	20
503	Neurotoxic Effects of Childhood Cancer Therapy and Its Potential Neurocognitive Impact. Journal of Clinical Oncology, 2021, 39, 1752-1765.	1.6	13
504	Tisagenlecleucel for treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2021, 68, e29123.	1.5	15
505	Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma. Blood, 2021, 137, 3454-3459.	1.4	4
506	CAR T-Cell Therapy in Hematologic Malignancies: Clinical Role, Toxicity, and Unanswered Questions. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, e246-e265.	3.8	27
507	Acute Kidney Injury After the CAR-T Therapy Tisagenlecleucel. American Journal of Kidney Diseases, 2021, 77, 990-992.	1.9	18
508	Blueprint for the discovery of biomarkers of toxicity and efficacy for CAR T cells and T-cell engagers. Blood Advances, 2021, 5, 2519-2522.	5.2	10
509	Optimization of CAR-T Cell-Based Therapies Using Small-Molecule-Based Safety Switches. Journal of Medicinal Chemistry, 2021, 64, 9577-9591.	6.4	19



#	ARTICLE	IF	CITATIONS
510	CAR T-cell therapy in mature lymphoid malignancies: clinical opportunities and challenges. <i>Annals of Translational Medicine</i> , 2021, 9, 1036-1036.	1.7	3
511	Molecular-based and antibody-based targeted pharmacological approaches in childhood acute lymphoblastic leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1871-1887.	1.8	1
512	Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 1959-1970.	1.6	228
513	The "Magic Bullet" Is Here? Cell-Based Immunotherapies for Hematological Malignancies in the Twilight of the Chemotherapy Era. <i>Cells</i> , 2021, 10, 1511.	4.1	3
514	T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors. <i>Journal of Hematology and Oncology</i> , 2021, 14, 102.	17.0	64
515	Emerging nanomaterials for cancer immunotherapy. <i>Exploration of Medicine</i> , 2021, 2, 208-231.	1.5	1
516	Immunotherapy in the treatment of lymphoma. <i>World Journal of Stem Cells</i> , 2021, 13, 503-520.	2.8	3
517	Description and Analysis of Cytokine Storm in Registered COVID-19 Clinical Trials: A Systematic Review. <i>Pathogens</i> , 2021, 10, 692.	2.8	9
518	Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplant. <i>Blood Advances</i> , 2021, 5, 2650-2659.	5.2	29
519	CAR T-Cell Therapy: Updates in Nursing Management. <i>Clinical Journal of Oncology Nursing</i> , 2021, 25, 255-258.	0.6	6
520	First-in-Human Trial of EphA2-Redirected CAR T-Cells in Patients With Recurrent Glioblastoma: A Preliminary Report of Three Cases at the Starting Dose. <i>Frontiers in Oncology</i> , 2021, 11, 694941.	2.8	37
521	Axicabtagene ciloleucel in vivo expansion and treatment outcome in aggressive B-cell lymphoma in a real-world setting. <i>Blood Advances</i> , 2021, 5, 2523-2527.	5.2	19
522	Hypometabolism on brain FDG-PET as a marker for neurotoxicity after CAR T-cell therapy: A case report. <i>Revue Neurologique</i> , 2021, , .	1.5	2
523	Clinical experience of CAR T cell therapy in lymphomas. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101281.	1.7	1
524	Toci or not toci: innovations in the diagnosis, prevention, and early management of cytokine release syndrome. <i>Leukemia and Lymphoma</i> , 2021, 62, 2600-2611.	1.3	9
525	The potential of CAR T cell therapy for prostate cancer. <i>Nature Reviews Urology</i> , 2021, 18, 556-571.	3.8	25
526	Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy. <i>Annals of Hematology</i> , 2021, 100, 2303-2310.	1.8	32
527	Case Report: Local Cytokine Release Syndrome in an Acute Lymphoblastic Leukemia Patient After Treatment With Chimeric Antigen Receptor T-Cell Therapy: A Possible Model, Literature Review and Perspective. <i>Frontiers in Immunology</i> , 2021, 12, 707191.	4.8	7



#	ARTICLE	IF	CITATIONS
528	Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 230.	7.4	139
529	Patient-Reported Symptom and Functioning Status during the First 12 Months after Chimeric Antigen Receptor T Cell Therapy for Hematologic Malignancies. Transplantation and Cellular Therapy, 2021, 27, 930.e1-930.e10.	1.2	24
530	Consequences of hemophagocytic lymphohistiocytosis-like cytokine release syndrome toxicities and concurrent bacteremia. Pediatric Blood and Cancer, 2021, 68, e29247.	1.5	11
531	Glofitamab CD20-TCB bispecific antibody. Leukemia and Lymphoma, 2021, 62, 1-11.	1.3	11
532	Risk of HBV Reactivation in Patients With Resolved HBV Infection Receiving Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Without Antiviral Prophylaxis. Frontiers in Immunology, 2021, 12, 638678.	4.8	11
533	Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy. British Journal of Haematology, 2021, 194, 701-707.	2.5	61
534	Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies. , 2021, 9, e002582.		14
535	Immunotherapy in Multiple Myeloma—Time for a Second Major Paradigm Shift. JCO Oncology Practice, 2021, 17, 405-413.	2.9	10
536	CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nature Medicine, 2021, 27, 1419-1431.	30.7	273
537	A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains. Nature Reviews Clinical Oncology, 2021, 18, 715-727.	27.6	136
538	Novel immunotherapies in multiple myeloma — chances and challenges. Haematologica, 2021, 106, 2555-2565.	3.5	21
539	Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms. Experimental and Molecular Medicine, 2021, 53, 1116-1123.	7.7	116
540	EEG findings in CAR T-cell-associated neurotoxicity: Clinical and radiological correlations. Neuro-Oncology, 2022, 24, 313-325.	1.2	16
541	Lethal hyperammonemia in a CAR-T cell recipient due to <i>Ureaplasma</i> pneumonia: a case report of a unique severe complication. BMJ Case Reports, 2021, 14, e242513.	0.5	6
542	Graft-versus-Host Disease Prophylaxis with Post-Transplantation Bendamustine in Patients with Refractory Acute Leukemia: A Dose-Ranging Study. Transplantation and Cellular Therapy, 2021, 27, 601.e1-601.e7.	1.2	3
543	CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study. Cancer Immunology Research, 2021, 9, 1061-1070.	3.4	37
544	Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients — a matched control multicenter cohort study. Haematologica, 2022, 107, 1111-1118.	3.5	25
545	Real-World Experience of Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed or Refractory Aggressive B-cell Lymphomas: A Single-Institution Experience. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 861-872.	0.4	13

#	ARTICLE	IF	CITATIONS
546	Chimeric Antigen Receptor T Cell Therapy: A Comprehensive Review of Clinical Efficacy, Toxicity, and Best Practices for Outpatient Administration. Transplantation and Cellular Therapy, 2021, 27, 558-570.	1.2	36
547	Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial. Journal of Clinical Oncology, 2021, 39, 3340-3351.	1.6	142
548	Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study*. Critical Care Medicine, 2022, 50, 81-92.	0.9	13
549	Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy. OncoTargets and Therapy, 2021, Volume 14, 4023-4037.	2.0	14
550	Successful Chimeric Antigen Receptor (CAR) T-Cell Treatment in Aggressive Lymphoma Despite Coronavirus Disease 2019 (CoVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication - Case Report. Frontiers in Oncology, 2021, 11, 706431.	2.8	1
551	Toxicity of Immunotherapeutic Agents. Critical Care Clinics, 2021, 37, 605-624.	2.6	2
552	Intensive Debulking Chemotherapy Improves the Short-Term and Long-Term Efficacy of Anti-CD19-CAR-T in Refractory/Relapsed DLBCL With High Tumor Bulk. Frontiers in Oncology, 2021, 11, 706087.	2.8	8
553	CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Advances, 2021, 5, 2799-2806.	5.2	57
554	Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma. Blood Cancer Journal, 2021, 11, 131.	6.2	28
555	Extracorporeal cytokine removal in chimeric antigen receptor T-cell therapy associated cytokine release syndrome in patient with acute lymphoblastic leukemia. Case report. Terapevticheskii Arkhiv, 2021, 93, 811-817.	0.8	1
556	Toxicities associated with adoptive cellular therapies. Best Practice and Research in Clinical Haematology, 2021, 34, 101287.	1.7	9
557	18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Following Chimeric Antigen Receptor T-cell Therapy in Large B-cell Lymphoma. Molecular Imaging and Biology, 2021, 23, 818-826.	2.6	8
558	Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet, The, 2021, 398, 314-324.	13.7	711
559	Assessing and Management of Neurotoxicity After CAR-T Therapy in Diffuse Large B-Cell Lymphoma. Journal of Blood Medicine, 2021, Volume 12, 775-783.	1.7	12
560	Akinetic mutism in COVID-19-related encephalopathy: A cytokine-mediated maladaptive sickness behavioral response?. Brain, Behavior, & Immunity - Health, 2021, 15, 100272.	2.5	3
561	Clinical experience of CAR T cells for multiple myeloma. Best Practice and Research in Clinical Haematology, 2021, 34, 101306.	1.7	8
563	Tisagenlecleucel Therapy: Nursing Considerations for the Outpatient Setting. Seminars in Oncology Nursing, 2021, 37, 151178.	1.5	7
564	Frontal predominant encephalopathy with early paligraphia as a distinctive signature of CAR T-cell therapy-related neurotoxicity. Journal of Neurology, 2022, 269, 609-615.	3.6	12

#	ARTICLE	IF	CITATIONS
565	The impact of granulocyte colony stimulating factor on patients receiving chimeric antigen receptor <sc>T</sc> cell therapy. American Journal of Hematology, 2021, 96, E399-E402.	4.1	14
566	Engineering-enhanced CAR T cells for improved cancer therapy. Nature Cancer, 2021, 2, 780-793.	13.2	60
567	Real-World Experiences of CAR T-Cell Therapy for Large B-Cell Lymphoma: How Similar Are They to the Prospective Studies?. Journal of Immunotherapy and Precision Oncology, 2021, 4, 150-159.	1.4	11
568	Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma. , 2021, 9, e002303.		16
569	Neurochemical biomarkers to study CNS effects of COVID-19: A narrative review and synthesis. Journal of Neurochemistry, 2021, 159, 61-77.	3.9	21
570	Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease. Frontiers in Immunology, 2021, 12, 720571.	4.8	25
571	Antibody and cellular immunotherapies for acute lymphoblastic leukemia in adults. Leukemia and Lymphoma, 2021, 62, 3333-3347.	1.3	2
572	Healthcare Utilization and End-of-Life Outcomes in Patients Receiving CAR T-Cell Therapy. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 928-934.	4.9	14
573	Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. Blood Advances, 2021, 5, 3397-3406.	5.2	59
574	Chimeric Antigen Receptor-T Cells: A Pharmaceutical Scope. Frontiers in Pharmacology, 2021, 12, 720692.	3.5	20
575	Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia. Cancer Immunology, Immunotherapy, 2022, 71, 689-703.	4.2	22
576	Use of Transcranial Doppler as a Biomarker of CAR T Cell-Related Neurotoxicity. Neurology: Clinical Practice, 2022, 12, 22-28.	1.6	0
577	Subacute Cognitive Impairment in Individuals With Mild and Moderate COVID-19: A Case Series. Frontiers in Neurology, 2021, 12, 678924.	2.4	9
578	Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells. Blood Cancer Journal, 2021, 11, 144.	6.2	18
579	Clinical and Product Features Associated with Outcome of DLBCL Patients to CD19-Targeted CAR T-Cell Therapy. Cancers, 2021, 13, 4279.	3.7	20
580	Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Blood Advances, 2021, 5, 4980-4991.	5.2	12
581	Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. Blood Advances, 2021, 5, 2982-2986.	5.2	45
582	Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2021, 39, 3352-3363.	1.6	59

#	ARTICLE	IF	CITATIONS
583	Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia. , 2021, 9, e002287.		24
584	Production and Application of CAR T Cells: Current and Future Role of Europe. Frontiers in Medicine, 2021, 8, 713401.	2.6	15
585	Efficacy and safety of <scp>CD19</scp>-directed <scp>CAR</scp> cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the <scp>JULIET</scp>, <scp>ZUMA</scp>, and <scp>TRANSCEND</scp> trials. American Journal of Hematology, 2021, 96, 1295-1312.	4.1	107
586	Clinical experience of CAR T cells for B cell acute lymphoblastic leukemia. Best Practice and Research in Clinical Haematology, 2021, 34, 101305.	1.7	4
587	Janus Kinase Inhibitors and Cell Therapy. Frontiers in Immunology, 2021, 12, 740847.	4.8	4
588	Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignancies. Future Oncology, 2021, 17, 3549-3560.	2.4	10
589	The Agony of Choice—Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond. Cancers, 2021, 13, 4701.	3.7	6
590	Monitoring and safety of CAR-T therapy in clinical practice. Expert Opinion on Drug Safety, 2022, 21, 363-371.	2.4	0
591	[18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 953-962.	6.4	27
592	High-frequency temperature monitoring for early detection of febrile adverse events in patients with cancer. Cancer Cell, 2021, 39, 1167-1168.	16.8	7
593	Chimeric antigen receptor T cells self-neutralizing IL6 storm in patients with hematologic malignancy. Cell Discovery, 2021, 7, 84.	6.7	16
594	Chimeric antigen receptor (CAR) immunotherapy: basic principles, current advances, and future prospects in neuro-oncology. Immunologic Research, 2021, 69, 471-486.	2.9	8
595	Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. Blood, 2022, 139, 1330-1339.	1.4	52
597	Management of chimeric antigen receptor T-cell induced cytokine release syndrome: Current and emerging approaches. Journal of Oncology Pharmacy Practice, 2022, 28, 107815522110392.	0.9	1
598	Characteristics and recognition of early infections in patients treated with commercial anti-CD19 CAR T cells. European Journal of Haematology, 2022, 108, 52-60.	2.2	10
599	CAR T-cell therapy for secondary CNS DLBCL. Blood Advances, 2021, 5, 5626-5630.	5.2	41
600	CD3xCD20 bispecific T-cell redirectors for relapsed or refractory B-cell lymphoma. Lancet, The, 2021, 398, 1109-1110.	13.7	2
601	Evaluation of the safety and efficacy of humanized anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed/refractory diffuse large B-cell lymphoma based on the comprehensive geriatric assessment system. Leukemia and Lymphoma, 2021, , 1-9.	1.3	5

#	ARTICLE	IF	CITATIONS
602	Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy. Blood Advances, 2022, 6, 2045-2054.	5.2	46
603	Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells. Blood, 2021, 138, 2469-2484.	1.4	79
604	Outcomes of Anti-CD19 CAR-T Treatment of Pediatric B-ALL with Bone Marrow and Extramedullary Relapse. Cancer Research and Treatment, 2022, 54, 917-925.	3.0	9
605	Hematopathologic Correlates of CAR T-Cell Therapy. Clinics in Laboratory Medicine, 2021, 41, 325-339.	1.4	3
606	Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. New England Journal of Medicine, 2021, 385, 1196-1206.	27.0	376
607	Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies. Journal of the National Cancer Institute, 2022, 114, 436-445.	6.3	29
608	Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma. Blood Advances, 2021, 5, 3563-3567.	5.2	5
609	Advanced biomaterials in cell preservation: Hypothermic preservation and cryopreservation. Acta Biomaterialia, 2021, 131, 97-116.	8.3	42
610	Safety and Efficacy of Anti-CD19-Chimeric Antigen Receptor T Cell Combined With Programmed Cell Death 1 Inhibitor Therapy in a Patient With Refractory Post-Transplant Lymphoproliferative Disease: Case Report and Literature Review. Frontiers in Oncology, 2021, 11, 726134.	2.8	9
611	Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy. Blood Advances, 2021, 5, 4465-4475.	5.2	28
612	Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell Lymphoma. Transplantation and Cellular Therapy, 2021, 27, 768.e1-768.e6.	1.2	4
613	Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma. , 2022, 232, 108007.		12
614	Real World Evidence of CAR T-Cell Therapies for the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: A Monocentric Experience. Cancers, 2021, 13, 4789.	3.7	18
615	HHV-6 Encephalitis After Chimeric Antigen Receptor T-cell Therapy (CAR-T): 2 Case Reports and a Brief Review of the Literature. Open Forum Infectious Diseases, 2021, 8, ofab470.	0.9	6
616	Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer. , 2021, 9, e003238.		19
617	Post-transplant Cyclophosphamide Versus Thymoglobulin in HLA-Mismatched Unrelated Donor Transplant for Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Transplantation and Cellular Therapy, 2021, 27, 760-767.	1.2	18
618	Delayed cytokine release syndrome after neoadjuvant nivolumab: a case report and literature review. Immunotherapy, 2021, 13, 1071-1078.	2.0	7
619	How I treat neurologic complications in patients with lymphoid cancer. Blood, 2022, 139, 1469-1478.	1.4	2

#	ARTICLE	IF	CITATIONS
620	Is Prophylaxis the Only Way Out for Cytokine Release Syndrome Associated With Chimeric Antigen T-cell Therapy?. <i>Cureus</i> , 2021, 13, e17709.	0.5	2
621	Clinical predictors of chimeric antigen receptor T-cell therapy neurotoxicity: a single-center study. <i>Immunotherapy</i> , 2021, 13, 1261-1269.	2.0	3
622	Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. <i>Lancet, The</i> , 2021, 398, 1157-1169.	13.7	159
623	Sequential different B-cell antigen-targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma. <i>Blood Advances</i> , 2022, 6, 717-730.	5.2	22
624	Identifying and managing CAR T-cell-mediated toxicities: on behalf of an Italian CAR-T multidisciplinary team. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 407-421.	3.1	1
625	Predictors and management of relapse to axicabtagene ciloleucel in patients with aggressive B-cell lymphoma. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, , .	0.9	2
627	Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1079-1109.	4.9	96
628	Human herpesvirus 6 myelitis after chimeric antigen receptor T-cell therapy. <i>International Journal of Infectious Diseases</i> , 2021, 112, 327-329.	3.3	8
629	CAR-T therapy in solid transplant recipients with post-transplant lymphoproliferative disease: case report and literature review. <i>Current Research in Translational Medicine</i> , 2021, 69, 103304.	1.8	12
630	Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. <i>Lancet Oncology, The</i> , 2021, 22, 1403-1415.	10.7	222
631	Standardization, workforce development and advocacy in cell and gene therapies: a summary of the 2020 Regenerative Medicine InterCHANGE. <i>Cytotherapy</i> , 2021, 23, 886-893.	0.7	3
632	Cardiotoxicity associated with immune checkpoint inhibitors and CAR T-cell therapy. <i>American Journal of Emergency Medicine</i> , 2021, 50, 51-58.	1.6	6
633	Chimeric antigen receptor T-cell therapy: An emergency medicine focused review. <i>American Journal of Emergency Medicine</i> , 2021, 50, 369-375.	1.6	2
634	Cellular Therapy. <i>Organ and Tissue Transplantation</i> , 2021, , 741-761.	0.0	0
635	A Systematic Review of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Engaging an Old Problem With New Solutions. <i>Annals of Pharmacotherapy</i> , 2021, 55, 1236-1253.	1.9	6
636	Cardiovascular Events After Chimeric Antigen Receptor T-Cell Therapy. , 2021, , 39-42.		0
637	High Sensitivity Troponin T and NT-proBNP in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy. <i>Clinical Hematology International</i> , 2021, 3, 96.	1.7	7
638	Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials. <i>Cancers</i> , 2021, 13, 271.	3.7	39



#	ARTICLE	IF	CITATIONS
639	Neurological Complications. , 2021, , 593-622.		0
640	Beyond the storm â€” subacute toxicities and late effects in children receiving CAR T cells. Nature Reviews Clinical Oncology, 2021, 18, 363-378.	27.6	37
641	Advances in pluripotent stem cell-derived natural killer cells for cancer immunotherapy. , 2021, , 165-181.		0
642	Cerebrospinal Fluid Biomarkers in Childhood Leukemias. Cancers, 2021, 13, 438.	3.7	4
643	Infectious complications of CAR T-cell therapy: a clinical update. Therapeutic Advances in Infectious Disease, 2021, 8, 204993612110367.	1.8	28
644	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Encephalitis Is a Cytokine Release Syndrome: Evidences From Cerebrospinal Fluid Analyses. Clinical Infectious Diseases, 2021, 73, e3019-e3026.	5.8	131
645	CAR T-Cells. Advances in Experimental Medicine and Biology, 2020, 1244, 215-233.	1.6	24
646	Chimeric Antigen Receptor (CAR) Redirected T Cells. Learning Materials in Biosciences, 2021, , 251-302.	0.4	1
647	Novel Therapies in the Treatment of Adult Acute Lymphoblastic Leukemia. Current Hematologic Malignancy Reports, 2020, 15, 294-304.	2.3	17
648	Immunotherapy for the Treatment of Acute Lymphoblastic Leukemia. Current Oncology Reports, 2020, 22, 11.	4.0	13
650	Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma. International Journal of Radiation Oncology Biology Physics, 2020, 108, 178-188.	0.8	60
654	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. , 2020, 8, e001511.		138
655	State of the art in CAR T cell therapy for CD19+ B cell malignancies. Journal of Clinical Investigation, 2020, 130, 1586-1594.	8.2	74
656	Sleeping Beautyâ€™engineered CAR T cells achieve antileukemic activity without severe toxicities. Journal of Clinical Investigation, 2020, 130, 6021-6033.	8.2	102
657	Safety and efficacy of axicabtagene ciloleucel in refractory large B-cell lymphomas. Therapeutic Advances in Hematology, 2020, 11, 204062072090289.	2.5	13
658	Real World Data on CAR T-Cell Recipients: Are We There Yet?. , 2019, 16, .		2
659	Anticancer Drugs and the Nervous System. CONTINUUM Lifelong Learning in Neurology, 2020, 26, 732-764.	0.8	13
660	CAR-T cell therapy â€™ toxicity and its management. Acta Haematologica Polonica, 2020, 51, 6-10.	0.3	4



#	ARTICLE	IF	CITATIONS
661	CART Cell Toxicities: New Insight into Mechanisms and Management. Clinical Hematology International, 2020, 2, 149.	1.7	19
662	Triggers, Timescales, and Treatments for Cytokine-Mediated Tissue Damage. European Medical Journal Innovations, 2021, 5, 52-62.	2.0	4
663	Cytokines in CAR T Cell-Associated Neurotoxicity. Frontiers in Immunology, 2020, 11, 577027.	4.8	110
664	Adaptor CAR Platforms-Next Generation of T Cell-Based Cancer Immunotherapy. Cancers, 2020, 12, 1302.	3.7	45
665	The Influence of Chimeric Antigen Receptor Structural Domains on Clinical Outcomes and Associated Toxicities. Cancers, 2021, 13, 38.	3.7	17
666	Why Immunotherapy Fails in Multiple Myeloma. Hemato, 2021, 2, 1-42.	0.6	5
667	Cardiovascular Complications of Chimeric Antigen Receptor T-Cell Therapy: The Cytokine Release Syndrome and Associated Arrhythmias. Journal of Immunotherapy and Precision Oncology, 2020, 3, 113-120.	1.4	10
668	Cardiovascular Complications of Novel Anti-Cancer Immunotherapy: Old Problems from New Agents?. Korean Circulation Journal, 2020, 50, 743.	1.9	6
669	Adverse Events of Oncologic Immunotherapy and Their Management. Asia-Pacific Journal of Oncology Nursing, 2019, 6, 212-226.	1.6	26
670	Review: The Impact of HIV Infection on Cancer Treatment with Immunotherapy. Journal of Immunotherapy and Precision Oncology, 2019, 2, 85-92.	1.4	2
671	CAR T-Cell Therapy: Adverse Events and Management. Journal of the Advanced Practitioner in Oncology, 2019, 10, 21-28.	0.4	20
672	The Role of Advanced Practitioners in Optimizing Clinical Management and Support of Patients With Cytokine Release Syndrome From CAR T-Cell Therapy. Journal of the Advanced Practitioner in Oncology, 2019, 10, 833-843.	0.4	1
673	Axicabtagene Ciloleucel: The First FDA-Approved CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma. Journal of the Advanced Practitioner in Oncology, 2019, 10, 878-882.	0.4	11
674	Beyond CAR T-Cell Therapy: Continued Monitoring and Management of Complications. Journal of the Advanced Practitioner in Oncology, 2020, 11, 159-167.	0.4	2
675	Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 81-112.	4.9	102
676	Management of adverse effects of new monoclonal antibody treatments in acute lymphoblastic leukemia. Drugs in Context, 2020, 9, 1-15.	2.2	5
677	Cytokine release syndrome after haploidentical hematopoietic stem cell transplantation with antithymocyte globulin: risk factors analysis and poor impact on outcomes for non-remission patients. Hematology, 2021, 26, 809-817.	1.5	3
678	Surface specifically modified NK-92 cells with CD56 antibody conjugated superparamagnetic Fe <sub>3</sub> O <sub>4</sub> nanoparticles for magnetic targeting immunotherapy of solid tumors. Nanoscale, 2021, 13, 19109-19122.	5.6	12

#	ARTICLE	IF	CITATIONS
679	Severe Motor Weakness Due to Disturbance in Peripheral Nerves Following Tisagenlecleucel Treatment. <i>In Vivo</i> , 2021, 35, 3407-3411.	1.3	3
680	Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Acute Lymphoblastic Leukemia (B-ALL). <i>Cancer Treatment and Research</i> , 2021, 181, 179-196.	0.5	2
681	The Role of Physical Therapy Following CAR T-Cell Therapy. <i>Journal of Acute Care Physical Therapy</i> , 2021, Publish Ahead of Print, .	0.2	1
682	Chimeric antigen receptor T-cell therapy in adults with B-cell acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 1608-1618.	5.2	15
683	Central Nervous System Complications Among Oncology Patients. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 217-236.	2.2	2
684	Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma. <i>Frontiers in Immunology</i> , 2021, 12, 745320.	4.8	41
685	Critical care management of chimeric antigen receptor T-cell therapy recipients. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 78-93.	329.8	29
686	An overview of multiplexed analyses of CAR T-cell therapies: insights and potential. <i>Expert Review of Proteomics</i> , 2021, 18, 767-780.	3.0	2
687	Factors Impacting Overall and Event-Free Survival following Post-Chimeric Antigen Receptor T Cell Consolidative Hematopoietic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 31.e1-31.e9.	1.2	8
688	Cellular Therapy Updates in B-Cell Lymphoma: The State of the CAR-T. <i>Cancers</i> , 2021, 13, 5181.	3.7	13
689	A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2021, 14, 161.	17.0	90
690	Cytokine release syndrome after CAR infusion in pediatric patients with refractory/relapsed B-ALL: is there a role for diclofenac?. <i>Tumori</i> , 2021, , 030089162110533.	1.1	1
691	Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis. <i>Blood Advances</i> , 2022, 6, 486-494.	5.2	25
692	CAR T-cell therapy and critical care. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 1318-1325.	1.9	18
693	Advances in immune therapies in hematological malignancies. <i>Journal of Internal Medicine</i> , 2022, 292, 205-220.	6.0	5
694	Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days. <i>Blood Advances</i> , 2021, 5, 5312-5322.	5.2	24
695	NK cell-based therapies for HIV infection: Investigating current advances and future possibilities. <i>Journal of Leukocyte Biology</i> , 2021, , .	3.3	4
697	Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436. <i>Cancers</i> , 2021, 13, 5287.	3.7	4

#	ARTICLE	IF	CITATIONS
698	The Unique Symptom Burden of Patients Receiving CAR T-Cell Therapy. <i>Seminars in Oncology Nursing</i> , 2021, 37, 151216.	1.5	13
699	Intravenous anakinra for tisagenlecleucel-related toxicities in children and young adults. <i>Pediatric Hematology and Oncology</i> , 2022, 39, 370-378.	0.8	6
700	CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia: a phase 1 trial. <i>Nature Medicine</i> , 2021, 27, 1797-1805.	30.7	125
702	Reducing Hinge Flexibility of CAR-T Cells Prolongs Survival In Vivo With Low Cytokines Release. <i>Frontiers in Immunology</i> , 2021, 12, 724211.	4.8	10
703	Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma. <i>Blood Advances</i> , 2021, 5, 5344-5348.	5.2	16
704	The immunologic aspects of cytokine release syndrome and graft versus host disease following CAR T cell therapy. <i>International Reviews of Immunology</i> , 2022, 41, 649-668.	3.3	7
705	Nonclinical safety assessment of engineered T cell therapies. <i>Regulatory Toxicology and Pharmacology</i> , 2021, 127, 105064.	2.7	2
706	The triumvirate of NF- $\kappa$ B, inflammation and cytokine storm in COVID-19. <i>International Immunopharmacology</i> , 2021, 101, 108255.	3.8	55
707	Educating Multidisciplinary Care Teams, Patients, and Caregivers on CAR T-Cell Therapy. <i>Journal of the Advanced Practitioner in Oncology</i> , 2019, 10, 29-40.	0.4	3
708	BASICS OF CAR-T CELL THERAPY AND ITS FUTURE DEVELOPMENT. <i>Japanese Journal of Transfusion and Cell Therapy</i> , 2019, 65, 851-857.	0.2	0
709	CAR Design, Independent of Costimulatory Domain, Impacts Safety and Immunogenicity of CAR T-cell Therapy. , 2020, 17, .		1
711	Proton Therapy as a Bridging Treatment in CAR T-Cell Therapy for Relapsed and Refractory Large B-Cell Lymphoma: Is There a Role?. <i>International Journal of Particle Therapy</i> , 2020, 7, 13-20.	1.8	3
712	Síndrome de neurotoxicidad asociada a células inmunoefectoras: un enfoque terapéutico en el paciente crítico. <i>Medicina Intensiva</i> , 2022, 46, 201-212.	0.7	2
713	Developing and Monitoring a Standard-of-Care Chimeric Antigen Receptor (CAR) T Cell Clinical Quality and Regulatory Program. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1386-1393.	2.0	5
714	T-cell Therapy-Mediated Myocarditis Secondary to Cytokine Release Syndrome. <i>Cureus</i> , 2020, 12, e10022.	0.5	1
715	Immune-based Therapies—What the Emergency Physician Needs to Know. <i>Emergency Medicine Clinics of North America</i> , 2021, 40, 135-148.	1.2	0
716	Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials. <i>Frontiers in Immunology</i> , 2021, 12, 755866.	4.8	18
717	Facing CAR T Cell Challenges on the Deadliest Paediatric Brain Tumours. <i>Cells</i> , 2021, 10, 2940.	4.1	5

#	ARTICLE	IF	CITATIONS
718	Quantification of cell-free DNA for the analysis of CD19-CAR-T cells during lymphoma treatment. Molecular Therapy - Methods and Clinical Development, 2021, 23, 539-550.	4.1	6
719	MRD-Negative Remission Induced in EP300-ZNF384 Positive B-ALL Patients by Tandem CD19/CD22 CAR T-Cell Therapy Bridging to Allogeneic Stem Cell Transplantation. OncoTargets and Therapy, 2021, Volume 14, 5197-5204.	2.0	2
720	CAR T Cell Therapy's Potential for Pediatric Brain Tumors. Cancers, 2021, 13, 5445.	3.7	10
721	Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges. Frontiers in Immunology, 2021, 12, 782775.	4.8	23
722	Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. Journal of Clinical Oncology, 2021, 39, 3978-3992.	1.6	121
723	Inflammatory Biomarkers and Neurotransmitter Perturbations in Delirium. , 2020, , 135-167.		0
724	Regulating innovation in the early development of cell therapies. Immunotherapy Advances, 2021, 1, .	3.0	2
726	Neurologic Complications in Patients With Cancer. CONTINUUM Lifelong Learning in Neurology, 2020, 26, 1629-1645.	0.8	3
728	Risk-adapted therapy for the management of cytokine release syndrome in children undergoing unmanipulated haploidentical stem cell transplantation. Pediatric Transplantation, 2021, 25, e13964.	1.0	2
729	Chimeric Antigen Receptor-Engineered T-Cells - A New Way and Era for Lymphoma Treatment. Recent Patents on Anti-Cancer Drug Discovery, 2020, 14, 312-323.	1.6	2
731	Adoptive Cell Therapies: Keeping Pace With New and Emerging Advances. Journal of the Advanced Practitioner in Oncology, 2020, 11, 240-244.	0.4	0
732	Immunotherapy in Pediatric Hematologic Malignant Neoplasms. Clinical Pediatric Hematology-Oncology, 2020, 27, 14-21.	0.2	0
733	Tunable control of CAR T cell activity through tetracycline mediated disruption of protein-protein interaction. Scientific Reports, 2021, 11, 21902.	3.3	12
734	Cytokine Release Syndrome in the Immunotherapy of Hematological Malignancies: The Biology behind and Possible Clinical Consequences. Journal of Clinical Medicine, 2021, 10, 5190.	2.4	21
735	Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large B-cell lymphoma in Chinese patients. Frontiers of Medicine, 2021, , 1.	3.4	1
736	Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem. Expert Review of Anticancer Therapy, 2021, 21, 1333-1353.	2.4	9
737	Cluster of differentiation 19 chimeric antigen receptor T-cell therapy in pediatric acute lymphoblastic leukemia (Review). Oncology Letters, 2020, 20, 36.	1.8	2
740	CAR T-cells: hot news in cancer therapy. Vnitřní Lekarství, 2020, 66, 420-424.	0.2	0

#	ARTICLE	IF	CITATIONS
741	A Primer on Chimeric Antigen Receptor T-cell Therapy: What Does It Mean for Pathologists?. Archives of Pathology and Laboratory Medicine, 2021, 145, 704-716.	2.5	1
742	The Role of Advanced Practice Providers and Telemedicine in Reinventing Care: The Transition of a CAR T-Cell Transplantation Program to the Outpatient Setting. Journal of the Advanced Practitioner in Oncology, 2020, 11, 757-763.	0.4	0
745	Blinatumomab for HLA loss relapse after haploidentical hematopoietic stem cell transplantation. American Journal of Cancer Research, 2021, 11, 3111-3122.	1.4	1
747	Management of oncologic emergencies. , 2022, , 659-674.		1
748	Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma. Haematologica, 2022, 107, 1555-1566.	3.5	15
749	The impact of early versus late tocilizumab administration in patients with cytokine release syndrome secondary to immune effector cell therapy. Journal of Oncology Pharmacy Practice, 2023, 29, 45-51.	0.9	0
750	Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy. Radiology, 2022, 302, 438-445.	7.3	9
751	Neurologic Complications of Cancer Therapies. Current Neurology and Neuroscience Reports, 2021, 21, 66.	4.2	8
752	The Roles of Neutrophils in Cytokine Storms. Viruses, 2021, 13, 2318.	3.3	27
753	Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma. Frontiers in Oncology, 2021, 11, 760382.	2.8	8
754	Increased early mortality after fludarabine and melphalan conditioning with peripheral blood grafts in haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide. Leukemia and Lymphoma, 2022, 63, 222-226.	1.3	0
755	Efficacy and Safety of Innovative Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review. Innovations in Pharmacy, 2021, 12, 18.	0.6	1
756	Cytopenias After CD19 Chimeric Antigen Receptor T-Cells (CAR-T) Therapy for Diffuse Large B-Cell Lymphomas or Transformed Follicular Lymphoma: A Single Institution Experience. Cancer Management and Research, 2021, Volume 13, 8901-8906.	1.9	12
757	A review of neurotoxicities associated with immunotherapy and a framework for evaluation. Neuro-Oncology Advances, 2021, 3, v108-v120.	0.7	6
758	Common points of therapeutic intervention in COVID-19 and in allogeneic hematopoietic stem cell transplantation associated severe cytokine release syndrome. Acta Microbiologica Et Immunologica Hungarica, 2021, 68, 240-255.	0.8	2
759	Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. Blood Advances, 2022, 6, 1961-1968.	5.2	47
760	Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report. Blood Advances, 2022, 6, 600-610.	5.2	32
761	Incidence and prophylaxis of herpes zoster in relapsed or refractory B-cell lymphoma patients after CD19-specific CAR-T cell therapy. Leukemia and Lymphoma, 2022, 63, 1001-1004.	1.3	5

#	ARTICLE	IF	CITATIONS
762	Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia. Transplantation and Cellular Therapy, 2022, 28, 72.e1-72.e8.	1.2	21
763	Patient Perspectives on Health-Related Quality of Life in Diffuse Large B-Cell Lymphoma Treated with Car T-Cell Therapy: A Qualitative Study. Oncology and Therapy, 2022, 10, 123-141.	2.6	8
764	Chimeric antigen receptor T-cell therapy: Challenges and framework of outpatient administration. EJHaem, 2022, 3, 54-60.	1.0	6
765	Cytokine Release Syndrome Following Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplantation and Cellular Therapy, 2022, 28, 111.e1-111.e8.	1.2	16
766	Associa��o Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. I: Structuring centers for the multidisciplinary clinical administration and management of CAR-T cell therapy patients. Hematology, Transfusion and Cell Therapy, 2021, 43, S3-S12.	0.2	3
767	TCR-independent Activation in Presence of a Src-family Kinase Inhibitor Improves CAR-T Cell Product Attributes. Journal of Immunotherapy, 2021, Publish Ahead of Print, .	2.4	0
768	Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma. Future Oncology, 2022, 18, 277-289.	2.4	20
769	T Cell Engaging Immunotherapies, Highlighting Chimeric Antigen Receptor (CAR) T Cell Therapy. Cancers, 2021, 13, 6067.	3.7	9
770	Terapia con linfocitos T con receptor de ant��geno quim��rico (CAR-T) en pacientes con linfoma de c��lula B agresivo. Perspectiva actual tras una d��cada de tratamiento. Medicina Cl��nica, 2021, , .	0.6	0
771	Neurologic Toxicities of Immunotherapy. Advances in Experimental Medicine and Biology, 2021, 1342, 417-429.	1.6	2
772	Toxicity of Chimeric Antigen Receptor T Cells and its Management. BLOOD CELL THERAPY / the Official Journal of APBMT, 2021, 4, .	0.1	0
774	Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study. Cancer Gene Therapy, 2022, 29, 1080-1096.	4.6	52
775	The Role of Advanced Practice Providers and Telemedicine in Reinventing Care: The Transition of a CAR T-Cell Transplantation Program to the Outpatient Setting. Journal of the Advanced Practitioner in Oncology, 2020, 11, 757-763.	0.4	1
776	Early use of canakinumab to prevent mechanical ventilation in select COVID-19 patients: A retrospective, observational analysis. International Journal of Immunopathology and Pharmacology, 2021, 35, 205873842110596.	2.1	11
778	CAR T-cells in acute lymphoblastic leukemia: Current results. Bulletin Du Cancer, 2021, 108, S40-S54.	1.6	3
779	CAR-T cell: Toxicities issues: Mechanisms and clinical management. Bulletin Du Cancer, 2021, 108, S117-S127.	1.6	7
781	Adoptive Cell Transfer of Allogeneic Epstein��Barr Virus-Specific T Lymphocytes for Treatment of Refractory EBV-Associated Posttransplant Smooth Muscle Tumors: A Case Report. Frontiers in Immunology, 2021, 12, 727814.	4.8	4
782	The Next Wave of Novel Agents in Aggressive B-Cell Lymphoma: Highlights From SOHO 2021. Journal of the Advanced Practitioner in Oncology, 2022, 13, 34-36.	0.4	0



#	ARTICLE	IF	CITATIONS
783	Autoimmune and Inflammatory Encephalopathies as Complications of Cancer. , 2022, , 430-459.		0
784	Profile of capillary-leak syndrome in patients received chimeric antigen receptor T cell therapy. Bone Marrow Transplantation, 2022, , .	2.4	2
785	Outcomes of relapsed B-cell acute lymphoblastic leukemia after sequential treatment with blinatumomab and inotuzumab. Blood Advances, 2022, 6, 1432-1443.	5.2	13
786	Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?. Radiotherapy and Oncology, 2022, 166, 171-179.	0.6	27
787	JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy. , 2022, 10, e003766.		15
788	Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment. Blood Advances, 2022, 6, 1941-1946.	5.2	21
789	CD19 CAR-T Cell Therapy Induced Immunotherapy Associated Interstitial Pneumonitis: A Case Report. Frontiers in Immunology, 2022, 13, 778192.	4.8	6
790	The treatment landscape for Relapsed Refractory B Acute Lymphoblastic Leukaemia (ALL). Leukemia and Lymphoma, 2022, , 1-10.	1.3	0
791	Continuous blood purification successfully treated severe cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy: A case report. Pediatric Blood and Cancer, 2022, 69, e29563.	1.5	2
792	Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment. Blood Advances, 2022, 6, 3022-3026.	5.2	13
794	Navigating Regulations in Gene and Cell Immunotherapy. Cancer Drug Discovery and Development, 2022, , 141-164.	0.4	0
796	Current State of Pediatric Cardio-Oncology: A Review. Children, 2022, 9, 127.	1.5	3
797	Engineering cell-based therapies. , 2022, , 271-285.		0
798	Neurological management and work-up of neurotoxicity associated with CAR T cell therapy. Neurological Research and Practice, 2022, 4, 1.	2.0	9
799	Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed/refractory B-cell lymphoma. Bone Marrow Transplantation, 2022, 57, 431-439.	2.4	26
801	Low utility of the H-Score and HLH-2004 criteria to identify patients with secondary hemophagocytic lymphohistiocytosis after CAR-T cell therapy for relapsed/refractory diffuse large B-Cell lymphoma. Leukemia and Lymphoma, 2022, 63, 1339-1347.	1.3	6
802	Roadmap for Starting an Outpatient Cellular Therapy Program. Cancer Drug Discovery and Development, 2022, , 355-368.	0.4	0
803	Imaging Primer on Chimeric Antigen Receptor T-Cell Therapy for Radiologists. Radiographics, 2022, 42, 176-194.	3.3	11



#	ARTICLE	IF	CITATIONS
804	Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL—a matched cohort analysis. <i>Annals of Hematology</i> , 2022, 101, 755.	1.8	1
805	Efficacy and follow-up of humanized anti-BCMA CAR-T cell therapy in relapsed/refractory multiple myeloma patients with extramedullary/extramedullary bone related, and without extramedullary disease. <i>Hematological Oncology</i> , 2022, 40, 223-232.	1.7	9
806	Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter's Transformation. <i>Frontiers in Oncology</i> , 2022, 12, 828471.	2.8	19
807	A combination of humanized anti-BCMA and murine anti-CD38 CAR-T cell therapy in patients with relapsed or refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2022, , 1-10.	1.3	10
808	Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 997-1004.	3.1	7
809	Extensive myelitis with eosinophilic meningitis after Chimeric antigen receptor T cells therapy. <i>EJHaem</i> , 2022, 3, 533-536.	1.0	2
810	Impact of High Disease Burden on Survival in Pediatric Patients with B-ALL Treated with Tisagenlecleucel. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 73.e1-73.e9.	1.2	20
811	Incidence of thrombosis in relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel: Mayo Clinic experience. <i>Leukemia and Lymphoma</i> , 2022, 63, 1363-1368.	1.3	4
812	Anti-CAIX BB-2716 CAR4/8 T cells exhibit superior efficacy in a ccRCC mouse model. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 385-399.	4.4	15
814	GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. <i>Nature</i> , 2022, 603, 934-941.	27.8	339
815	CD19 or CD20 CAR T Cell Therapy Demonstrates Durable Antitumor Efficacy in Patients with Central Nervous System Lymphoma. <i>Human Gene Therapy</i> , 2022, 33, 318-329.	2.7	10
816	Robust immune responses to SARS-CoV-2 in a pediatric patient with B-Cell ALL receiving tisagenlecleucel. <i>Pediatric Hematology and Oncology</i> , 2022, , 1-9.	0.8	0
817	Prognostic Value of Radiomic Features of 18F-FDG PET/CT in Patients With B-Cell Lymphoma Treated With CD19/CD22 Dual-Targeted Chimeric Antigen Receptor T Cells. <i>Frontiers in Oncology</i> , 2022, 12, 834288.	2.8	12
818	Cancer Immunotherapies: What the Perioperative Physician Needs to Know. <i>Current Oncology Reports</i> , 2022, 24, 399-414.	4.0	6
819	Neurotoxicity-associated sinus bradycardia after chimeric antigen receptor T cell therapy. <i>Hematological Oncology</i> , 2022, , .	1.7	2
820	Cognitive adverse effects of chemotherapy and immunotherapy: are interventions within reach?. <i>Nature Reviews Neurology</i> , 2022, 18, 173-185.	10.1	31
821	Clozapine-induced Myocarditis: Pathophysiologic Mechanisms and Implications for Therapeutic Approaches. <i>Current Molecular Pharmacology</i> , 2023, 16, 60-70.	1.5	2
822	Haploidentical CD7 CAR T-cells induced remission in a patient with TP53 mutated relapsed and refractory early T-cell precursor lymphoblastic leukemia/lymphoma. <i>Biomarker Research</i> , 2022, 10, 6.	6.8	20

#	ARTICLE	IF	CITATIONS
823	CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network. <i>Blood</i> , 2022, 139, 792-796.	1.4	34
824	Neurotoxicity following CD19/CD28 $\zeta$ CAR T-cells in children and young adults with B-cell malignancies. <i>Neuro-Oncology</i> , 2022, 24, 1584-1597.	1.2	12
825	Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). <i>Annals of Oncology</i> , 2022, 33, 259-275.	1.2	139
826	Relapsed ALL: CAR T vs transplant vs novel therapies. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 1-6.	2.5	13
827	Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. <i>Nature Medicine</i> , 2021, 27, 2099-2103.	30.7	92
828	Managing therapy-associated neurotoxicity in children with ALL. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 376-383.	2.5	4
829	2021, 110, 414-419.	0.0	0
830	Recent advances in the prevention and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy. <i>European Journal of Inflammation</i> , 2022, 20, 1721727X2210787.	0.5	0
831	Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL). <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210807.	2.5	7
832	Metabolic and nutritional nervous system dysfunction in cancer patients. , 2022, , 179-194.		0
833	Neurologic complications of immune modulatory therapy. , 2022, , 537-551.		0
834	A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2022, 34, 53-62.	2.2	4
835	Dissecting the mechanism of cytokine release induced by T-cell engagers highlights the contribution of neutrophils. <i>Oncolmmunology</i> , 2022, 11, 2039432.	4.6	14
836	Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies. <i>Haematologica</i> , 2022, 107, 2096-2107.	3.5	17
837	Cytokine Release Syndrome during Antithymocyte Globulin/Anti-T Lymphocyte Globulin Serotherapy for Graft-versus-Host Disease Prophylaxis before Allogeneic Hematopoietic Stem Cell Transplantation: Incidence and Early Clinical Impact According to American Society of Transplantation and Cellular Therapy Grading Criteria. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 260.e1-260.e9.	1.2	3
838	Glypican-3: A Novel and Promising Target for the Treatment of Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 824208.	2.8	28
839	Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials. <i>Cytotherapy</i> , 2022, 24, 742-749.	0.7	2
840	Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucl in CARTITUDE studies. <i>Blood Cancer Journal</i> , 2022, 12, 32.	6.2	73

#	ARTICLE	IF	CITATIONS
841	Disseminated tuberculosis infection in a CAR Tâ€cell recipient. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29615.	1.5	3
842	Immune effector cell-associated neurotoxicity syndrome: A therapeutic approach in the critically ill. <i>Medicina Intensiva (English Edition)</i> , 2022, , .	0.2	2
843	Immunotherapy Associated Neurotoxicity in Pediatric Oncology. <i>Frontiers in Oncology</i> , 2022, 12, 836452.	2.8	5
844	Point-of-care anti-CD19 CAR T-cells for treatment of relapsed and refractory aggressive B-cell lymphoma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 251-257.	1.2	14
845	Clinical Activity of Single Dose Systemic Oncolytic VSV Virotherapy in Patients with Relapsed Refractory T-Cell Lymphoma. <i>Blood Advances</i> , 2022, , .	5.2	11
846	Targeting NK Cells for HIV-1 Treatment and Reservoir Clearance. <i>Frontiers in Immunology</i> , 2022, 13, 842746.	4.8	5
847	Genetic Therapy and Molecular Targeted Therapy in Oncology: Safety, Pharmacovigilance, and Perspectives for Research and Clinical Practice. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3012.	4.1	6
848	Cytokine Release Syndrome and Associated Acute Toxicities in Pediatric Patients Undergoing Immune Effector Cell Therapy or Hematopoietic Cell Transplantation. <i>Frontiers in Oncology</i> , 2022, 12, 841117.	2.8	9
849	Efficacy and safety of CD19-specific CAR T cellâ€based therapy in B-cell acute lymphoblastic leukemia patients with CNSL. <i>Blood</i> , 2022, 139, 3376-3386.	1.4	36
850	CAR19/22 T cell cocktail therapy for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation. <i>Cytotherapy</i> , 2022, 24, 841-849.	0.7	12
851	Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. <i>Nature Medicine</i> , 2022, 28, 713-723.	30.7	117
852	Diminished durability of <scp>chimeric antigen receptor</scp> Tâ€cell efficacy with severe or prolonged <scp>postinfusion</scp> cytopenias. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	1
853	Results of <scp>ARI</scp>â€0001 <scp>CART19</scp> cell therapy in patients with relapsed/refractory <scp>CD19</scp>â€positive acute lymphoblastic leukemia with isolated extramedullary disease. <i>American Journal of Hematology</i> , 2022, 97, 731-739.	4.1	6
854	Identification of the Predictive Models for the Treatment Response of Refractory/Relapsed B-Cell ALL Patients Receiving CAR-T Therapy. <i>Frontiers in Immunology</i> , 2022, 13, 858590.	4.8	4
855	CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?. <i>Blood</i> , 2022, 139, 2737-2746.	1.4	60
856	Endocan in Acute Leukemia: Current Knowledge and Future Perspectives. <i>Biomolecules</i> , 2022, 12, 492.	4.0	1
857	Health Care Resource Utilization and Total Costs of Care Among Patients with Diffuse Large B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy in the United States. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 404.e1-404.e6.	1.2	15
858	Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. <i>Blood</i> , 2022, 140, 16-24.	1.4	14

#	ARTICLE	IF	CITATIONS
859	Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report. <i>Journal of Clinical Oncology</i> , 2022, 40, 945-955.	1.6	79
860	Chimeric antigen receptor T-cell (CAR-T) therapy in patients with aggressive B-cell lymphomas. Current outlook after a decade of treatment. <i>Medicina Clínica (English Edition)</i> , 2022, , .	0.2	0
861	Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 294-302.	1.2	17
862	Rehabilitation Needs for Patients Undergoing CAR T-Cell Therapy. <i>Current Oncology Reports</i> , 2022, 24, 741-749.	4.0	7
863	Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 1939-1948.	1.6	29
864	Short and Long-Term Toxicity in Pediatric Cancer Treatment: Central Nervous System Damage. <i>Cancers</i> , 2022, 14, 1540.	3.7	11
865	Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies. <i>European Heart Journal</i> , 2022, 43, 1928-1940.	2.2	39
866	Pathogen-Specific Humoral Immunity and Infections in B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Recipients with Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 304.e1-304.e9.	1.2	12
867	Efficacy of programmed cell death 1 inhibitor maintenance therapy after combined treatment with programmed cell death 1 inhibitors and anti-CD19 chimeric antigen receptor T cells in patients with relapsed/refractory diffuse large B-cell lymphoma and high tumor burden. <i>Hematological Oncology</i> , 2023, 41, 275-284.	1.7	6
868	Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma. <i>Blood Advances</i> , 2022, 6, 3606-3610.	5.2	35
869	Comparison of single copy gene-based duplex quantitative PCR and digital droplet PCR for monitoring of expansion of CD19-directed CAR T cells in treated patients. <i>International Journal of Oncology</i> , 2022, 60, .	3.3	5
870	Immunotherapies in acute leukemia. <i>Therapie</i> , 2022, 77, 241-250.	1.0	3
871	Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. <i>Blood Advances</i> , 2022, 6, 5774-5785.	5.2	43
872	CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 119.	8.6	167
873	Toxicity and Local Irritation Action of the Biomedical Cell Product Anti-HER2-CAR-T-NK Upon Multiply Repeated Administration. <i>Pharmaceutical Chemistry Journal</i> , 2022, 55, 1276-1281.	0.8	1
874	Monitoring of Circulating CAR T Cells: Validation of a Flow Cytometric Assay, Cellular Kinetics, and Phenotype Analysis Following Tisagenlecleucel. <i>Frontiers in Immunology</i> , 2022, 13, 830773.	4.8	21
875	Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Adults. <i>Cancers</i> , 2022, 14, 1805.	3.7	10
876	Odronextamab, a human CD20-CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. <i>Lancet Haematology</i> , 2022, 9, e327-e339.	4.6	98

#	ARTICLE	IF	CITATIONS
877	Fulminant cerebral edema following CAR T-cell therapy: case report and pathophysiological insights from literature review. <i>Journal of Neurology</i> , 2022, , 1.	3.6	8
878	Nanodiamond as a Cytokine Sponge in Infectious Diseases. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, 862495.	4.1	6
879	How I treat <scp>tripleâ€class</scp> refractory multiple myeloma. <i>British Journal of Haematology</i> , 2022, 198, 244-256.	2.5	9
880	Clinical Significance of Haplo-Fever and Cytokine Profiling After Graft Infusion in Allogeneic Stem Cell Transplantation From Haplo-Identical Donors. <i>Frontiers in Medicine</i> , 2022, 9, 820591.	2.6	2
881	EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapyâ€™A Cohort Study. <i>Frontiers in Immunology</i> , 2022, 13, 877477.	4.8	17
882	Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell Therapy. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 305.e1-305.e9.	1.2	14
883	Acute and delayed cytopenias following CAR T-cell therapy: an investigation of risk factors and mechanisms. <i>Leukemia and Lymphoma</i> , 2022, 63, 1849-1860.	1.3	14
884	Tebentafusp for the treatment of metastatic uveal melanoma. <i>Future Oncology</i> , 2022, 18, 1303-1311.	2.4	1
885	Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians. <i>Expert Review of Hematology</i> , 2022, 15, 305-320.	2.2	25
886	Anti-PD-1 Therapy Enhances the Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy in Patients With Relapsed/Refractory CD30+ Lymphoma. <i>Frontiers in Immunology</i> , 2022, 13, 858021.	4.8	23
887	Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 387-405.	4.9	124
888	Interleukin-1 (IL-1) and the inflammasome in cancer. <i>Cytokine</i> , 2022, 153, 155850.	3.2	30
889	Immunotherapy-Related Acute Kidney Injury. <i>Advances in Chronic Kidney Disease</i> , 2021, 28, 429-437.e1.	1.4	5
890	Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 367.	8.6	72
891	Extracorporeal Membrane Oxygenation Candidacy in Pediatric Patients Treated With Hematopoietic Stem Cell Transplant and Chimeric Antigen Receptor T-Cell Therapy: An International Survey. <i>Frontiers in Oncology</i> , 2021, 11, 798236.	2.8	7
893	Targeting Solid Tumors with Bispecific T Cell Engager Immune Therapy. <i>Annual Review of Cancer Biology</i> , 2022, 6, 17-34.	4.5	23
894	Case Report: Sirolimus Alleviates Persistent Cytopenia After CD19 CAR-T-Cell Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 798352.	2.8	7
895	Early Dynamics and Depth of Response in Multiple Myeloma Patients Treated With BCMA CAR-T Cells. <i>Frontiers in Oncology</i> , 2021, 11, 783703.	2.8	4

#	ARTICLE	IF	CITATIONS
896	Brain capillary obstruction during neurotoxicity in a mouse model of anti-CD19 chimeric antigen receptor T-cell therapy. Brain Communications, 2022, 4, fcab309.	3.3	8
897	CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies. Frontiers of Medicine, 2021, 15, 783-804.	3.4	3
898	Prognostic Significance of Cytokine Release Syndrome in B Cell Hematological Malignancies Patients After Chimeric Antigen Receptor T Cell Therapy. Journal of Interferon and Cytokine Research, 2021, 41, 469-476.	1.2	9
899	Noninfectious lung complications of hematopoietic cell transplantation. Hematology American Society of Hematology Education Program, 2021, 2021, 578-586.	2.5	4
900	Transient left ventricular dysfunction following chimeric antigen receptor T-cell-mediated encephalopathy: A form of stress cardiomyopathy. EJHaem, 2022, 3, 231-234.	1.0	2
902	CAR T-cell hematotoxicity: is inflammation the key?. Blood, 2021, 138, 2447-2448.	1.4	3
903	Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities. , 2021, 9, e003894.		50
904	Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy. BMC Cancer, 2022, 22, 393.	2.6	11
905	Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia. Leukemia, 2022, 36, 1508-1515.	7.2	21
906	Chimeric antigen receptor T-cell therapy in adult patients with B-cell lymphoproliferative diseases. Gematologiya I Transfuziologiya, 2022, 67, 8-28.	0.6	1
907	Outcomes of Tisagenlecleucel in Lymphoma Patients With Predominant Management in an Ambulatory Setting. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e730-e737.	0.4	6
908	Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial. Blood, 2022, 139, 2306-2315.	1.4	62
909	HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma. Blood Advances, 2023, 7, 744-755.	5.2	5
910	CAR T-Cell Therapy in the Older Person: Indications and Risks. Current Oncology Reports, 2022, 24, 1189-1199.	4.0	11
911	Axicabtagene Ciloleucel in Patients Ineligible for ZUMA-1 Because of CNS Involvement and/or HIV: A Multicenter Experience. Journal of Immunotherapy, 2022, 45, 254-262.	2.4	6
912	Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL. Blood, 2022, 139, 3722-3731.	1.4	28
913	Successful treatment of a case with synchronous follicular lymphoma and gastric adenocarcinoma with CD19 CAR T cells and literature review. Journal of Clinical Pharmacy and Therapeutics, 2022, 47, 1466-1470.	1.5	2
914	T-cell "redirecting bispecific antibodies in multiple myeloma: a revolution?. Blood, 2022, 139, 3681-3687.	1.4	20



#	ARTICLE	IF	CITATIONS
915	Engineered cellular immunotherapies in cancer and beyond. <i>Nature Medicine</i> , 2022, 28, 678-689.	30.7	106
918	Chimeric antigen receptor T-cell therapy for a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia and leukoencephalopathy who relapsed after bone marrow transplantation. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29734.	1.5	1
919	CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study. <i>Leukemia</i> , 2022, 36, 1525-1532.	7.2	27
920	CAR-T cell therapy in paediatric acute lymphoblastic leukaemia – past, present and future. <i>British Journal of Haematology</i> , 2020, 191, 617-626.	2.5	5
921	Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL. <i>Blood Advances</i> , 2022, 6, 5737-5749.	5.2	20
922	Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma. <i>Blood Advances</i> , 2023, 7, 768-777.	5.2	15
932	Development of Cancer Immunotherapies. <i>Cancer Treatment and Research</i> , 2022, 183, 1-48.	0.5	4
933	Review of Hematological and Oncological Emergencies. <i>Advanced Emergency Nursing Journal</i> , 2022, 44, 84-102.	0.5	2
934	A national service for delivering <scp>CD19 CAR-T</scp> in large B-cell lymphoma – The <scp>UK</scp> real-world experience. <i>British Journal of Haematology</i> , 2022, 198, 492-502.	2.5	40
935	Outcomes of blinatumomab based therapy in children with relapsed, persistent, or refractory acute lymphoblastic leukemia: a multicenter study focusing on predictors of response and post-treatment immunoglobulin production. <i>Pediatric Hematology and Oncology</i> , 2022, 39, 613-628.	0.8	2
936	Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. <i>Lancet Haematology</i> , the, 2022, 9, e374-e384.	4.6	11
937	Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell Transplant. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 473-482.	1.2	20
938	Patient-reported outcomes and neurotoxicity markers in patients treated with bispecific LV20.19 CAR T cell therapy. <i>Communications Medicine</i> , 2022, 2, .	4.2	5
939	Invasive Yeast Infection after Haploidentical Donor Hematopoietic Cell Transplantation Associated with Cytokine Release Syndrome. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 508.e1-508.e8.	1.2	6
940	Demographic differences among patients treated with chimeric antigen receptor <scp>T-cell</scp> therapy in the United States. <i>Cancer Medicine</i> , 2022, 11, 4440-4448.	2.8	6
941	Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. <i>Nature Medicine</i> , 2022, 28, 1189-1198.	30.7	190
942	A novel adoptive synthetic <scp>TCR</scp> and antigen receptor (<scp>STAR</scp>) <scp>T-cell</scp> therapy for <scp>B-cell</scp> acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2022, 97, 992-1004.	4.1	8
943	Iron Chelators in Treatment of Iron Overload. <i>Journal of Toxicology</i> , 2022, 2022, 1-18.	3.0	40



#	ARTICLE	IF	CITATIONS
944	The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches. International Journal of Molecular Sciences, 2022, 23, 5242.	4.1	7
945	Neuroimaging findings in immune effector cell associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy. Leukemia and Lymphoma, 2022, 63, 2364-2374.	1.3	6
946	Gene knockout in cellular immunotherapy: Application and limitations. Cancer Letters, 2022, 540, 215736.	7.2	10
947	Change in Patients's Perceived Cognition Following Chimeric Antigen Receptor T-Cell Therapy for Lymphoma. Transplantation and Cellular Therapy, 2022, 28, 401.e1-401.e7.	1.2	10
948	CD19 CAR-T cell therapy in relapsed and refractory acute lymphoblastic leukemia: A systematic review and meta-analysis. Frontiers in Immunology, 2022, 13, 884567.	4.1	7
949	BCMA CAR-T cell therapy in relapsed and refractory multiple myeloma: A systematic review and meta-analysis. Frontiers in Immunology, 2022, 13, 884567.	0.3	0
950	Neurotoxicity Associated with Treatment of Acute Lymphoblastic Leukemia Chemotherapy and Immunotherapy. International Journal of Molecular Sciences, 2022, 23, 5515.	4.1	7
951	Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia. Blood Advances, 2022, 6, 4251-4255.	5.2	20
952	Time to evolve: predicting engineered T cell-associated toxicity with next-generation models. , 2022, 10, e003486.		21
953	The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. , 2022, 10, e004475.		50
954	Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation. , 2022, 10, e004483.		21
955	Phenotypic Composition of Commercial Anti-CD19 CAR T Cells Affects <i>In Vivo</i> Expansion and Disease Response in Patients with Large B-cell Lymphoma. Clinical Cancer Research, 2022, 28, 3378-3386.	7.0	15
956	Emerging Concepts in Managing Malignancy in Kidney Transplant Patients. Seminars in Nephrology, 2022, 42, 63-75.	1.6	4
957	Advances in modular control of CAR-T therapy with adapter-mediated CARs. Advanced Drug Delivery Reviews, 2022, 187, 114358.	13.7	3
958	CAR-T cell therapy in relapsed and refractory acute lymphoblastic leukemia: A systematic review and meta-analysis. Frontiers in Immunology, 2022, 13, 884567.	4.1	7
959	A Case Report on Dysgraphia in a Patient Receiving Blinatumomab: Complex Characters Are Easy to Find in a Handwriting Test. Medicina (Lithuania), 2022, 58, 733.	2.0	1
960	Longitudinal Collection of Patient-Reported Outcomes and Activity Data during CAR-T Therapy: Feasibility, Acceptability, and Data Visualization. Cancers, 2022, 14, 2742.	3.7	6
961	Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma. Frontiers in Immunology, 2022, 13, .	4.8	8

#	ARTICLE	IF	CITATIONS
962	Bispecific targeting of CD20 and CD19 increases polyfunctionality of chimeric antigen receptor T-cell products in B-cell malignancies. <i>Cytotherapy</i> , 2022, 24, 767-773.	0.7	10
963	BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma—Finding a Dancing Partner. <i>Current Oncology Reports</i> , 2022, 24, 1299-1311.	4.0	10
964	CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR. <i>Blood</i> , 2022, 140, 451-463.	1.4	56
965	Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 581.e1-581.e8.	1.2	61
966	Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	7
967	Physiological lentiviral vectors for the generation of improved CAR-T cells. <i>Molecular Therapy - Oncolytics</i> , 2022, 25, 335-349.	4.4	4
968	Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors. <i>Oncolimmunology</i> , 2022, 11, .	4.6	15
969	Ciltacabtagene Autoleucel, an Anti-CD19 B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. <i>Journal of Clinical Oncology</i> , 2023, 41, 1265-1274.	1.6	160
970	Teclistamab in Relapsed or Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2022, 387, 495-505.	27.0	291
971	Case Report: Chimeric Antigen Receptor T Cells Induced Late Severe Cytokine Release Syndrome. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1
972	Cytokine release syndrome and relevant factors of CD19 targeted chimeric antigen receptor T cell therapy in relapsed/refractory B cell hematological malignancies. <i>Transfusion and Apheresis Science</i> , 2022, 61, 103473.	1.0	1
973	Cancer therapeutic drug guide. , 2023, , 451-506.		0
974	Dramatic Recovery after Etoposide Phosphate Infusion for Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome following Treatment with Tisagenlecleucel in a Young Patient with Relapsed Acute Lymphoblastic Leukemia: A Case Report. <i>Acta Haematologica</i> , 2022, 145, 537-541.	1.4	5
975	Introducing innovative cellular therapies into the clinic: a 2-year retrospective experience of a chimeric antigen receptor T-cell programme at a single centre in Switzerland. , 2022, 152, .		5
976	Cardiovascular Toxicities with Chimeric Antigen Receptor T-cell Therapy. <i>Current Cardiology Reviews</i> , 2022, 18, .	1.5	1
977	Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2022, 116, 315-329.	1.6	3
978	Thrombopoietin receptor agonist for treating bone marrow aplasia following anti-CD19 CAR-T cells—single-center experience. <i>Annals of Hematology</i> , 2022, 101, 1769-1776.	1.8	13
979	What SARS-CoV-2 does to our brains. <i>Immunity</i> , 2022, 55, 1159-1172.	14.3	28

#	ARTICLE	IF	CITATIONS
980	Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy. <i>Nature Cancer</i> , 2022, 3, 1039-1051.	13.2	12
981	Systemic Relapse in a Young Adult Patient with Primary CNS Diffuse Large B-Cell Lymphoma. <i>Case Reports in Hematology</i> , 2022, 2022, 1-9.	0.4	1
982	Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia. <i>Blood Cancer Journal</i> , 2022, 12, .	6.2	14
983	Synthetic Immunotherapy: Programming Immune Cells with Novel and Sophisticated Logic Capabilities. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 560-571.	1.2	4
984	Application of Monoclonal Antibody Drugs in Treatment of COVID-19: a Review. <i>BioNanoScience</i> , 2022, 12, 1436-1454.	3.5	2
985	Cell-based drug delivery systems and their in vivo fate. <i>Advanced Drug Delivery Reviews</i> , 2022, 187, 114394.	13.7	28
986	Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas. <i>Annals of Oncology</i> , 2022, 33, 916-928.	1.2	30
987	Bispecific Tâ€cell engagers for treatment of multiple myeloma. <i>American Journal of Hematology</i> , 2023, 98, .	4.1	13
988	Treatments of Ph-like acute lymphoblastic leukemia: a real-world retrospective analysis from a single large center in China. <i>Leukemia and Lymphoma</i> , 2022, 63, 2652-2662.	1.3	4
989	Timing of Tocilizumab Administration Under the Guidance of IL-6 in CAR-T Therapy for R/R Acute Lymphoblastic Leukemia. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	4
990	Extending the Continual Reassessment Method to accommodate stepâ€up dosing in Phase I trials. <i>Statistics in Medicine</i> , 0, , .	1.6	1
991	CASP-Model Sepsis Triggers Systemic Innate Immune Responses Revealed by the Systems-Level Signaling Pathways. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	2
992	Phase I study of VSV-GP (BI 1831169) as monotherapy or combined with ezabenlimab in advanced and refractory solid tumors. <i>Future Oncology</i> , 2022, 18, 2627-2638.	2.4	8
993	Toxicity management strategies for next-generation novel therapeutics in multiple myeloma. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072211006.	2.5	4
994	Chimeric antigen receptor T cells and management of toxicities: implications of biomarkers. , 2022, , 245-281.		0
995	Feasibility of outpatient administration of axicabtagene ciloleucel and brexucabtagene autoleucel using telemedicine tools: The Vanderbilt experience. <i>British Journal of Haematology</i> , 2022, 198, 1073-1075.	2.5	9
996	Stage 4 Cytokine Release Syndrome Caused by the First Dose of Nivolumab and Ipilimumab Combination Therapy in a Patient with Metastatic Melanoma Successfully Treated with Methylprednisolone, Tocilizumab, and Etanercept. <i>Case Reports in Oncology</i> , 2022, 15, 648-653.	0.7	7
997	Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 546-559.	1.2	16

#	ARTICLE	IF	CITATIONS
998	Influence of Culture Conditions on Ex Vivo Expansion of T Lymphocytes and Their Function for Therapy: Current Insights and Open Questions. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	4.1	4
999	Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma. <i>Haematologica</i> , 2023, 108, 110-121.	3.5	39
1000	The EBMT Immune Effector Cell Nursing Guidelines on CAR-T Therapy: A Framework for Patient Care and Managing Common Toxicities. <i>Clinical Hematology International</i> , 2022, 4, 75-88.	1.7	11
1001	Targeting the Microenvironment for Treating Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7627.	4.1	9
1002	Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy. <i>Neurology</i> , 2022, 99, 511-515.	1.1	9
1003	The role of neurologists in the era of cancer immunotherapy: Focus on CAR T-cell therapy and immune checkpoint inhibitors. <i>Frontiers in Neurology</i> , 0, 13, .	2.4	9
1004	Impact of Chronic Kidney Disease and Acute Kidney Injury on Safety and Outcomes of CAR T-Cell Therapy in Lymphoma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 863-868.	0.4	3
1005	Chimeric antigen receptor T-cell therapy in adults: management of toxicities and implications for critical care. <i>BJA Education</i> , 2022, 22, 330-333.	1.4	1
1006	A novel antibody-TCR (AbTCR) T-cell therapy is safe and effective against CD19-positive relapsed/refractory B-cell lymphoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 2757-2769.	2.5	4
1007	Axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 903-914.	2.4	1
1008	Clinical trials for chimeric antigen receptor T-cell therapy: lessons learned and future directions. <i>Current Opinion in Hematology</i> , 2022, 29, 225-232.	2.5	3
1009	Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2022, 23, 1055-1065.	10.7	119
1010	Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study. <i>Blood Cancer Journal</i> , 2022, 12, .	6.2	27
1011	The impact of tocilizumab treatment for cytokine release syndrome on the incidence of early blood stream infections after peripheral blood haploidentical hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 0, , 1-7.	1.3	0
1012	Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma. <i>Blood Advances</i> , 2022, 6, 4821-4830.	5.2	20
1013	Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	13
1014	Interleukin Inhibitors in Cytokine Release Syndrome and Neurotoxicity Secondary to CAR-T Therapy. <i>Diseases (Basel, Switzerland)</i> , 2022, 10, 41.	2.5	6
1015	Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 669-676.	1.2	36

#	ARTICLE	IF	CITATIONS
1016	Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma. Haematologica, 2023, 108, 98-109.	3.5	29
1017	Gene-Based Natural Killer Cell Therapies for the Treatment of Pediatric Hematologic Malignancies. Hematology/Oncology Clinics of North America, 2022, 36, 745-768.	2.2	1
1018	Chimeric Antigen Receptor T-cell Therapy. Hematology/Oncology Clinics of North America, 2022, 36, 701-727.	2.2	6
1019	Newer Cancer Therapies and Perioperative Implications. , 2023, , 56-69.		0
1020	Evaluating the Therapeutic Potential of Idecabtagene Vicleucel in the Treatment of Multiple Myeloma: Evidence to Date. OncoTargets and Therapy, 0, Volume 15, 799-813.	2.0	3
1021	Mechanisms of immune effector <sc>cell-associated</sc> neurotoxicity syndrome after <sc>CAR-T</sc> treatment. WIREs Mechanisms of Disease, 2022, 14, .	3.3	5
1022	Chimeric Antigen Receptor T Cell Therapy versus Hematopoietic Stem Cell Transplantation: An Evolving Perspective. Transplantation and Cellular Therapy, 2022, 28, 727-736.	1.2	5
1023	Future development of chimeric antigen receptor T cell therapies for patients suffering from malignant glioma. Current Opinion in Oncology, 2022, 34, 661-669.	2.4	1
1024	Cardiotoxicity of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Pathophysiology, Clinical Implications, and Echocardiographic Assessment. International Journal of Molecular Sciences, 2022, 23, 8242.	4.1	4
1025	Chimeric Antigen Receptor T-Cell-Associated Hemophagocytic Lymphohistiocytosis (carHLH) Predicts Poor Survival with Real-World Use of Tisagenlecleucel for B-ALL. SSRN Electronic Journal, 0, , .	0.4	2
1026	Neurologic adverse events of cancer immunotherapy. Arquivos De Neuro-Psiquiatria, 2022, 80, 270-280.	0.8	1
1027	Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer. Cancer Discovery, 2022, 12, 2372-2391.	9.4	19
1028	A Focus on CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma. Journal of the Advanced Practitioner in Oncology, 2022, 13, 31-43.	0.4	0
1029	Real time experience applying CAR T-cells for B-cell lymphomaâ€”What we have learned so far: Acute toxicity management. Memo - Magazine of European Medical Oncology, 0, , .	0.5	0
1030	Identification of genomic determinants contributing to cytokine release in immunotherapies and human diseases. Journal of Translational Medicine, 2022, 20, .	4.4	1
1031	Monitoring Neurocognitive Functioning After Pediatric Cellular Therapy or Hematopoietic Cell Transplant: Guidelines From the COG Neurocognition in Cellular Therapies Task Force. Transplantation and Cellular Therapy, 2022, 28, 625-636.	1.2	5
1032	Severe infections in recipients of cancer immunotherapy: what intensivists need to know. Current Opinion in Critical Care, 2022, 28, 540-550.	3.2	5
1033	Humanized CD19-directed CAR-T Cell Therapy in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia With CNSL or Neurological Comorbidity. Journal of Immunotherapy, 0, Publish Ahead of Print, .	2.4	0

#	ARTICLE	IF	CITATIONS
1034	Timely administration of tocilizumab improves outcome of hospitalized COVID-19 patients. PLoS ONE, 2022, 17, e0271807.	2.5	10
1035	Chimeric Antigen Receptor-T Cell Therapy. Korean Journal of Medicine, 2022, 97, 229-237.	0.3	0
1036	Understanding CAR T-Cell-tumor interactions: Paving the way for successful clinical outcomes. Med, 2022, 3, 538-564.	4.4	11
1037	Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy. Blood Advances, 2022, 6, 4719-4725.	5.2	25
1038	Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies. Pharmaceutics, 2022, 14, 1762.	4.5	4
1039	The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes. Blood Advances, 2022, 6, 6040-6050.	5.2	8
1041	The use of ICU resources in CAR-T cell recipients: a hospital-wide study. Annals of Intensive Care, 2022, 12, .	4.6	9
1042	CAR T-Based Therapies in Lymphoma: A Review of Current Practice and Perspectives. Biomedicines, 2022, 10, 1960.	3.2	5
1043	Comparison of short- and long-term adverse kidney outcomes after chimeric antigen receptor T cell therapy and autologous hematopoietic stem cell transplant for diffuse large B cell lymphoma. Bone Marrow Transplantation, 2022, 57, 1623-1625.	2.4	1
1045	Impact of glucocorticoids on short-term and long-term outcomes in patients with relapsed/refractory multiple myeloma treated with CAR-T therapy. Frontiers in Immunology, 0, 13, .	4.8	4
1046	Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphoma. Frontiers in Immunology, 0, 13, .	4.8	3
1047	Application of nanotechnology in CAR-T-cell immunotherapy. Chinese Chemical Letters, 2023, 34, 107747.	9.0	5
1048	Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma. Blood Advances, 2022, 6, 6109-6119.	5.2	23
1049	Cardiovascular perspectives on stem cell transplant and Car-T cell therapy: The old and the new for assessment and management. American Heart Journal Plus, 2022, , 100198.	0.6	0
1050	Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy. Frontiers in Immunology, 0, 13, .	4.8	20
1051	GFAP and NfL increase during neurotoxicity from high baseline levels in pediatric CD19-CAR T-cell patients. Blood Advances, 2023, 7, 1001-1010.	5.2	6
1052	Vitamin D Insufficiency and Clinical Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Large B-cell Lymphoma. Transplantation and Cellular Therapy, 2022, 28, 751.e1-751.e7.	1.2	2
1053	Assessing the role of radiotherapy in patients with refractory or relapsed high-grade B-cell lymphomas treated with CAR T-cell therapy. Radiotherapy and Oncology, 2022, 175, 65-72.	0.6	13



#	ARTICLE	IF	CITATIONS
1054	Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. <i>Blood</i> , 2023, 141, 219-230.	1.4	52
1055	Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study. <i>Lancet Haematology</i> , 2022, 9, e766-e775.	4.6	18
1056	A Case of Relapsed Primary Central Nervous System Lymphoma Treated with CD19-directed Chimeric Antigen Receptor T Cell Therapy. <i>NMC Case Report Journal</i> , 2022, 9, 275-280.	0.5	0
1057	A Case of Central Nervous System Post-Transplant Lymphoproliferative Disorder Following Haploidentical Stem Cell Transplantation in a Patient With Acute Lymphoblastic Leukemia. <i>Cell Transplantation</i> , 2022, 31, 096368972211175.	2.5	3
1058	Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy. <i>Theranostics</i> , 2022, 12, 6273-6290.	10.0	25
1059	Emerging approaches for preventing cytokine release syndrome in CAR-T cell therapy. <i>Journal of Materials Chemistry B</i> , 2022, 10, 7491-7511.	5.8	8
1060	Acute Kidney Injury in Cancer Patients. <i>Nephrology Self-assessment Program: NephSAP</i> , 2022, 21, 100-107.	3.0	0
1061	Towards Remote Continuous Monitoring of Cytokine Release Syndrome. , 2022, , .		1
1062	CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 0, Volume 12, 119-136.	2.7	15
1063	T-Cell-Based Cellular Immunotherapy of Multiple Myeloma: Current Developments. <i>Cancers</i> , 2022, 14, 4249.	3.7	2
1064	Investigation of the risk factors to predict cytokine release syndrome in relapsed or refractory B-cell acute lymphoblastic leukemia patients receiving IL-6 knocking down anti-CD19 chimeric antigen receptor T-cell therapy. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	4
1065	Chimeric antigen receptor T cell therapy for cancer: clinical applications and practical considerations. <i>BMJ, The</i> , 0, , e068956.	6.0	4
1066	Comparable outcomes in patients with B-cell acute lymphoblastic leukemia receiving haploidentical hematopoietic stem cell transplantation: Pretransplant minimal residual disease-negative complete remission following chimeric antigen receptor T-cell therapy versus chemotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	1
1067	Potential Therapeutic Role of Mesenchymal-Derived Stem Cells as an Alternative Therapy to Combat COVID-19 through Cytokines Storm. <i>Cells</i> , 2022, 11, 2686.	4.1	1
1068	Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis. <i>Clinical Cancer Research</i> , 2022, 28, 5156-5166.	7.0	10
1069	Chimeric Antigen Receptor (CAR) T-cell Treatment in Renal Cell Carcinoma: Current Clinical Trials and Future Directions. <i>Kidney Cancer</i> , 2022, 6, 159-168.	0.4	1
1070	Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 829.e1-829.e8.	1.2	7
1071	Association of bridging therapy utilization with clinical outcomes in patients receiving chimeric antigen receptor (CAR) T-cell therapy. , 2022, 10, e004567.		3



#	ARTICLE	IF	CITATIONS
1072	GPRC5D-Targeted CAR T Cells for Myeloma. New England Journal of Medicine, 2022, 387, 1196-1206.	27.0	114
1073	The Evolution of Chimeric Antigen Receptor T-Cell Therapy in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukemia. Biomedicines, 2022, 10, 2286.	3.2	1
1074	Assessment of Pretreatment and Posttreatment Evolution of Neurofilament Light Chain Levels in Patients Who Develop Immune Effector Cellâ€Associated Neurotoxicity Syndrome. JAMA Oncology, 2022, 8, 1652.	7.1	4
1075	Supportive methods for childhood acute lymphoblastic leukemia then and now: A compilation for clinical practice. Frontiers in Pediatrics, 0, 10, .	1.9	1
1077	Clinical Strategies for Enhancing the Efficacy of CAR T-Cell Therapy for Hematological Malignancies. Cancers, 2022, 14, 4452.	3.7	1
1078	Impact of Cytomegalovirus Replication in Patients with Aggressive B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy. Transplantation and Cellular Therapy, 2022, 28, 851.e1-851.e8.	1.2	10
1079	Point-of-care CAR T-cell therapy as salvage strategy for out-of-specification tisagenlecleucel. Leukemia and Lymphoma, 0, , 1-9.	1.3	4
1080	Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma. Frontiers in Immunology, 0, 13, .	4.8	16
1081	Periâ€CAR-T practice patterns and survival predictors for all CAR-T patients and postâ€CAR-T failure in aggressive B-NHL. Blood Advances, 2023, 7, 2657-2669.	5.2	11
1082	Chimeric antigen receptor engineered cells and their clinical application in infectious disease. Clinical and Translational Discovery, 2022, 2, .	0.5	0
1084	Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy. Nature Medicine, 2022, 28, 1860-1871.	30.7	80
1085	CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia. Experimental Hematology and Oncology, 2022, 11, .	5.0	12
1086	Metabolic Imaging in B-Cell Lymphomas during CAR-T Cell Therapy. Cancers, 2022, 14, 4700.	3.7	6
1087	The Cytokine Release Syndrome and/or the Proinflammatory Cytokines as Underlying Mechanisms of Downregulation of Drug Metabolism and Drug Transport: A Systematic Review of the Clinical Pharmacokinetics of Victim Drugs of this Drugâ€Disease Interaction Under Different Clinical Conditions. Clinical Pharmacokinetics. 2022, 61, 1519-1544.	3.5	9
1088	A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nature Medicine, 2022, 28, 2145-2154.	30.7	106
1089	The correlation factors and prognostic significance of coagulation disorders after chimeric antigen receptor T cell therapy in hematological malignancies: a cohort study. Annals of Translational Medicine, 2022, 10, 975-975.	1.7	2
1091	CAR-T cell therapy for multiple myeloma: a practical toolkit for treatment in Brazil. Hematology, Transfusion and Cell Therapy, 2023, 45, 266-274.	0.2	3
1092	Cardiovascular disease and chimeric antigen receptor cellular therapy. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	1

#	ARTICLE	IF	CITATIONS
1093	T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscape. <i>Leukemia and Lymphoma</i> , 2022, 63, 3032-3043.	1.3	5
1094	Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	5
1095	Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapy. <i>Leukemia</i> , 2022, 36, 2669-2677.	7.2	7
1096	Neurocritical Care in the General Intensive Care Unit. <i>Critical Care Clinics</i> , 2022, , .	2.6	0
1097	Patient-reported cognitive function among hematopoietic stem cell transplant and cellular therapy patients: a scoping review. <i>Quality of Life Research</i> , 0, , .	3.1	0
1098	Ciltacabtagene autoleucl in patients with relapsed/refractory multiple myeloma: <scp>CARITUDE</scp>â€¹ (phase 2) Japanese cohort. <i>Cancer Science</i> , 2022, 113, 4267-4276.	3.9	6
1099	Outcomes of Critically Ill Children With Acute Lymphoblastic Leukemia and Cytokine Release Syndrome Due to Chimeric Antigen Receptor T Cell Therapy: US, Multicenter PICU, Cohort Database Study. <i>Pediatric Critical Care Medicine</i> , 2022, 23, e595-e600.	0.5	2
1100	BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma. <i>Cancer Letters</i> , 2023, 553, 215949.	7.2	11
1101	Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial. <i>Haematologica</i> , 2023, 108, 1827-1839.	3.5	7
1102	Associations between socioeconomic status and bispecific LV20.19 CAR T cell therapy outcomes. <i>Haematologica</i> , 0, , .	3.5	1
1103	Fever Characteristics and Impact on Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2023, 23, e14-e18.	0.4	1
1104	A multicenter study of ICU resource utilization in pediatric, adolescent and young adult patients post CAR-T therapy. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1
1105	Anakinra to Mitigate Hemophagocytic Lymphohistiocytosis-Like Toxicity Following Chimeric Antigen Receptor T-cell Therapy in Pediatric B-cell ALL. <i>Clinical Pediatric Hematology-Oncology</i> , 2022, 29, 92-96.	0.2	2
1106	Continuous EEG monitoring detects nonconvulsive seizure and Ictal-Interictal Continuum abnormalities in moderate to severe ICANS following systemic CAR-T therapy. <i>Neurohospitalist</i> , The, 2023, 13, 53-60.	0.8	2
1107	Whole-process management of complications during CAR-T therapy. , 2022, 1, .		0
1109	Decreased serum phosphate levels are a useful biomarker to predict occurrence and severity of cytokine release syndrome in <scp>chimeric antigen receptor T</scp>â€œcell therapy. <i>British Journal of Haematology</i> , 2023, 200, .	2.5	4
1111	Kinetics of Humoral Immunodeficiency With Bispecific Antibody Therapy in Relapsed Refractory Multiple Myeloma. <i>JAMA Network Open</i> , 2022, 5, e2238961.	5.9	15
1112	Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant. <i>Haematologica</i> , 2023, 108, 615-620.	3.5	7

#	ARTICLE	IF	CITATIONS
1113	Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial. <i>Nature Medicine</i> , 2022, 28, 2364-2373.	30.7	45
1114	Cytokine Storm Syndrome. <i>Annual Review of Medicine</i> , 2023, 74, 321-337.	12.2	32
1115	Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors. <i>Cancers</i> , 2022, 14, 5108.	3.7	9
1116	Emerging frontiers in immuno- and gene therapy for cancer. <i>Cytotherapy</i> , 2023, 25, 20-32.	0.7	3
1117	A Model to Estimate Cytokine Release Syndrome and Neurological Event Management Costs Associated With CAR T-Cell Therapy. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 59.e1-59.e6.	1.2	1
1118	The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	7
1119	Radiation prior to chimeric antigen receptor T-cell therapy is an optimizing bridging strategy in relapsed/refractory aggressive B-cell lymphoma. <i>Radiotherapy and Oncology</i> , 2022, 177, 53-60.	0.6	6
1120	Cytokine Stormâ€”Definition, Causes, and Implications. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11740.	4.1	61
1121	Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30+ lymphoma. <i>Experimental Hematology and Oncology</i> , 2022, 11, .	5.0	9
1122	Cross-study safety analysis of risk factors in CAR Tâ€”cell clinical trials: An FDA database pilot project. <i>Molecular Therapy - Oncolytics</i> , 2022, 27, 182-194.	4.4	1
1123	Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL. <i>Clinical Cancer Research</i> , 2023, 29, 742-753.	7.0	11
1124	Hypophosphatemia Due to Increased Effector Cell Metabolic Activity Is Associated with Neurotoxicity Symptoms in CD19-Targeted CAR T-cell Therapy. <i>Cancer Immunology Research</i> , 2022, 10, 1433-1440.	3.4	8
1126	Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Antiâ€”B-Cell Maturation Antigen Chimeric Antigen Receptorâ€”T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1). <i>Journal of Clinical Oncology</i> , 2023, 41, 1275-1284.	1.6	15
1127	Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities. <i>Blood</i> , 2023, 141, 467-480.	1.4	33
1128	Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13332.	4.1	10
1129	Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma. <i>Blood Cancer Journal</i> , 2022, 12, .	6.2	19
1130	Toxicities following CAR-T therapy for hematological malignancies. <i>Cancer Treatment Reviews</i> , 2022, 111, 102479.	7.7	13
1131	Cytokine Release Syndrome and Sepsis. <i>Infectious Disease Clinics of North America</i> , 2022, 36, 735-748.	5.1	4

#	ARTICLE	IF	CITATIONS
1132	CAR T Cell Immunotherapy That Revolutionary Breakthrough in Human Oncology Treatment: A Review. Pharmacology & Pharmacy, 2022, 13, 483-515.	0.7	0
1133	Blinatumomab Prior to CAR-T Cell Therapyâ€”A Treatment Option Worth Consideration for High Disease Burden. Biomedicines, 2022, 10, 2915.	3.2	1
1134	Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy. Blood Advances, 2023, 7, 3192-3198.	5.2	9
1136	Supportive Care for Patients with Lymphoma Undergoing CAR-T-cell Therapy: the Advanced Practice Providerâ€™s Perspective. Current Oncology Reports, 2022, 24, 1863-1872.	4.0	4
1137	Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma. Leukemia, 2023, 37, 154-163.	7.2	14
1139	TriTECM: A tetrafunctional T-cell engaging antibody with built-in risk mitigation of cytokine release syndrome. Frontiers in Immunology, 0, 13, .	4.8	2
1140	Incidence and severity of ICANS following CAR-T therapy in patients previously receiving ifosfamide. Bone Marrow Transplantation, 0, , .	2.4	0
1141	Changing the Tune for CAR T-Cell Therapy: A Music City Experience in Remote Patient Monitoring. Oncology Issues, 2022, 37, 20-24.	0.1	1
1142	Interleukin-6 and cytokine release syndrome. Annals of Allergy, Asthma and Immunology, 2023, 130, 178-184.	1.0	8
1143	Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II Trial. Journal of Clinical Oncology, 2023, 41, 1670-1683.	1.6	35
1144	Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia. Journal of Hematology and Oncology, 2022, 15, .	17.0	27
1145	Cytokine Release Syndrome in the Pediatric Population and Implications for Intensive Care Management. Critical Care Clinics, 2022, , .	2.6	0
1146	Learning from TCR Signaling and Immunological Synapse Assembly to Build New Chimeric Antigen Receptors (CARs). International Journal of Molecular Sciences, 2022, 23, 14255.	4.1	8
1147	Host metabolome predicts the severity and onset of acute toxicities induced by CAR T-cell therapy. Blood Advances, 2023, 7, 4690-4700.	5.2	1
1148	Gene and Cell Therapy: How to Build a BioDrug. Pediatric Oncology, 2022, , 51-88.	0.5	0
1149	Recent Innovative Approaches to Intensify the Efficacy and Safety of CAR-T Cell Therapy in Cancers. , 2023, , 117-155.		1
1150	A systematic review on performance analysis of critical time points in multiple myeloma treated by CAR-T cell immunotherapy. International Immunopharmacology, 2023, 114, 109592.	3.8	1
1151	Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR TÂcells are as effective as freshly infused cells. Molecular Therapy - Methods and Clinical Development, 2023, 28, 51-61.	4.1	3

#	ARTICLE	IF	CITATIONS
1153	What matters most to patients with multiple myeloma? A Pan-European patient preference study. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	2
1154	CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma. <i>Cancer Discovery</i> , 2023, 13, 580-597.	9.4	18
1155	The Autologous Hematopoietic Stem Cells Transplantation Combination-Based Chimeric Antigen Receptor T-Cell Therapy Improves Outcomes of Relapsed/Refractory Central Nervous System B-Cell Lymphoma. <i>Journal of Oncology</i> , 2022, 2022, 1-20.	1.3	6
1156	Psychosocial characteristics of patients undergoing cellular immunotherapies and their caregivers across time. <i>Leukemia and Lymphoma</i> , 2023, 64, 364-370.	1.3	0
1157	Organ toxicities associated with chimeric antigen receptor T-cell therapy. <i>Leukemia and Lymphoma</i> , 2023, 64, 491-494.	1.3	0
1159	Anti-CD19 chimeric antigen receptor T-cell followed by interferon- $\gamma$ therapy induces durable complete remission in donor cell-derived acute lymphoblastic leukemia: A case report. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	0
1160	Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy. <i>Blood Cancer Discovery</i> , 2023, 4, 118-133.	5.0	22
1161	EEG-based grading of immune effector cell-associated neurotoxicity syndrome. <i>Scientific Reports</i> , 2022, 12, .	3.3	0
1162	Forecasting immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor t-cell therapy. , 2022, 10, e005459.		4
1163	Predictors of response to axicabtagene- $\epsilon$ iloleucel CAR T cells in aggressive B cell lymphomas: A real-world study. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 5976-5983.	3.6	3
1164	Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with <scp>anti-CD19 CAR</scp> cells. <i>British Journal of Haematology</i> , 2023, 201, 86-94.	2.5	4
1165	Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome. <i>Blood Advances</i> , 2023, 7, 4765-4772.	5.2	2
1166	Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2022, 387, 2220-2231.	27.0	151
1167	â€œYou give me fever!â€™: are health services ready for immune cell engager therapy in advanced solid malignancies?. , 2022, 10, e006073.		0
1168	Cancer Immunotherapy Beyond Checkpoint Blockade. <i>JACC: CardioOncology</i> , 2022, 4, 563-578.	4.0	1
1169	Chimeric Antigen Receptor T Cells: Toxicity and Management Considerations. <i>AACN Advanced Critical Care</i> , 2022, 33, 301-307.	1.1	1
1170	Prolonged duration of lymphocyte deficiency, high-grade CRS, and ventilation are linked to fungal breakthrough in patients with hematologic malignancies 60 days after CAR-T infusion: A single center case-control study. <i>Journal of Infection and Public Health</i> , 2022, 15, 1521-1530.	4.1	2
1171	Using natural killer cell-derived exosomes as a cell-free therapy for leukemia. <i>Hematological Oncology</i> , 2023, 41, 487-498.	1.7	6

#	ARTICLE	IF	CITATIONS
1172	Blinatumomab in Relapsed/Refractory Burkitt Lymphoma. <i>Cancers</i> , 2023, 15, 44.	3.7	2
1173	Allogeneic CD34 <sup>+</sup> selected hematopoietic stem cell boost following CAR T-cell therapy in a patient with prolonged cytopenia and active infection. <i>Pediatric Blood and Cancer</i> , 2023, 70, .	1.5	5
1174	Chimeric antigen receptor T-cell therapy for multiple myeloma. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	4
1175	Mechanism and Experimental Verification of the Use of <i>Rhodiola crenulata</i> to Cytokine Storm Based on Network Pharmacology and Molecular Docking. <i>Natural Product Communications</i> , 2022, 17, 1934578X2211427.	0.5	0
1176	Development of a Core Set of Patient- and Caregiver-Reported Signs and Symptoms to Facilitate Early Recognition of Acute Chimeric Antigen Receptor T-Cell Therapy Toxicities. <i>JCO Oncology Practice</i> , 2023, 19, e407-e416.	2.9	2
1177	Acute Kidney Injury in Cancer Immunotherapy Recipients. <i>Cells</i> , 2022, 11, 3991.	4.1	4
1178	Costs, effectiveness, and safety associated with Chimeric Antigen Receptor (CAR) T-cell therapy: Results from a comprehensive cancer center. <i>PLoS ONE</i> , 2022, 17, e0278950.	2.5	3
1179	Dasatinib for treatment of CAR T-cell therapy-related complications. , 2022, 10, e005956.		10
1180	Serious adverse events and coping strategies of CAR-T cells in the treatment of malignant tumors. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	1
1181	Cardiotoxicity of T-Cell Antineoplastic Therapies. <i>JACC: CardioOncology</i> , 2022, 4, 616-623.	4.0	10
1182	The place of allogeneic stem cell transplantation in aggressive B-cell non-Hodgkin lymphoma in the era of CAR-T-cell therapy. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	0
1183	Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. <i>Journal of Clinical Oncology</i> , 2023, 41, 2238-2247.	1.6	107
1184	Evaluating the Patient with Neurotoxicity after Chimeric Antigen Receptor T-cell Therapy. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1845-1860.	3.0	2
1185	Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial. <i>Nature Medicine</i> , 2023, 29, 104-114.	30.7	31
1186	Multifocal demyelinating leukoencephalopathy and oligodendroglial lineage cell loss with immune effector cell-associated neurotoxicity syndrome (ICANS) following CD19 CAR T-cell therapy for mantle cell lymphoma. <i>Journal of Neuropathology and Experimental Neurology</i> , 2023, 82, 160-168.	1.7	2
1187	Peripheral blood cellular profile at pre-lymphodepletion is associated with CD19-targeted CAR-T cell-associated neurotoxicity. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	3
1189	Cardiac involvement in a patient with B-cell lymphoblastic lymphoma/acute lymphoblastic leukemia and a history of allogeneic hematopoietic stem cell transplantation and CAR T-cell therapy: A case report. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	0
1190	Pre-lymphodepletion & infusion endothelial activation and stress index as predictors of clinical outcomes in CAR-T therapy for B-cell lymphoma. <i>Blood Cancer Journal</i> , 2023, 13, .	6.2	2



#	ARTICLE	IF	CITATIONS
1191	Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium. Journal of Clinical Oncology, 2023, 41, 2087-2097.	1.6	67
1192	Use of blinatumomab and CAR T-cell therapy in children with relapsed/refractory leukemia: A case series study. Frontiers in Pediatrics, 0, 10, .	1.9	1
1193	Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results. Signal Transduction and Targeted Therapy, 2023, 8, .	17.1	23
1195	Is CD19-directed chimeric antigen receptor T cell therapy a smart strategy to combat central nervous system lymphoma?. Frontiers in Oncology, 0, 12, .	2.8	2
1196	Patient Care Practices and Challenges in CAR-T cell therapy from a transfusion department nurse's perspective. Journal of Illusion, 2023, 12, 48-58.	0.1	1
1197	Cytokine Storm, Immunomodulators and Mucormycosis in COVID-19: Bench To Bed Side. Research Journal of Pharmacy and Technology, 2022, , 4871-4875.	0.8	3
1198	CAR T-Cells for the Treatment of Refractory or Relapsed Large B-Cell Lymphoma: A Single-Center Retrospective Canadian Study. Clinical Lymphoma, Myeloma and Leukemia, 2023, 23, 203-210.	0.4	1
1199	It Is in the Eye of the Beholder: Ocular Ultrasound Enhanced Monitoring of Neurotoxicity after CAR-T Cell Therapy. Hematology Reports, 2023, 15, 1-8.	0.8	1
1200	Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies. Bone Marrow Transplantation, 2023, 58, 386-392.	2.4	15
1201	Flare-up phenomenon or pseudoprogression after CAR T-cell infusion in non-Hodgkin aggressive lymphomas. Leukemia and Lymphoma, 2023, 64, 707-711.	1.3	3
1202	Bridging Radiation Rapidly and Effectively Cyto-reduces High-Risk Relapsed/Refractory Aggressive B Cell Lymphomas Prior to Chimeric Antigen Receptor T Cell Therapy. Transplantation and Cellular Therapy, 2023, 29, 259.e1-259.e10.	1.2	9
1203	CD19 CAR-T therapy in solid organ transplant recipients: case report and systematic review. Bone Marrow Transplantation, 2023, 58, 353-359.	2.4	9
1204	Apoptosis of Hematopoietic Stem Cells Contributes to Bone Marrow Suppression Following Chimeric Antigen Receptor T Cell Therapy. Transplantation and Cellular Therapy, 2023, 29, 165.e1-165.e7.	1.2	6
1205	Neurotoxicidades apresentadas por pacientes submetidos ao transplante de células-tronco hematopoéticas: uma revisão de escopo. ACTA Paulista De Enfermagem, 2022, 35, .	0.6	0
1206	Diabetes insipidus and Guillain-Barré-like syndrome following CAR-T cell therapy: a case report. , 2023, 11, e006059.		3
1207	Bright future or blind alley? CAR-T cell therapy for solid tumors. Frontiers in Immunology, 0, 14, .	4.8	10
1208	Tumor immunology. , 2023, , 245-452.		0
1209	Immunotherapy using CAR T: What we have learned from trials and where we are heading. , 2023, , 369-384.		0



#	ARTICLE	IF	CITATIONS
1210	Cellular and Vaccine-Based Immunotherapy for Hematologic Malignancies. , 2023, , .		0
1211	CAR-T: What Is Next?. Cancers, 2023, 15, 663.	3.7	41
1215	Novel CD19-specific $\hat{\text{I}}^3/\hat{\text{I}}^{\text{T}}$ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma. Journal of Hematology and Oncology, 2023, 16, .	17.0	5
1216	The Role of the Research Advanced Practice Provider in CAR T-Cell Clinical Trials. Journal of the Advanced Practitioner in Oncology, 2023, 14, 54-66.	0.4	1
1217	High risk-myelodysplastic syndrome following CAR T-cell therapy in a patient with relapsed diffuse large B cell lymphoma: A case report and literature review. Frontiers in Oncology, 0, 13, .	2.8	1
1218	Current progress and challenges of immunotherapy in gastric cancer: A focus on CAR-T cells therapeutic approach. Life Sciences, 2023, 318, 121459.	4.3	6
1219	Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma. Clinical Hematology International, 2023, 5, 43-51.	1.7	5
1220	Recent Developments in Application of Multiparametric Flow Cytometry in CAR-T Immunotherapy. , 0, , .		0
1221	Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nature Medicine, 2023, 29, 422-429.	30.7	56
1222	Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium. Journal of Clinical Oncology, 2023, 41, 2594-2606.	1.6	37
1223	Durable remissions achieved with reinfusion of CD19 $\hat{\text{e}}$ directed CAR $\hat{\text{e}}$ T despite failure to induce or maintain B $\hat{\text{e}}$ cell aplasia and single $\hat{\text{e}}$ center experience with reinfusion of tisagenlecleucel. Pediatric Blood and Cancer, 2023, 70, .	1.5	3
1224	GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial. Lancet Haematology,the, 2023, 10, e107-e116.	4.6	36
1225	2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Cancer Biology and Medicine, 0, , 129-146.	3.0	0
1226	CAR-T cells for cancer immunotherapy. Chinese Chemical Letters, 2023, 34, 108202.	9.0	3
1227	CAR t-cell therapy in BOlogNa $\hat{\text{e}}$ “NEUrotoxicity TReatment and Assessment in Lymphoma (CARBON $\hat{\text{e}}$ “NEUTRAL): proposed protocol and results from an Italian study. Journal of Neurology, 2023, 270, 2659-2673.	3.6	5
1228	Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions. Blood Advances, 2023, 7, 4528-4538.	5.2	7
1229	Association Between Pretreatment Skeletal Muscle and Outcomes After CAR T-Cell Therapy. Journal of the National Comprehensive Cancer Network: JNCCN, 2023, 21, 373-382.e1.	4.9	1
1230	Switching from salvage chemotherapy to immunotherapy in adult B-cell acute lymphoblastic leukemia. Blood Reviews, 2023, 59, 101042.	5.7	2

#	ARTICLE	IF	CITATIONS
1231	Potential synergy between radiotherapy and CAR T-cells - a multicentric analysis of the role of radiotherapy in the combination of CAR T cell therapy. Radiotherapy and Oncology, 2023, 183, 109580.	0.6	10
1232	Cytokine profiling during conditioning in haploidentical stem cell transplantation and its prognostic impact on early transplant outcomes. Transplant Immunology, 2023, 78, 101830.	1.2	1
1233	Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma. Cytotherapy, 2023, 25, 653-658.	0.7	3
1234	Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL. HemaSphere, 2023, 7, e858.	2.7	10
1235	CAR T-cell therapy: Reprogramming patient's immune cell to treat cancer. Cellular Signalling, 2023, 105, 110638.	3.6	1
1237	Chimeric Antigen Receptor T-cell Therapy in Hematologic Malignancies and Patient-reported Outcomes: A Scoping Review. HemaSphere, 2022, 6, e802.	2.7	7
1238	Mechanistically modeling peripheral cytokine dynamics following bispecific dosing in solid tumors. CPT: Pharmacometrics and Systems Pharmacology, 2023, 12, 1726-1737.	2.5	6
1239	Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy. Clinical Cancer Research, 2023, 29, 1484-1495.	7.0	6
1240	A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma. Blood Advances, 2023, 7, 3516-3529.	5.2	14
1241	Development and validation of a patient-reported outcome measure to assess symptom burden after chimeric antigen receptor T-cell therapy. British Journal of Haematology, 2023, 201, 738-746.	2.5	2
1242	Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma. Expert Opinion on Drug Safety, 2023, 22, 5-15.	2.4	1
1243	Medical emergencies in pediatric blood & marrow transplant and cellular therapies. Frontiers in Pediatrics, 0, 11, .	1.9	1
1244	Case report: Reversible punctate inflammatory foci in the corpus callosum: A novel radiological finding of CAR T-cell therapy-related neurotoxicity. Frontiers in Neurology, 0, 14, .	2.4	2
1245	Procalcitonin as a biomarker for predicting bacterial infection in chimeric antigen receptor T-cell therapy recipients. Cancer Medicine, 2023, 12, 9228-9235.	2.8	7
1246	CAR-T Cell Therapy: the Efficacy and Toxicity Balance. Current Hematologic Malignancy Reports, 2023, 18, 9-18.	2.3	15
1247	Resource utilization in patients with large B-cell lymphoma receiving tisagenlecleucel and axicabtagene ciloleucel. Bone Marrow Transplantation, 2023, 58, 590-593.	2.4	1
1248	A systematic framework for predictive biomarkers in immune effector cell-associated neurotoxicity syndrome. Frontiers in Neurology, 0, 14, .	2.4	4
1249	Optimizing the manufacturing and antitumour response of CAR-T therapy. , 2023, 1, 271-285.		14

#	ARTICLE	IF	CITATIONS
1250	Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome. <i>Biomolecules</i> , 2023, 13, 382.	4.0	8
1251	Neuropsychiatric disorders in adults undergoing chimeric antigen receptor T cells therapy for aggressive lymphomas and acute lymphoblastic leukemia. <i>Leukemia Research Reports</i> , 2023, 19, 100364.	0.4	0
1252	The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 311.e1-311.e7.	1.2	2
1253	Chimeric antigen receptor-T cell therapy-related cardiotoxicity in adults and children cancer patients: A clinical appraisal. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	2.4	4
1254	Analysis of citation trends to identify articles on delirium worth reading using DDPP model with temporal heatmaps (THM): A bibliometric analysis. <i>Medicine (United States)</i> , 2023, 102, e32955.	1.0	10
1255	An Overview of Cytokine Release Syndrome and Other Side Effects of CAR-T Cell Therapy. <i>Praxis</i> , 2023, 112, 189-193.	0.4	2
1257	Endocrine and Neurological Toxicities of Immunotherapies. <i>Praxis</i> , 2023, 112, 178-183.	0.4	1
1258	HLH-like toxicities predict poor survival following use of tisagenlecleucel in children and young adults with B-ALL. <i>Blood Advances</i> , 0, , .	5.2	1
1259	Chimeric antigen receptor T cells therapy in solid tumors. <i>Clinical and Translational Oncology</i> , 2023, 25, 2279-2296.	2.4	2
1260	Management of neuropsychiatric adverse events in a prostate cancer patient undergoing chimeric antigen receptor T-cell immunotherapy (a phase I clinical trial): A case report. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2023, 10, 100211.	1.6	0
1262	Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 349.e1-349.e8.	1.2	4
1263	Donor Hematopoietic Stem Cell/Lymphocyte Maintenance Treatment After CAR T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia Relapse Following Stem Cell Transplant. <i>Cell Transplantation</i> , 2023, 32, 096368972311581.	2.5	0
1264	Anti-CD19 CAR-T Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase I Trial. <i>Journal of Clinical Oncology</i> , 2023, 41, 2583-2593.	1.6	17
1265	Novel pathophysiological insights into CAR-T cell associated neurotoxicity. <i>Frontiers in Neurology</i> , 0, 14, .	2.4	4
1266	Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 438.e1-438.e16.	1.2	36
1267	Bone marrow microenvironment disruption and sustained inflammation with prolonged haematologic toxicity after CAR-T cell therapy. <i>British Journal of Haematology</i> , 2023, 202, 294-307.	2.5	7
1268	Management of adverse events in young adults and children with acute B-cell lymphoblastic leukemia receiving anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. <i>Blood Research</i> , 2023, 58, S20-S28.	1.3	3
1269	A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. <i>Nature Medicine</i> , 2023, 29, 906-916.	30.7	44

#	ARTICLE	IF	CITATIONS
1270	Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era. Bone Marrow Transplantation, 2023, 58, 673-679.	2.4	5
1271	Long-Term Follow-Up of Bridging Therapies Prior to CAR T-Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma. Cancers, 2023, 15, 1747.	3.7	3
1272	Targeted Treatment of Relapsed or Refractory Follicular Lymphoma: Focus on the Therapeutic Potential of Mosunetuzumab. Cancer Management and Research, 0, Volume 15, 257-264.	1.9	1
1273	Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: case report and systematic review of the literature. , 2023, 11, e005841.		12
1274	Introduction to a How I Treat series on emergent CAR T-cell toxicities. Blood, 2023, 141, 2405-2407.	1.4	0
1275	Cardiotoxicities of Novel Therapies in Hematologic Malignancies: Chimeric Antigen Receptor T-Cell Therapy and Bispecific T-Cell Engager Therapy. JCO Oncology Practice, 0, , .	2.9	0
1276	Emergency department use by patients who received chimeric antigen receptor T cell infusion therapy. Frontiers in Oncology, 0, 13, .	2.8	2
1277	Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple Myeloma. Transplantation and Cellular Therapy, 2023, 29, 350-355.	1.2	6
1278	Case report: CAR-T cell therapy-induced cardiac tamponade. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	1
1279	Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients. European Heart Journal, 2023, 44, 2029-2042.	2.2	7
1280	Diagnosis and Management of Adult Malignancy-Associated Hemophagocytic Lymphohistiocytosis. Cancers, 2023, 15, 1839.	3.7	1
1281	Cytokine storm in HSCT for severe combined immunodeficiency infant with SARS-COV-2: PICU challenges - A case report. Journal of Pediatric Critical Care, 2023, 10, 76.	0.0	0
1282	Immune-related adverse events associated with the use of immunotherapy in patients with B-cell lymphoblastic leukemia: A protocol for a systematic review and meta-analysis. Medicine (United Tj ETQq0 0 0 rgBT1/Overlocko10 Tf 50 2		
1283	Response rates of extra-nodal diffuse large B cell lymphoma to anti-CD19 CAR T cells: A real word retrospective multicenter study. European Journal of Haematology, 2023, 111, 63-71.	2.2	2
1284	Impact of Preemptive Use of Tocilizumab on Chimeric Antigen Receptor T Cell Outcomes in Non-Hodgkin Lymphoma. Transplantation and Cellular Therapy, 2023, 29, 429.e1-429.e6.	1.2	2
1285	Infectious complications of bispecific antibody therapy in patients with multiple myeloma. Blood Cancer Journal, 2023, 13, .	6.2	13
1286	Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy. Journal of Translational Medicine, 2023, 21, .	4.4	2
1287	Fungal Infections Associated with CD19-Targeted Chimeric Antigen Receptor T Cell Therapy. Current Fungal Infection Reports, 0, , .	2.6	0

#	ARTICLE	IF	CITATIONS
1288	Bridging the Gap: Early Transition and Hybrid Models of Care to Improve Access to Chimeric Antigen Receptor T Cell Therapy. Transplantation and Cellular Therapy, 2023, 29, 399-402.	1.2	2
1289	Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTECâ€1 study of patients with relapsed/refractory multiple myeloma. Cancer, 2023, 129, 2035-2046.	4.1	8
1290	HBV reactivation in patients with chronic or resolved HBV infection following BCMA-targeted CAR-T cell therapy. Bone Marrow Transplantation, 0, , .	2.4	1
1291	CAR T-cell cancer therapies: do not forget the heart. European Heart Journal, 2023, 44, 2043-2045.	2.2	3
1292	Teclistamab-cqyv: The First Bispecific T-Cell Engager Antibody for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma. Journal of the Advanced Practitioner in Oncology, 2023, 14, 163-171.	0.4	2
1293	Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory study. Cardio-Oncology, 2023, 9, .	1.7	0
1294	Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors. Nature Cancer, 2023, 4, 485-501.	13.2	11
1295	CAR T-Cell therapy for the management of mantle cell lymphoma. Molecular Cancer, 2023, 22, .	19.2	11
1296	Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia. Journal of Hematology and Oncology, 2023, 16, .	17.0	12
1297	CAR T-cell-associated neurotoxicity in central nervous system hematologic disease: Is it still a concern?. Frontiers in Neurology, 0, 14, .	2.4	6
1298	Tumor inflammation-associated neurotoxicity. Nature Medicine, 2023, 29, 803-810.	30.7	19
1299	Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma. Transplantation and Cellular Therapy, 2023, 29, 440-448.	1.2	9
1300	Immunotherapy for Acute Leukemia. , 2022, , 1-41.		0
1301	Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy. Cancer Immunology Research, 2023, 11, 707-719.	3.4	7
1302	Combining post-transplant cyclophosphamide with antithymocyte globulin for graft-versus-host disease prophylaxis in hematological malignancies. Blood Reviews, 2023, 62, 101080.	5.7	8
1303	Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell malignancies. Frontiers in Immunology, 0, 14, .	4.8	7
1304	Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel)Âfor triple-class exposed relapsed/refractory multiple myeloma patients. BMC Cancer, 2023, 23, .	2.6	13
1305	Cell Therapy, Nursing Implications and Care. , 2023, , 101-122.		0

#	ARTICLE	IF	CITATIONS
1306	âœœl just wanted to speak to someone- and there was no oneâ€¦ using Burden of Treatment Theory to understand the impact of a novel ATMP on early recipients. Orphanet Journal of Rare Diseases, 2023, 18, .	2.7	1
1308	Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma. Blood Advances, 2023, 7, 4926-4935.	5.2	12
1309	Gene Targets of CAR-T Cell Therapy for Glioblastoma. Cancers, 2023, 15, 2351.	3.7	4
1310	Safety and efficacy of tisagenlecleucel in patients with relapsed or refractory B-cell lymphoma: the first real-world evidence in Japan. International Journal of Clinical Oncology, 2023, 28, 816-826.	2.2	5
1311	A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed/refractory multiple myeloma patients treated with CAR-T cells. Frontiers in Immunology, 0, 14, .	4.8	4
1312	Prospective geriatric assessment and geriatric consultation in CAR T-cell therapy for older patients with lymphoma. Blood Advances, 2023, 7, 3501-3505.	5.2	4
1313	Recapitulated Late-Onset Inflammatory Toxicities and Progressive Dysautonomia with Persistence of Central Memory CD4+ Chimeric Antigen Receptor T Cells in a Case of Transformed Follicular Lymphoma: Case Report. Acta Haematologica, 2023, 146, 338-342.	1.4	1
1314	CAR-T Therapy in Lymphoma Patients With Coexisting Cardiomyopathy or Cardiac Lymphomatous Involvement. JACC: Case Reports, 2023, 15, 101840.	0.6	0
1315	Frontal Intermittent Rhythmic Delta Activity Is a Useful Diagnostic Tool of Neurotoxicity After CAR T-Cell Infusion. Neurology: Neuroimmunology and NeuroInflammation, 2023, 10, .	6.0	2
1316	New cell sources for CAR-based immunotherapy. Biomarker Research, 2023, 11, .	6.8	7
1317	Cytomegalovirus DNAemia in haematological patients undergoing CD19-directed chimeric antigen receptor T-cell therapy: should it be systematically monitored?. Clinical Microbiology and Infection, 2023, 29, 1093-1095.	6.0	3
1318	Thrombotic Events Are Unusual Toxicities of Chimeric Antigen Receptor T-Cell Therapies. International Journal of Molecular Sciences, 2023, 24, 8349.	4.1	2
1319	Management and Prevention of Cellular-Therapy-Related Toxicity: Early and Late Complications. Current Oncology, 2023, 30, 5003-5023.	2.2	1
1320	Early versus standard management of chimeric antigen receptor therapy toxicities and management's impact on safety and efficacy. Journal of Oncology Pharmacy Practice, 2024, 30, 151-158.	0.9	0
1321	Tarlatamab: New Star on the Horizon for Small-Cell Lung Cancer?. Journal of Clinical Oncology, 2023, 41, 2877-2880.	1.6	3
1322	CAR-T Cells Therapy: What Cardiovascular Adverse Effects Should We Expect?. , 2022, 2, 404-409.		0
1323	Longitudinal patient-reported outcomes in patients receiving chimeric antigen receptor T-cell therapy. Blood Advances, 2023, 7, 3541-3550.	5.2	3
1324	Long-Term Host Immune Modulation Following Tisagenlecleucel Administration in Patients with Diffuse Large B-Cell Lymphoma and B-Lineage Acute Lymphoblastic Leukemia. Cancers, 2023, 15, 2411.	3.7	2



#	ARTICLE	IF	CITATIONS
1325	Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?. Blood Cancer Journal, 2023, 13, .	6.2	3
1326	Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies. Blood Cancer Journal, 2023, 13, .	6.2	13
1327	Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myeloma. Frontiers in Immunology, 0, 14, .	4.8	5
1328	Fatal cytokine-release syndrome in a patient receiving toripalimab: a case report. Immunotherapy, 2023, 15, 641-645.	2.0	1
1329	Current status of CAR-T cell therapy for pediatric hematologic malignancies. International Journal of Clinical Oncology, 2023, 28, 729-735.	2.2	3
1330	Thinking “outside the germinal center”: Re-educating T cells to combat follicular lymphoma. Blood Reviews, 2023, 61, 101099.	5.7	0
1331	Post CAR T-cell therapy outcomes and management in HSCT-naïve patients: a single-center experience. , 0, 2, .		1
1332	Efficacy and safety-related factors of BTK inhibitors as a bridge to CAR-T therapy in R/R FL. Annals of Hematology, 2023, 102, 1789-1799.	1.8	0
1333	Tocilizumab for Cytokine Release Syndrome Management After Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis. Transplantation and Cellular Therapy, 2023, 29, 515.e1-515.e7.	1.2	1
1335	Cytokine release syndrome and cancer immunotherapies “historical challenges and promising futures. Frontiers in Immunology, 0, 14, .	4.8	2
1336	Spontaneous resolution of “therapy-related myelodysplasia” occurred after treatment with <sc>CAR-T</sc> cells: All that glitters is not gold. International Journal of Laboratory Hematology, 2023, 45, 810-812.	1.3	1
1337	Advances in CAR-T Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Advances in Clinical Medicine, 2023, 13, 8386-8391.	0.0	0
1338	Endpoint selection and evaluation in hematology studies. Best Practice and Research in Clinical Haematology, 2023, 36, 101479.	1.7	0
1339	The clinical application of immuno-therapeutics. , 2024, , 237-288.e7.		0
1340	The major clinical components of cancer immunotherapy (modulating cell-mediated immune) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 182		
1341	A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development. Cancer Discovery, 2023, 13, 1982-1997.	9.4	12
1342	Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. Lancet Oncology, The, 2023, 24, e255-e269.	10.7	20
1343	Early granulocyte colony stimulating factor administration increases the risk of cytokine release syndrome in acute lymphoblastic leukemia patients receiving anti-CD19 chimeric antigen receptor T cell therapy. Hematological Oncology, 2023, 41, 933-941.	1.7	0



#	ARTICLE	IF	CITATIONS
1345	A Panorama of Immune Fighters Armored with CARs in Acute Myeloid Leukemia. <i>Cancers</i> , 2023, 15, 3054.	3.7	0
1346	Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2023, 389, 335-347.	27.0	78
1347	Early cytopenias and infections following chimeric antigen receptor T-Cell therapy for hematologic malignancies. <i>Leukemia and Lymphoma</i> , 0, , 1-4.	1.3	1
1348	A retrospective single-center analysis of CD-19 directed CAR T-cell therapy in relapsed/refractory mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2023, 64, 1472-1475.	1.3	1
1349	Neutralizing IFN $\gamma$ improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies. <i>Nature Communications</i> , 2023, 14, .	12.8	4
1350	CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity. , 2023, 11, e005898.		4
1351	Brain FDG-PET findings in chimeric antigen receptor T-cell therapy neurotoxicity for diffuse large B-cell lymphoma. <i>Journal of Neuroimaging</i> , 2023, 33, 825-836.	2.0	2
1352	Chimeric Antigen Receptor T-Cell Therapy and Imaging Applications for Large B-Cell Lymphoma. <i>Radiology</i> , 2023, 307, .	7.3	1
1353	CAR-NK Cells Targeting HER1 (EGFR) Show Efficient Anti-Tumor Activity against Head and Neck Squamous Cell Carcinoma (HNSCC). <i>Cancers</i> , 2023, 15, 3169.	3.7	2
1354	CAR T-Cell Therapy and Critical Care Considerations. , 2023, , 427-435.		0
1355	The Role of Chimeric Antigen Receptor T-Cell Therapy in the Era of Bispecific Antibodies. <i>Hematology/Oncology Clinics of North America</i> , 2023, 37, 1201-1214.	2.2	2
1356	Validation of a High-Sensitivity Assay for Detection of Chimeric Antigen Receptor T-Cell Vectors Using Low-Partition Digital PCR Technology. <i>Journal of Molecular Diagnostics</i> , 2023, , .	2.8	0
1357	CAR-T cells neurotoxicity from consolidated practice in hematological malignancies to fledgling experience in CNS tumors: fill the gap. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	2
1358	Neuroimaging of complications arising after CD19 chimeric antigen receptor T-cell therapy: A review. <i>Journal of Neuroimaging</i> , 2023, 33, 703-715.	2.0	2
1359	Donor-derived CD19 CAR-T Cells versus Chemotherapy Plus Donor Lymphocyte Infusion for Treatment of Recurrent CD19-positive B-ALL After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Current Medical Science</i> , 2023, 43, 733-740.	1.8	2
1360	CD4+ CAR T-cell expansion is associated with response and therapy related toxicities in patients with B-cell lymphomas. <i>Bone Marrow Transplantation</i> , 0, , .	2.4	0
1361	Effectiveness and safety of anti-BCMA chimeric antigen receptor T-cell treatment in relapsed/refractory multiple myeloma: a comprehensive review and meta-analysis of prospective clinical trials. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	2
1362	Idecabtagene Vicleucel Is Well Tolerated and Effective in Relapsed/Refractory Myeloma Patients with Prior Allogeneic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 609.e1-609.e6.	1.2	3

#	ARTICLE	IF	CITATIONS
1363	Neurologic Complications of Cancer Immunotherapy. Current Oncology, 2023, 30, 5876-5897.	2.2	0
1364	Early and Late Toxicities of Chimeric Antigen Receptor T-Cells. Hematology/Oncology Clinics of North America, 2023, , .	2.2	0
1365	Infections occurring following IL6 blockade for the management of cytokine release syndrome in onco-hematology patients. Cancer Chemotherapy and Pharmacology, 0, , .	2.3	0
1366	Acute Lymphoblastic Leukemia Immunotherapy Treatment: Now, Next, and Beyond. Cancers, 2023, 15, 3346.	3.7	2
1367	Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer. Frontiers in Immunology, 0, 14, .	4.8	0
1368	Restrictive versus permissive use of broad-spectrum antibiotics in patients receiving allogeneic SCT and early fever due to cytokine release syndrome: Evidence for beneficial microbiota protection without increase of infectious complications. Clinical Infectious Diseases, 0, , .	5.8	0
1369	Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel Recipients for B Cell Non-Hodgkin Lymphoma. Transplantation and Cellular Therapy, 2023, 29, 449.e1-449.e7.	1.2	5
1370	<scp>Realâ€world</scp> evidence of the safety and survival with <scp>CD19 CARâ€T</scp> cell therapy for relapsed/refractory solid organ <scp>transplantâ€related PTLD</scp>. British Journal of Haematology, 2023, 202, 248-255.	2.5	6
1371	Chimeric Antigen Receptor T-Cell Therapy in Acute Lymphoblastic Leukemia. , 2024, , 233-245.		0
1372	Neurologic Complications of Chimeric Antigen Receptor Therapy. , 2024, , 525-536.		0
1373	Pharmacology of Drugs Used in Hematopoietic Cell Transplant and Chimeric Antigen Receptor Therapies. , 2024, , 145-165.		0
1374	Pre-existing frontal lobe dysfunction signs as predictors of subsequent neurotoxicity in CAR T cell therapy: insights from a case series. Neurological Sciences, 0, , .	1.9	1
1375	Cytokine Release Syndrome Following CD19 Directed Chimeric Antigen Receptor T-Cell Therapy. , 2024, , 509-524.		0
1376	Process and General Management of Patients Undergoing Chimeric Antigen Receptor Therapies. , 2024, , 115-122.		0
1377	Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer. Cancer Immunology Research, 2023, 11, 925-945.	3.4	3
1378	KymriahÂ® (tisagenlecleucel) â€“ An overview of the clinical development journey of the first approved CAR-T therapy. Human Vaccines and Immunotherapeutics, 2023, 19, .	3.3	5
1379	T-Cell Engagers in Solid Cancersâ€“Current Landscape and Future Directions. Cancers, 2023, 15, 2824.	3.7	2
1380	An updated overview of the application of <scp>CARâ€T</scp> cell therapy in neurological diseases. Biotechnology Progress, 2023, 39, .	2.6	1

#	ARTICLE	IF	CITATIONS
1382	Novel insights into cancer stem cells targeting: CAR-T therapy and epigenetic drugs as new pillars in cancer treatment. <i>Frontiers in Molecular Medicine</i> , 0, 3, .	1.9	0
1383	Safety and efficacy of CRISPR-based non-viral PD1 locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin's lymphoma: a first-in-human phase I study. <i>EClinicalMedicine</i> , 2023, 60, 102010.	7.1	8
1384	Granulocyte transfusion during cord blood transplant for relapsed, refractory <scp>AML</scp> is associated with massive <scp>CD8</scp><sup>+</sup> Tâ€cell expansion, significant cytokine release syndrome and induction of disease remission. <i>British Journal of Haematology</i> , 2023, 202, 589-598.	2.5	2
1385	Cytokine release syndrome in haploidentical stem cell transplant may impact T-cell recovery and relapse. <i>Blood Advances</i> , 2023, 7, 4080-4088.	5.2	1
1386	Recovery-model: A model for CAR T-cell-related thrombocytopenia in relapsed/refractory multiple myeloma. <i>Thrombosis Research</i> , 2023, 227, 62-70.	1.7	0
1387	Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 567-571.	1.2	9
1388	Efficacy and safety of chimeric antigen receptor T cell therapy in relapsed/refractory diffuse large B-cell lymphoma with different HBV status: a retrospective study from a single center. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
1389	Intensity of Cyclophosphamide-Based Bridging Therapy Before Chimeric Antigen Receptor T Cell Therapy in Myeloma. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 504.e1-504.e7.	1.2	2
1390	Cardiotoxicity of Targeted Therapies in Children with Haematological Malignancies and Solid Tumors. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2023, 23, 1702-1709.	1.7	0
1391	Prognostic value of early positron emission tomography in patients with large B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapy. <i>Haematologica</i> , 2023, 108, 3433-3437.	3.5	1
1392	T-cell-engaging bispecific antibodies in cancer. <i>Lancet, The</i> , 2023, 402, 142-158.	13.7	27
1393	Targeting the Interplay of Independent Cellular Pathways and Immunity: A Challenge in Cancer Immunotherapy. <i>Cancers</i> , 2023, 15, 3009.	3.7	2
1394	Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma. <i>Blood Advances</i> , 2023, 7, 4247-4257.	5.2	3
1396	Sepsis and Adrenal Insufficiency. <i>Journal of Intensive Care Medicine</i> , 2023, 38, 987-996.	2.8	2
1397	Cell Therapy Informatics: Updates on the Integration of HCT/IEC Functionalities into an Electronic Medical Record System in the US to Promote Efficiency, Patient Safety, Research, and Data Interoperability. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 539-547.	1.2	1
1398	Dose-escalation part of Phase I study of single-agent mosunetuzumab in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma. <i>Japanese Journal of Clinical Oncology</i> , 0, , .	1.3	1
1399	Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies. <i>Clinical Cancer Research</i> , 2023, 29, 4449-4463.	7.0	4
1401	A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma. <i>Blood Advances</i> , 2023, 7, 6785-6789.	5.2	5

#	ARTICLE	IF	CITATIONS
1402	Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure. Transplantation and Cellular Therapy, 2023, 29, 574.e1-574.e10.	1.2	2
1403	Immune-based Therapies—What the Emergency Physician Needs to Know. Immunology and Allergy Clinics of North America, 2023, 43, 569-582.	1.9	0
1404	Negative Prognostic Impact of High-Dose or Long-Term Corticosteroid Use in Patients with Relapsed or Refractory B-Cell Lymphoma Who Received Tisagenlecleucel. Transplantation and Cellular Therapy, 2023, 29, 573.e1-573.e8.	1.2	1
1405	Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study. Lancet Oncology, The, 2023, 24, 913-924.	10.7	13
1406	Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management. Current Oncology, 2023, 30, 6330-6352.	2.2	2
1407	Development of a radiomic-clinical nomogram for prediction of survival in patients with diffuse large B-cell lymphoma treated with chimeric antigen receptor T cells. Journal of Cancer Research and Clinical Oncology, 2023, 149, 11549-11560.	2.5	1
1408	CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results. Nature Medicine, 2023, 29, 1710-1717.	30.7	15
1409	A phase 2 trial of defibrotide for the prevention of chimeric antigen receptor T-cell-associated neurotoxicity syndrome. Blood Advances, 2023, 7, 6790-6799.	5.2	3
1410	Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter Study. Cancers, 2023, 15, 3430.	3.7	4
1411	Î³-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial. Lancet Oncology, The, 2023, 24, 811-822.	10.7	15
1412	Clinical Advances in CAR T Cell Therapies for the Patients with Multiple Myeloma. Advances in Clinical Medicine, 2023, 13, 10568-10573.	0.0	0
1413	Neurotoxicity and management of primary and secondary CNS lymphoma after adoptive immunotherapy with CD19-directed CAR T-cells. Neuro-Oncology, 0, , .	1.2	2
1414	FDA Approval Summary: Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma. Clinical Cancer Research, 2023, 29, 4331-4337.	7.0	4
1415	Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies: A Practical Review. JCO Oncology Practice, 2023, 19, 706-713.	2.9	4
1417	Donor-derived CAR-T therapy improves the survival of relapsed B-ALL after allogeneic transplantation compared with donor lymphocyte infusion. Human Cell, 0, , .	2.7	0
1418	Blinatumomab as salvage therapy in patients with relapsed/refractory B-ALL who have failed/progressed after anti-CD19-CAR T therapy. Annals of Medicine, 2023, 55, .	3.8	1
1419	Supportive care for chimeric antigen receptor T-cell patients. Current Opinion in Supportive and Palliative Care, 2023, 17, 231-239.	1.3	0
1420	Uveal melanoma: In the era of new treatments. Cancer Treatment Reviews, 2023, 119, 102599.	7.7	2

#	ARTICLE	IF	CITATIONS
1421	Knowledge Gaps in Generating Cell-Based Drug Delivery Systems and a Possible Meeting with Artificial Intelligence. <i>Molecular Pharmaceutics</i> , 2023, 20, 3757-3778.	4.6	5
1422	Noninfectious causes of fever in hematologic malignancies. Are antibiotics still indicated?. <i>Current Opinion in Infectious Diseases</i> , 2023, 36, 209-217.	3.1	0
1423	Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use. <i>HemaSphere</i> , 2023, 7, e907.	2.7	3
1424	Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp. <i>European Journal of Cancer</i> , 2023, 191, 112986.	2.8	1
1425	Immunotherapy for Meningiomas. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 225-234.	1.6	0
1426	Elranatamab: a new promising BispAb in multiple myeloma treatment. <i>Expert Review of Anticancer Therapy</i> , 2023, 23, 775-782.	2.4	3
1427	Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST study. <i>Blood Advances</i> , 2023, 7, 5316-5319.	5.2	4
1428	Limited utility of chimeric antigen receptor (CAR) T-cell retreatment: experience with a human anti-CD19 CAR. <i>Bone Marrow Transplantation</i> , 0, , .	2.4	0
1429	Chemotherapy-induced reversal of ciltacabtagene autoleucelâ€“associated movement and neurocognitive toxicity. <i>Blood</i> , 2023, 142, 1248-1252.	1.4	6
1430	INSPIRED Symposium Part 1: Clinical Variables Associated with Improved Outcomes for Children and Young Adults treated with Chimeric Antigen Receptor T cells for B cell Acute Lymphoblastic Leukemia. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 598-607.	1.2	2
1431	Fever, Cognitive Decline, and Multifocal T2 Hyperintensities on Brain MRI: A Case Report of Cytokine Release Syndrome. <i>Cureus</i> , 2023, , .	0.5	0
1432	A distinct cytokine network distinguishes chimeric antigen receptor T cell (CAR-T)â€“associated hemophagocytic lymphohistiocytosis-like toxicity (carHLH) from severe cytokine release syndrome following CAR-T therapy. <i>Cytotherapy</i> , 2023, 25, 1167-1175.	0.7	0
1433	Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial. <i>Journal of Hematology and Oncology</i> , 2023, 16, .	17.0	6
1434	The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). <i>Annals of the Rheumatic Diseases</i> , 2023, 82, 1271-1285.	0.9	10
1435	The 2022 <sc>EULAR</sc>/<sc>ACR</sc> Points to Consider at the Early Stages of Diagnosis and Management of Suspected Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (<sc>HLH</sc>/<sc>MAS</sc>). <i>Arthritis and Rheumatology</i> , 2023, 75, 1714-1732.	5.6	2
1436	Construction of CD19 targeted dual- and enhanced dual-antibodies and their efficiency in the treatment of B cell malignancy. <i>Experimental Hematology and Oncology</i> , 2023, 12, .	5.0	3
1437	CAR-T State of the Art and Future Challenges, A Regulatory Perspective. <i>International Journal of Molecular Sciences</i> , 2023, 24, 11803.	4.1	4
1438	Respiratory infections predominate after day 100 following B-cell maturation antigenâ€“directed CAR T-cell therapy. <i>Blood Advances</i> , 2023, 7, 5485-5495.	5.2	2

#	ARTICLE	IF	CITATIONS
1439	A comprehensive analysis of adverse events in the first 30 days of phase 1 pediatric CAR T-cell trials. Blood Advances, 2023, 7, 5566-5578.	5.2	1
1440	Quantifying the available capacity and resource needs for provision of CAR-T therapies in the National Health Service in Spain: a survey-based study. BMJ Open, 2023, 13, e071371.	1.9	0
1441	The nutritional impact of CD19-targeted CAR-T therapy versus BEAM chemotherapy for adult patients with lymphoma. Journal of Human Nutrition and Dietetics, 2023, 36, 2099-2107.	2.5	1
1442	The Potential Role of Immunotherapy in Wilms' Tumor: Opportunities and Challenges. Current Pharmaceutical Design, 2023, 29, 1617-1627.	1.9	2
1443	The Current State of Chimeric Antigen Receptor T Cell Therapy for B Lymphoblastic Leukemia. Hematology/Oncology Clinics of North America, 2023, 37, 1041-1052.	2.2	1
1444	Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results. Nature Medicine, 2023, 29, 2099-2109.	30.7	8
1445	A Modern-Day Chimera. , 2023, , 139-145.		0
1446	Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma. Future Oncology, 2023, 19, 2297-2311.	2.4	2
1447	Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era. Experimental Hematology and Oncology, 2023, 12, .	5.0	1
1448	IL-6 translation is a therapeutic target of human cytokine release syndrome. Journal of Experimental Medicine, 2023, 220, .	8.5	2
1449	Complexities in comparing the impact of costimulatory domains on approved CD19 CAR functionality. Journal of Translational Medicine, 2023, 21, .	4.4	2
1450	The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma. Journal of Hematology and Oncology, 2023, 16, .	17.0	11
1451	Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma. Blood Advances, 2023, 7, 5579-5585.	5.2	4
1452	Short-course blinatumomab for refractory/relapse precursor B acute lymphoblastic leukemia in children. Frontiers in Pediatrics, 0, 11, .	1.9	0
1453	The risk factors for coagulation disorder of chimeric antigen receptor-T cell therapy in patients with hematological tumors: A systematic review and meta-analysis. Technology and Health Care, 2023, , 1-18.	1.2	0
1454	Automated detection of immune effector cell-associated neurotoxicity syndrome via quantitative EEG. Annals of Clinical and Translational Neurology, 0, , .	3.7	0
1455	A Predictive Model of Severe Cytokine Release Syndrome After Coadministration of CD19- and CD22-Chimeric Antigen Receptor T-Cell Therapy in Children With B-Cell Hematological Malignancies Based on Patient-Reported Outcomes. Cancer Nursing, 0, , .	1.5	0
1456	Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer Journal, 2023, 13, .	6.2	14



#	ARTICLE	IF	CITATIONS
1457	Predictive Factors of Response to Immunotherapy in Lymphomas: A Multicentre Clinical Data Warehouse Study (PRONOSTIM). <i>Cancers</i> , 2023, 15, 4028.	3.7	0
1458	Point-of-care anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2023, 64, 1956-1963.	1.3	1
1460	Neurological adverse effects of chimeric antigen receptor T-cell therapy. <i>Expert Review of Clinical Immunology</i> , 2023, 19, 1361-1383.	3.0	3
1461	Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. <i>Nature Medicine</i> , 2023, 29, 2259-2267.	30.7	54
1462	Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study. <i>Blood Advances</i> , 2023, 7, 6055-6065.	5.2	2
1463	Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T <sup>+</sup> cells in HLA-A*02:01 patients with advanced soft tissue sarcoma. <i>Cell Reports Medicine</i> , 2023, 4, 101133.	6.5	6
1464	Prolonged cytopenia following CD19 CAR T <sup>+</sup> cell therapy is linked with bone marrow infiltration of clonally expanded IFN $\gamma$ -expressing CD8 T <sup>+</sup> cells. <i>Cell Reports Medicine</i> , 2023, 4, 101158.	6.5	4
1465	Clinical efficacy and safety of chimeric antigen receptor T <sup>+</sup> cell therapy for mantle cell lymphoma with secondary central nervous system involvement. <i>British Journal of Haematology</i> , 2023, 203, 774-780.	2.5	3
1466	Novel Cellular and Immunotherapy: Toxicities and Perioperative Implications. <i>Current Oncology</i> , 2023, 30, 7638-7653.	2.2	0
1467	A major role for CD4 <sup>+</sup> T <sup>+</sup> cells in driving cytokine release syndrome during CAR T <sup>+</sup> cell therapy. <i>Cell Reports Medicine</i> , 2023, , 101161.	6.5	1
1468	Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	17.1	5
1469	The CAR <sup>+</sup> HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL. <i>American Journal of Hematology</i> , 2023, 98, 1699-1710.	4.1	1
1470	Chimeric antigen receptor-modified T cells therapy in prostate cancer: A comprehensive review on the current state and prospects. <i>Heliyon</i> , 2023, 9, e19147.	3.2	2
1471	Cancer immunotherapies: advances and bottlenecks. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	9
1472	Update on Immunotherapy Cardiotoxicity: Checkpoint Inhibitors, CAR T, and Beyond. <i>Current Treatment Options in Oncology</i> , 0, , .	3.0	0
1473	Significance of alkaline Phosphatase After Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2023, 23, 911-916.	0.4	0
1474	Outpatient CD19 <sup>+</sup> -directed CAR <sup>+</sup> T <sup>+</sup> cell therapy is feasible in patients of all ages. <i>British Journal of Haematology</i> , 2023, 203, 688-692.	2.5	3
1475	The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands. <i>Cancers</i> , 2023, 15, 4334.	3.7	2



#	ARTICLE	IF	CITATIONS
1476	RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trial. <i>EClinicalMedicine</i> , 2023, 63, 102175.	7.1	3
1477	CD19/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL. <i>Blood</i> , 2024, 143, 118-123.	1.4	6
1478	Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia. <i>Blood Advances</i> , 2023, 7, 6492-6505.	5.2	2
1479	Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T Cell Therapy Efficacy in Aggressive B Lymphoma: A Real-World GELTAMO/GETH Study. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 747.e1-747.e10.	1.2	2
1480	Exploring CAR-T Cell Therapy Side Effects: Mechanisms and Management Strategies. <i>Journal of Clinical Medicine</i> , 2023, 12, 6124.	2.4	1
1481	How can Cytokine-induced killer cells overcome CAR-T cell limits. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
1482	Modulation of Radiation Doses and Chimeric Antigen Receptor T Cells: A Promising New Weapon in Solid Tumors—A Narrative Review. <i>Journal of Personalized Medicine</i> , 2023, 13, 1261.	2.5	1
1483	A Pharmacovigilance Study on the Safety of Axicabtagene Ciloleucel Based on Spontaneous Reports from the EudraVigilance Database. <i>Biomedicines</i> , 2023, 11, 2162.	3.2	0
1484	Management of Adverse Reactions for BCMA-Directed Therapy in Relapsed Multiple Myeloma: A Focused Review. <i>Journal of Clinical Medicine</i> , 2023, 12, 5539.	2.4	1
1485	Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial. <i>Nature Medicine</i> , 2023, 29, 2593-2601.	30.7	8
1486	Suppression of cytokine release syndrome during CAR-T-cell therapy via a subcutaneously injected interleukin-6-adsorbing hydrogel. <i>Nature Biomedical Engineering</i> , 2023, 7, 1129-1141.	22.5	7
1487	Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. <i>Nature Medicine</i> , 2023, 29, 2570-2576.	30.7	10
1488	A brief overview of SARS-CoV-2 infection and its management strategies: a recent update. <i>Molecular and Cellular Biochemistry</i> , 0, , .	3.1	2
1489	CD19-targeted chimeric antigen receptor T-cell therapy in patients with concurrent B-cell Non-Hodgkin lymphoma and rheumatic autoimmune diseases: a propensity score matching study. <i>Bone Marrow Transplantation</i> , 2023, 58, 1223-1228.	2.4	3
1490	CAR T-Cells in Acute Lymphoblastic Leukemia: Current Status and Future Prospects. <i>Biomedicines</i> , 2023, 11, 2693.	3.2	0
1491	Bispecific Antibodies in Hematological Malignancies: A Scoping Review. <i>Cancers</i> , 2023, 15, 4550.	3.7	2
1492	Revolutionizing cancer treatment: a comprehensive review of CAR-T cell therapy. , 2023, 40, .		3
1493	Infections after chimeric antigen receptor (CAR)â€”Tâ€”cell therapy for hematologic malignancies. <i>Transplant Infectious Disease</i> , 2023, 25, .	1.7	5

#	ARTICLE	IF	CITATIONS
1494	Infectious complications of car T-cell therapy: A longitudinal risk model. Transplant Infectious Disease, 0, , .	1.7	0
1495	Nursing Care Throughout the Chimeric Antigen Receptor T-Cell Therapy Process for Multiple Myeloma. Seminars in Oncology Nursing, 2023, 39, 151505.	1.5	0
1496	Longitudinal Serum Proteomics Characterization of CD19-CAR-T Cell Therapy for B-Cell Malignancies. Journal of Proteome Research, 2023, 22, 2985-2994.	3.7	0
1497	Autoimmune Limbic Encephalitis in Patients with Hematologic Malignancies after Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide. Cells, 2023, 12, 2049.	4.1	1
1498	Cardiovascular Magnetic Resonance Assessment of Immunotherapy Cardiotoxicity. Current Cardiovascular Imaging Reports, 0, , .	0.6	0
1499	Chimeric antigen receptor T-cell immunotherapies adverse events reported to FAERS database: focus on cytopenias. Leukemia and Lymphoma, 2023, 64, 2071-2080.	1.3	0
1500	Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies. Journal of Biomedical Science, 2023, 30, .	7.0	0
1501	BCMA-targeting chimeric antigen receptor T cell therapy for relapsed and/or refractory multiple myeloma. Annals of Hematology, 0, , .	1.8	1
1502	An <i>In Vitro</i> Model to Assess CRS Potential of CAR T Cells Using a Tumor Cell Line and Autologous Monocytes. Current Protocols, 2023, 3, .	2.9	1
1503	CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nature Medicine, 2023, 29, 2844-2853.	30.7	9
1504	Patient-reported outcome (PRO) instruments used in patients undergoing adoptive cell therapy (ACT) for the treatment of cancer: a systematic review. Systematic Reviews, 2023, 12, .	5.3	0
1505	Abnormal bone marrow findings in patients following treatment with chimeric antigen receptorâ€”T cell therapy. European Journal of Haematology, 2024, 112, 111-121.	2.2	1
1506	Risk factors and outcome of Chimeric Antigen Receptor T-Cell patients admitted to Pediatric Intensive Care Unit: CART-PICU study. Frontiers in Immunology, 0, 14, .	4.8	0
1507	Nursing Management in Pediatric Patients Undergoing Chimeric Antigen Receptor T (CAR-T) Cell Therapy: A Systematic Literature Review. Seminars in Oncology Nursing, 2023, 39, 151478.	1.5	0
1508	Chimeric antigen receptor T-cell treatment patterns in relapsed or refractory large B-cell lymphoma. Future Oncology, 2023, 19, 1535-1547.	2.4	0
1509	Second Chances. , 2023, , 129-144.		0
1510	Molecular and Clinical Characteristics of Different Toxicity Rates in Anti-CD19 Chimeric Antigen Receptor T Cells: Real-World Experience. Cancers, 2023, 15, 4253.	3.7	0
1511	CD19-Targeted Chimeric Antigen Receptor T-cell Therapy for Concomitant Diffuse Large B-cell Lymphoma and Multiple Myeloma. Cureus, 2023, , .	0.5	0

#	ARTICLE	IF	CITATIONS
1513	Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphoma. American Journal of Hematology, 2023, 98, 1751-1761.	4.1	5
1514	HLA Fully-Mismatched Sibling-Derived CD7 CAR-T Therapy Bridging to Haploidentical Hematopoietic Stem Cell Transplantation for Hepatosplenic T-cell Lymphoma. Cell Transplantation, 2023, 32, .	2.5	3
1515	Effectiveness and safety of <scp>CD22</scp> and <scp>CD19</scp> dual-targeting chimeric antigen receptor T-cell therapy in patients with relapsed or refractory B-cell malignancies: A meta-analysis. Cancer Medicine, 2023, 12, 18767-18785.	2.8	0
1516	CD7 targeted "off-the-shelf" CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies. Leukemia, 2023, 37, 2176-2186.	7.2	3
1517	PET-based radiomics signature can predict durable responses to CAR T-cell therapy in patients with large B-cell lymphoma. EJHaem, 2023, 4, 1081-1088.	1.0	0
1518	Use of locally produced anti-CD19 CAR-T cells in the treatment of relapsed/refractory B-cell lymphomas in adults. Oncogematologiya, 2023, 18, 26-34.	0.3	0
1519	Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL. Clinical Lymphoma, Myeloma and Leukemia, 2023, , .	0.4	1
1520	Baseline [18F]FDG PET features are associated with survival and toxicity in patients treated with CAR T cells for large B cell lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 0, , .	6.4	0
1521	New Biological Therapies for Multiple Myeloma. Annual Review of Medicine, 2024, 75, .	12.2	0
1522	Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment. Haematologica, 2024, 109, 777-786.	3.5	2
1525	Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion. Science Advances, 2023, 9, .	10.3	1
1526	Immune-Cell-Mediated Cancer Treatment: Advantages, Drawbacks And Future Direction. Journal of Experimental Biology and Agricultural Sciences, 2023, 11, 625-639.	0.4	0
1527	Analysis of 60 patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with <scp>CD7</scp>-targeted chimeric antigen receptor T cell therapy. American Journal of Hematology, 2023, 98, 1898-1908.	4.1	2
1528	Early quantification of anti-CD19 CAR T-cells by flow cytometry predicts response in R/R DLBCL. Blood Advances, 0, , .	5.2	0
1529	Patient-Reported Outcomes among Multiple Myeloma Patients Treated with Standard of Care Idecabtagene Vicleucel. Cancers, 2023, 15, 4711.	3.7	2
1530	IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies. Blood Cancer Discovery, 2023, 4, 440-451.	5.0	8
1531	Tislelizumab augment the efficacy of CD19/22 dual-targeted chimeric antigen receptor T cell in advanced stage relapsed or refractory B-cell non-Hodgkin lymphoma. Hematological Oncology, 2024, 42, .	1.7	1
1532	Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients. HemaSphere, 2023, 7, e957.	2.7	2

#	ARTICLE	IF	CITATIONS
1533	Childhood Acute Lymphoblastic Leukemia. , 2023, , .		0
1534	Evolution and synthetic biology. Current Opinion in Microbiology, 2023, 76, 102394.	5.1	1
1535	Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial. Clinical Cancer Research, 2023, 29, 5069-5078.	7.0	1
1537	Recent advancement in targeted therapy and role of emerging technologies to treat cancer. , 2023, 40, .		2
1538	IL-10 plus the EASIX score predict bleeding events after anti-CD19 CAR T-cell therapy. Annals of Hematology, 0, , .	1.8	0
1539	Understanding the Role of Bispecific Antibodies in the Management of B-Cell Non-Hodgkin Lymphoma: A New Immunotherapy That Is Here to Stay. , 2023, 1, 244-256.		0
1540	Cerebral Spinal Fluid Parameters Following CD19-Targeted Therapies in Children and Young Adults. Journal of Pediatric Hematology/Oncology, 0, , .	0.6	0
1541	Incidence of MACE in Patients Treated With CAR-T Cell Therapy. JACC: CardioOncology, 2023, , .	4.0	0
1542	INSPIRED Symposium Part 3: Prevention and Management of Pediatric Chimeric Antigen Receptor T Cell-Associated Emergent Toxicities. Transplantation and Cellular Therapy, 2024, 30, 38-55.	1.2	1
1543	Cognition following chimeric antigen receptor T-cell therapy: A systematic review. Journal of Autoimmunity, 2023, 140, 103126.	6.5	0
1544	Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma. Blood Cancer Journal, 2023, 13, .	6.2	3
1545	Enhancing cord blood stem cell-derived NK cell growth and differentiation through hyperosmosis. Stem Cell Research and Therapy, 2023, 14, .	5.5	1
1546	Outcomes of Second Anti-CD19 CAR T-Cell Therapy (CART2) in Acute B Lymphoblastic Leukemia and the Impact of Allo-HSCT on Efficacy. Cell Transplantation, 2023, 32, .	2.5	1
1547	Development of bispecific T cell engagers: harnessing quantitative systems pharmacology. Trends in Pharmacological Sciences, 2023, , .	8.7	0
1548	Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma. Leukemia, 2024, 38, 149-159.	7.2	3
1550	INSPIRED Symposium Part 4B: Chimeric Antigen Receptor T Cell Correlative Studiesâ€”Established Findings and Future Priorities. Transplantation and Cellular Therapy, 2024, 30, 155-170.	1.2	0
1551	Predictive value of pre-infusion tumor growth rate for the occurrence and severity of CRS and ICANS in lymphoma under CAR T-cell therapy. Annals of Hematology, 0, , .	1.8	0
1552	Toxicities of CAR T-cell therapy: a review of current literature. Annals of Medicine and Surgery, 0, , .	1.1	0

#	ARTICLE	IF	CITATIONS
1553	Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2023, 389, 2063-2075.	27.0	15
1554	Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma. <i>New England Journal of Medicine</i> , 2023, 389, 2256-2266.	27.0	11
1555	Advancing the frontiers of adaptive cell therapy: A transformative mechanistic journey from preclinical to clinical settings. <i>International Immunopharmacology</i> , 2023, 125, 111095.	3.8	0
1556	Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy. <i>Journal of Clinical Oncology</i> , 2024, 42, 205-217.	1.6	5
1557	Functional connectivity MRI provides an imaging correlate for CAR T cell associated neurotoxicity. <i>Neuro-Oncology Advances</i> , 0, , .	0.7	0
1558	T-Cell Engaging Antibodies in Diffuse Large B Cell Lymphoma—An Update. <i>Journal of Clinical Medicine</i> , 2023, 12, 6737.	2.4	0
1559	Infection epidemiology in relation to different therapy phases in patients with haematological malignancies receiving <sc>CAR</sc> Tâ€cell therapy. <i>European Journal of Haematology</i> , 2024, 112, 371-378.	2.2	0
1560	CAR-T Cell Therapy: From the Shop to Cancer Therapy. <i>International Journal of Molecular Sciences</i> , 2023, 24, 15688.	4.1	4
1561	Role of the microbiota in response to and recovery from cancer therapy. <i>Nature Reviews Immunology</i> , 0, , .	22.7	4
1562	The academic pointâ€ofâ€care <sc>antiâ€CD19</sc> chimeric antigen receptor Tâ€cell product varnimcabtagene autoleucel (<sc>ARI</sc>â€0001 cells) shows efficacy and safety in the treatment of relapsed/refractory Bâ€cell <sc>nonâ€Hodgkin</sc> lymphoma. <i>British Journal of Haematology</i> , 2024, 204, 525-533.	2.5	1
1563	Neurotoxicity of Cancer Immunotherapies Including CAR T Cell Therapy. <i>Current Neurology and Neuroscience Reports</i> , 0, , .	4.2	0
1564	Intrathecal hydrocortisone for treatment of children and young adults with CAR Tâ€cell immuneâ€effector cellâ€associated neurotoxicity syndrome. <i>Pediatric Blood and Cancer</i> , 2024, 71, .	1.5	0
1565	Insights gained from single-cell analysis of chimeric antigen receptor T-cell immunotherapy in cancer. <i>Military Medical Research</i> , 2023, 10, .	3.4	0
1566	Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future. <i>International Journal of Molecular Sciences</i> , 2023, 24, 15674.	4.1	1
1567	Population-Based External Validation of the EASIX Scores to Predict CAR T-Cell-Related Toxicities. <i>Cancers</i> , 2023, 15, 5443.	3.7	0
1568	Cytokine release syndrome was an independent risk factor associated with hypoalbuminemia for patients with relapsed/refractory hematological malignancies after CAR-T cell therapy. <i>BMC Cancer</i> , 2023, 23, .	2.6	0
1569	A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma. <i>Expert Opinion on Drug Safety</i> , 2023, 22, 1049-1071.	2.4	0
1570	Hormetic and synergistic effects of cancer treatments revealed by modelling combinations of radio - or chemotherapy with immunotherapy. <i>BMC Cancer</i> , 2023, 23, .	2.6	1

#	ARTICLE	IF	CITATIONS
1571	A Primer on Chimeric Antigen Receptor T-cell Therapy-related Toxicities for the Intensivist. Journal of Intensive Care Medicine, 0, , .	2.8	0
1572	Chimeric antigen receptor T cell therapy: a new emerging landscape in autoimmune rheumatic diseases. Rheumatology, 0, , .	1.9	1
1573	The Role of Antibody-Based Therapies in Neuro-Oncology. Antibodies, 2023, 12, 74.	2.5	0
1574	Mosunetuzumab and the emerging role of T-cell-engaging therapy in follicular lymphoma. Future Oncology, 2023, 19, 2083-2101.	2.4	0
1575	Torque Teno Virus plasma DNA load: a novel prognostic biomarker in CAR-T therapy. Bone Marrow Transplantation, 2024, 59, 93-100.	2.4	1
1576	The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors. Biomarker Research, 2023, 11, .	6.8	1
1577	Building safety into CAR-T therapy. Human Vaccines and Immunotherapeutics, 2023, 19, .	3.3	1
1578	Long-term analysis of cellular immunity in patients with RRMM treated with CAR-T cell therapy. Clinical and Experimental Medicine, 2023, 23, 5241-5254.	3.6	0
1579	CAR-T cell therapy: Where are we now, and where are we heading?. Blood Science, 2023, 5, 237-248.	0.9	0
1580	Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large <sc>Bâ€cell</sc> lymphoma. Cancer Science, 2023, 114, 4643-4653.	3.9	0
1581	Successful treatment of ultra-high-risk refractory multiple myeloma with anti-BCMA CAR-T therapy followed by allogeneic hematopoietic stem cell transplantation: a case report. , 2023, 2, .		0
1582	Cell-Based Models of â€Cytokine Release Syndromeâ€™™ Endorse CD40L and Granulocyteâ€™Macrophage Colony-Stimulating Factor Knockout in Chimeric Antigen Receptor T Cells as Mitigation Strategy. Cells, 2023, 12, 2581.	4.1	1
1583	Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial. Blood Advances, 2024, 8, 802-814.	5.2	1
1585	Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Transplantation and Cellular Therapy, 2024, 30, 131-142.	1.2	1
1586	Incorporating radiation with antiâ€™CD19 chimeric antigen receptor Tâ€™cell therapy for relapsed/refractory nonâ€™Hodgkin lymphoma: A multicenter consensus approach. American Journal of Hematology, 2024, 99, 124-134.	4.1	1
1587	A novel two-step administration of XPO-1 inhibitor may enhance the effect of anti-BCMA CAR-T in relapsed/refractory extramedullary multiple myeloma. Journal of Translational Medicine, 2023, 21, .	4.4	0
1588	Cytomegalovirus (CMV) Reactivation and CMV-Specific Cell-Mediated Immunity After Chimeric Antigen Receptor T-Cell Therapy. Clinical Infectious Diseases, 0, , .	5.8	2
1589	Opportunistic Infections in Patients Receiving Post-Transplantation Cyclophosphamide: Impact of Haploidentical versus Unrelated Donor Allograft. Transplantation and Cellular Therapy, 2024, 30, 233.e1-233.e14.	1.2	1



#	ARTICLE	IF	CITATIONS
1590	Effectiveness of inÂvivo Tâ€cellâ€depleted regimen containing porcine antiâ€lymphocyte globulin or rabbit antiâ€thymocyte globulin in preventing acute graftâ€versusâ€host disease after haploidentical haematopoietic stem cell transplantation. British Journal of Haematology, 2024, 204, 283-291.	2.5	0
1591	Important Considerations in the Intensive Care Management of Acute Leukemias. Journal of Intensive Care Medicine, 2024, 39, 291-305.	2.8	0
1592	BCMA CAR-T cells in multiple myelomaâ€“ready for take-off?. Leukemia and Lymphoma, 2024, 65, 143-157.	1.3	2
1593	Cellular Therapies: A Description of the Types of Existing Cellular Therapies and Associated Toxicities. , 2023, , 55-67.		0
1594	Forks in the road for CAR T and CAR NK cell cancer therapies. Nature Immunology, 2023, 24, 1994-2007.	14.5	4
1595	The Clinical Significance of Circulating Lymphocytes Morphology in Diffuse Large B-Cell Lymphoma As Determined by a Novel, Highly Sensitive Microscopy. Cancers, 2023, 15, 5611.	3.7	0
1596	Immune-Inflammatory Disorders in the ICU. Lessons From the ICU, 2023, , 557-572.	0.1	0
1597	Real-world associations of cytokine release syndrome and neurotoxicity with efficacy in patients receiving anti-CD-19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: the Mayo Clinic experience. Leukemia and Lymphoma, 2024, 65, 389-393.	1.3	0
1598	Infections in children following chimeric antigen receptor Tâ€cell therapy for Bâ€cell acute lymphoblastic leukemia. Transplant Infectious Disease, 2023, 25, .	1.7	0
1599	Nursing care of patients with relapsed and refractory multiple myeloma treated with B-cell mature antigen-targeted universal chimeric antigen receptor T cells. Medicine (United States), 2023, 102, e36067.	1.0	0
1600	Safety and efficacy of eltrombopag in patients with postâ€scp>CAR T</scp> cytopenias. European Journal of Haematology, 0, , .	2.2	0
1601	CAR-T treatment for cancer: prospects and challenges. Frontiers in Oncology, 0, 13, .	2.8	1
1602	Chimeric antigen receptor and bispecific Tâ€cell engager therapies in multiple myeloma patients with prior allogeneic transplantation. British Journal of Haematology, 0, , .	2.5	0
1604	Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL. Hematology American Society of Hematology Education Program, 2023, 2023, 77-83.	2.5	1
1605	Current use of CAR T cells to treat multiple myeloma. Hematology American Society of Hematology Education Program, 2023, 2023, 340-347.	2.5	2
1606	Managing side effects: guidance for use of immunotherapies in multiple myeloma. Hematology American Society of Hematology Education Program, 2023, 2023, 348-356.	2.5	1
1607	Multiple myeloma: a paradigm for blending community and academic care. Hematology American Society of Hematology Education Program, 2023, 2023, 318-323.	2.5	1
1608	Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study. Molecular Cancer, 2023, 22, .	19.2	0



#	ARTICLE	IF	CITATIONS
1609	Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial. <i>Nature Medicine</i> , 2024, 30, 229-239.	30.7	5
1610	Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2023, , .	0.4	0
1611	Effective sequencing of chimeric antigen receptor T-cell therapy in the treatment of LBCL in 2023. <i>Seminars in Hematology</i> , 2023, , .	3.4	1
1612	Neurologic Complications of Cancer Immunotherapy. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2023, 29, 1827-1843.	0.8	0
1613	Cytokine Modification of Adoptive Chimeric Antigen Receptor Immunotherapy for Glioblastoma. <i>Cancers</i> , 2023, 15, 5852.	3.7	1
1614	CAR NK Cell Therapy for the Treatment of Metastatic Melanoma: Potential & Prospects. <i>Cells</i> , 2023, 12, 2750.	4.1	0
1615	The multifaceted roles of GSDME-mediated pyroptosis in cancer: therapeutic strategies and persisting obstacles. <i>Cell Death and Disease</i> , 2023, 14, .	6.3	1
1616	Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns. <i>EClinicalMedicine</i> , 2023, 65, 102268.	7.1	1
1617	CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study. <i>Blood</i> , 2024, 143, 673-684.	1.4	4
1619	CAR-T Cell Therapy Shows Similar Efficacy and Toxicity in Patients With DLBCL Regardless of CNS Involvement. <i>HemaSphere</i> , 2023, 7, e984.	2.7	0
1620	Patterns of neurotoxicity among patients receiving chimeric antigen receptor Tâ€cell therapy: A singleâ€centre cohort study. <i>European Journal of Neurology</i> , 2024, 31, .	3.3	0
1622	Radiation therapy as bridging and salvage strategy among patients with secondary central nervous system lymphoma undergoing CD19â€targeted chimeric antigen receptor Tâ€cell therapy. <i>Hematological Oncology</i> , 0, , .	1.7	0
1623	A bibliometric and knowledge-map study of CAR-T cell-related cytokine release syndrome (CRS) from 2012 to 2023. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	3.3	0
1624	KyoTox-e score; prediction of post-CAR-T prolonged thrombocytopenia using peripheral blood data before apheresis. <i>Bone Marrow Transplantation</i> , 2024, 59, 419-421.	2.4	1
1625	Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines. <i>Blood Advances</i> , 2024, 8, 653-666.	5.2	0
1626	Intracranial pressure management in fulminant cerebral oedema after <scp>CAR Tâ€cell</scp> therapy: Not all is lost!. <i>British Journal of Haematology</i> , 0, , .	2.5	0
1627	Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy. <i>Transplantation and Cellular Therapy</i> , 2023, , .	1.2	0
1628	Chimeric Antigen Receptor T-Cell Therapy in Acute Myeloid Leukemia: State of the Art and Recent Advances. <i>Cancers</i> , 2024, 16, 42.	3.7	0

#	ARTICLE	IF	CITATIONS
1629	Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 0, , .	6.4	0
1630	Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience. <i>Blood Cancer Journal</i> , 2023, 13, .	6.2	0
1631	Chemical genetic control of cytokine signaling in CAR-T cells using lenalidomide-controlled membrane-bound degradable IL-7. <i>Leukemia</i> , 2024, 38, 590-600.	7.2	1
1632	Autologous engineered T cell receptor therapy in advanced cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	3.3	0
1633	GD2-CAR T cells in patients with osteosarcoma and neuroblastoma – it's not only the T cells that matter. <i>Cancer Cell</i> , 2024, 42, 8-10.	16.8	0
1634	Impact of Frailty on Outcomes after Chimeric Antigen Receptor T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2023, , .	1.2	2
1635	Efficacy of multiple SARS-CoV-2 vaccine doses in patients with B-cell hematologic malignancies receiving CAR-T therapy – A contemporary, cohort analysis. <i>Transplantation and Cellular Therapy</i> , 2023, , .	1.2	1
1636	Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience. <i>Transplantation and Cellular Therapy</i> , 2024, 30, 308.e1-308.e13.	1.2	0
1637	CAR-CAR Aptamers Enable Traceless Enrichment and Monitoring of CAR-Positive Cells and Overcome Tumor Immune Escape. <i>Advanced Science</i> , 2024, 11, .	11.2	0
1638	Nurses' roles in CAR-T therapy for B-cell malignancies and managing associated cytokine release syndrome. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2024, 11, 100367.	1.6	0
1639	Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domain. <i>Molecular Therapy</i> , 2024, 32, 503-526.	8.2	0
1640	An update on ICU outcomes in patients after CAR T therapy: A four-year tertiary UK centre experience. <i>Journal of Critical Care</i> , 2024, 80, 154511.	2.2	0
1641	Immuntherapie mit CAR-T-Zellen: der Durchbruch in der Krebsbehandlung. , 2023, , 147-159.		0
1642	Chimeric antigen receptor T-cell therapy-induced nervous system toxicity: a real-world study based on the FDA Adverse Event Reporting System database. <i>BMC Cancer</i> , 2024, 24, .	2.6	1
1643	Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma. <i>Leukemia</i> , 2024, 38, 372-382.	7.2	0
1644	Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma. <i>Cell Discovery</i> , 2024, 10, .	6.7	0
1645	Mechanical forces amplify TCR mechanotransduction in T cell activation and function. <i>Applied Physics Reviews</i> , 2024, 11, .	11.3	0
1646	Targeted immunotherapy: harnessing the immune system to battle multiple myeloma. <i>Cell Death Discovery</i> , 2024, 10, .	4.7	0

#	ARTICLE	IF	CITATIONS
1647	Teclistamab salvage therapy for multiple myeloma relapse after allogeneic hemopoietic stem cell transplant: A case report. American Journal of Hematology, 2024, 99, .	4.1	0
1648	Evaluation of central nervous system involvement in patients undergoing chimeric antigen receptor-engineered T-cell therapy by magnetic resonance imaging. Radiologia, 2023, , .	0.5	0
1650	Prophylactic use of interleukin 6 monoclonal antibody can reduce CRS response of CAR-T cell therapy. Frontiers in Medicine, 0, 10, .	2.6	0
1651	Emerging Strategies for the Prevention of Immune Toxicities Associated with T cellâ€“Engaging Cancer Therapies. Blood Cancer Discovery, 2024, 5, 90-94.	5.0	0
1652	The Mechanisms of Altered Bloodâ€“Brain Barrier Permeability in CD19 CAR Tâ€“Cell Recipients. International Journal of Molecular Sciences, 2024, 25, 644.	4.1	0
1654	Bloodâ€“brain barrier breakdown, central nervous system cell damage, and infiltrated T cells as major adverse effects in CAR-T-related deaths: a literature review. Frontiers in Medicine, 0, 10, .	2.6	0
1655	Overcoming toxicity challenges in CAR-T therapy: mechanisms and mitigation strategies. , 2024, , .		0
1657	Improving the safety of CARâ€“Tâ€“cell therapy: The risk and prevention of viral infection for patients with relapsed or refractory Bâ€“cell lymphoma undergoing CARâ€“Tâ€“cell therapy. American Journal of Hematology, 2024, 99, 662-678.	4.1	1
1658	Bispecific antibodies in indolent B-cell lymphomas. Frontiers in Immunology, 0, 14, .	4.8	0
1659	Current Challenges in Chimeric Antigen Receptor T-cell Therapy in Patients With B-cell Lymphoid Malignancies. Annals of Laboratory Medicine, 2024, 44, 210-221.	2.5	1
1660	Entanglement Generation in Capacitively Coupled Transmonâ€“Cavity System. Annalen Der Physik, 0, , .	2.4	0
1661	Treatment strategies for relapse after CAR T-cell therapy in B cell lymphoma. Frontiers in Pediatrics, 0, 11, .	1.9	0
1662	Modified EASIX scores predict severe CRS/ICANS in patients with acute myeloid leukemia following CLL1 CAR-T cell therapy. Annals of Hematology, 2024, 103, 969-980.	1.8	0
1665	Frontal Lobe Status Epilepticus Related to CAR T-Cell Therapy Responsive to Anakinra. Canadian Journal of Neurological Sciences, 0, , 1-3.	0.5	1
1666	The Advent of Bispecific Antibodies for Large B-cell Lymphomas. , 2024, 21, .		0
1667	A new way of identifying viral pathogens reactivating in cellular therapy products. Immunology and Cell Biology, 2024, 102, 153-155.	2.3	0
1668	Quality of Life and Prognostic Awareness in Caregivers of Patients Receiving Chimeric Antigen Receptor T Cell Therapy. Transplantation and Cellular Therapy, 2024, 30, 452.e1-452.e11.	1.2	0
1669	Brief research report: in-depth immunophenotyping reveals stability of CD19 CAR T-cells over time. Frontiers in Immunology, 0, 15, .	4.8	0

#	ARTICLE	IF	CITATIONS
1670	Harnessing Biomaterials for Safeguarding Chimeric Antigen Receptor T Cell Therapy: An Artful Expedition in Mitigating Adverse Effects. Pharmaceuticals, 2024, 17, 139.	3.8	0
1671	Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement. Leukemia and Lymphoma, 2024, 65, 669-673.	1.3	0
1672	Efficacy and safety of idecabtagene vicleucel in patients with relapsedâ€“refractory multiple myeloma not meeting the <scp>KarMMa</scp>â€™s trial eligibility criteria: A realâ€“world multicentre study. British Journal of Haematology, 2024, 204, 1293-1299.	2.5	0
1673	T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nature Medicine, 2024, 30, 984-989.	30.7	4
1674	Immune cells in the B-cell lymphoma microenvironment: From basic research to clinical applications. Chinese Medical Journal, 2024, 137, 776-790.	2.3	0
1675	Out of specification Tisagenlecleucel is associated with outcomes comparable to standard of care product in relapsed or refractory diffuse large B-cell lymphoma. Bone Marrow Transplantation, 2024, 59, 569-571.	2.4	0
1676	Axicabtagene Ciloleucel versus Tisagenlecleucel for Relapsed or Refractory Large B Cell Lymphoma: A Systematic Review and Meta-Analysis. Transplantation and Cellular Therapy, 2024, , .	1.2	0
1677	Clinical Impact of Cytokine Release Syndrome on Prolonged Hematotoxicity after Chimeric Antigen Receptor T Cell Therapy: KyoTox A-Score, a Novel Prediction Model. Transplantation and Cellular Therapy, 2024, 30, 404-414.	1.2	0
1678	Reduced Cytokine Release Syndrome and Improved Outcomes with Earlier Immunosuppressive Therapy in Haploidentical Stem Cell Transplantation. Transplantation and Cellular Therapy, 2024, 30, 438.e1-438.e11.	1.2	0
1679	High pretreatment disease burden as a risk factor for infectious complications following CD19 chimeric antigen receptor Tâ€™cell therapy for large Bâ€™cell lymphoma. HemaSphere, 2024, 8, .	2.7	0
1680	Features and outcomes of patients admitted to the ICU for chimeric antigen receptor T cell-related toxicity: a French multicentre cohort. Annals of Intensive Care, 2024, 14, .	4.6	1
1681	Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell lymphoma. Blood Advances, 2024, 8, 1474-1486.	5.2	0
1682	Optimizing the CAR T-Cell Therapy Experience in Multiple Myeloma: Clinical Pearls From an Expert Roundtable. Clinical Lymphoma, Myeloma and Leukemia, 2024, 24, e217-e225.	0.4	0
1683	Clofitamab as a salvage treatment for Bâ€™cell lymphomas in the real world: A multicenter study in Taiwan. Cancer, 0, , .	4.1	0
1684	Metastatic gastric cancer target lesion complete response with Claudin18.2-CAR T cells. , 2024, 12, e007927.		0
1685	Effectiveness of CAR-T cell therapy in patients with refractory and relapsed CD19-positive B-cell lymphomas. Onkologiya Zhurnal Imeni P A Gertsena, 2024, 13, 11.	0.2	0
1686	Efficacy and Safety of Children With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia After Anti-CD19 CAR T-Cell Therapy Without Bridging Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2024, , .	0.4	0
1688	The critical role of endothelial cell in the toxicity associated with chimeric antigen receptor T cell therapy and intervention strategies. Annals of Hematology, 0, , .	1.8	0

#	ARTICLE	IF	CITATIONS
1689	A novel therapeutic approach to modulate the inflammatory cascade: A timely exogenous local inflammatory response attenuates the sepsis-induced cytokine storm. <i>Cytokine</i> , 2024, 176, 156533.	3.2	0
1690	Protocol of a first-in-human clinical trial to evaluate the safety, tolerability, and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer (CoRe_CC-3). <i>Frontiers in Oncology</i> , 0, 14, .	2.8	0
1691	Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2024, 59, 647-652.	2.4	0
1692	Tumor- und therapieassoziierte Notfälle. , 2024, , 305-329.		0
1693	Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2024, 42, 1665-1675.	1.6	0
1694	Clinical presentation of cardiac symptoms following treatment with tumor-infiltrating lymphocytes: diagnostic challenges and lessons learned. <i>ESMO Open</i> , 2024, 9, 102383.	4.5	0
1697	The preclinical discovery and clinical development of ciltacabtagene autoleucel (Cilta-cel) for the treatment of multiple myeloma. <i>Expert Opinion on Drug Discovery</i> , 2024, 19, 377-391.	5.0	0
1698	Harnessing the Transcriptional Signatures of CAR-T-Cells and Leukemia/Lymphoma Using Single-Cell Sequencing Technologies. <i>International Journal of Molecular Sciences</i> , 2024, 25, 2416.	4.1	0
1699	New-onset seizure and acute encephalopathy. <i>Practical Neurology</i> , 0, , pn-2023-003994.	1.1	0
1700	CD19 CAR T-Cell Therapy in Autoimmune Disease – A Case Series with Follow-up. <i>New England Journal of Medicine</i> , 2024, 390, 687-700.	27.0	0
1701	Clinical Outcomes and Toxicity in Older Adults Receiving Chimeric Antigen Receptor T Cell Therapy. <i>Transplantation and Cellular Therapy</i> , 2024, 30, 490-499.	1.2	0
1702	B cell lineage reconstitution underlies CAR-T cell therapeutic efficacy in patients with refractory myasthenia gravis. <i>EMBO Molecular Medicine</i> , 2024, 16, 966-987.	6.9	0
1703	Unlocking Predictive Power: Quantitative Assessment of CAR-T Expansion with Digital Droplet Polymerase Chain Reaction (ddPCR). <i>International Journal of Molecular Sciences</i> , 2024, 25, 2673.	4.1	0
1704	Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Therapy and Coagulopathies. , 2024, , .		0
1705	Evaluation of all-cause mortality and cardiovascular safety in patients receiving chimeric antigen receptor T cell therapy: a prospective cohort study. <i>EClinicalMedicine</i> , 2024, 69, 102504.	7.1	0
1706	Multi-centers experience using therapeutic plasma exchange for corticosteroid/tocilizumab-refractory cytokine release syndrome following CAR-T therapy. <i>International Immunopharmacology</i> , 2024, 130, 111761.	3.8	0
1707	A phase I trial of SON-1010, a tumor-targeted, interleukin-12-linked, albumin-binding cytokine, shows favorable pharmacokinetics, pharmacodynamics, and safety in healthy volunteers. <i>Frontiers in Immunology</i> , 0, 15, .	4.8	0
1708	CAR T-Cell Therapy. , 2023, , 35-44.		0

#	ARTICLE	IF	CITATIONS
1709	CD19-CAR-DNT cells (RJMty19) in patients with relapsed or refractory large B-cell lymphoma: a phase 1, first-in-human study. <i>EClinicalMedicine</i> , 2024, 70, 102516.	7.1	0
1710	Case report: Acute HHV6B encephalitis/myelitis post CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma. <i>Frontiers in Neurology</i> , 0, 15, .	2.4	0
1711	Cellular therapies in older adults with hematological malignancies: A case-based, state-of-the-art review. <i>Journal of Geriatric Oncology</i> , 2024, 15, 101734.	1.0	0
1712	Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study. <i>Clinical Microbiology and Infection</i> , 2024, , .	6.0	0
1713	Immune therapies of B-cell acute lymphoblastic leukaemia in children and adults. <i>Critical Reviews in Oncology/Hematology</i> , 2024, 196, 104317.	4.4	0
1714	Development of a Safety Surveillance Plan for the Academic Medicine Sponsor Performing First-in-Human Cellular Therapy Clinical Trials: A Report from the Consortium for Pediatric Cellular Immunotherapy. <i>Transplantation and Cellular Therapy</i> , 2024, 30, 475-487.	1.2	0
1715	Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma. <i>OncolImmunology</i> , 2024, 13, .	4.6	0
1716	Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study. <i>Blood Cancer Journal</i> , 2024, 14, .	6.2	0
1717	Toxicities, intensive care management, and outcome of chimeric antigen receptor T cells in adults: an update. <i>Critical Care</i> , 2024, 28, .	5.8	0
1718	What are CAR T-cells?. <i>Archives of Disease in Childhood: Education and Practice Edition</i> , 0, , edpract-2023-326081.	0.5	0
1719	Early Chimeric Antigen Receptor T Cell Expansion Is Associated with Prolonged Progression-Free Survival for Patients with Relapsed/Refractory Multiple Myeloma Treated with Ide-Cel: A Retrospective Monocentric Study. <i>Transplantation and Cellular Therapy</i> , 2024, , .	1.2	0
1720	Reducing and controlling metabolic active tumor volume prior to CAR T-cell infusion can improve survival outcomes in patients with large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2024, 14, .	6.2	0
1721	Phase I pharmacokinetic, safety, and preliminary efficacy study of tiragolumab in combination with atezolizumab in Chinese patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 0, , .	2.3	0
1723	Efficacy and side effects of <sc>antiâ€CD19 CAR</sc> Tâ€cell therapy in patients with relapsed/refractory gastrointestinal lymphoma. <i>Cancer Medicine</i> , 2024, 13, .	2.8	0
1724	The value of bispecific antibodies in relapsed and refractory DLBCL. <i>Leukemia and Lymphoma</i> , 0, , 1-16.	1.3	0
1725	Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study. <i>Leukemia</i> , 2024, 38, 1107-1114.	7.2	0
1726	Chimeric Antigen Receptor-T (CAR-T) Cells as â€œLiving Drugsâ€ A Clinical Pharmacist Perspective. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2024, 2024, 1-18.	1.5	0
1727	CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results. <i>Leukemia</i> , 2024, 38, 963-968.	7.2	0



#	ARTICLE	IF	CITATIONS
1728	Reduced-dose chemotherapy followed by blinatumomab in induction therapy for newly diagnosed B-cell acute lymphoblastic leukemia. <i>Cancer Medicine</i> , 2024, 13, .	2.8	0
1729	Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2024, , .	1.2	0
1730	Chimeric antigen receptor <sup>+</sup> T cell therapy shows similar efficacy and toxicity in patients with diffuse large B-cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study. <i>HemaSphere</i> , 2024, 8, .	2.7	0
1731	Impact of Treatment Modality and Route of Administration on Cytokine Release Syndrome in Relapsed or Refractory Multiple Myeloma: A Meta-Analysis. <i>Clinical Pharmacology and Therapeutics</i> , 0, , .	4.7	0
1732	Early CAR <sup>+</sup> CD4 <sup>+</sup> T lymphocytes recovery following CAR <sup>+</sup> cell infusion: A worse outcome in diffuse large B cell lymphoma. <i>BJHaem</i> , 2024, 5, 360-368.	1.0	0
1733	Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy. <i>Neurological Sciences</i> , 0, , .	1.9	0
1734	Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure. <i>Frontiers in Oncology</i> , 0, 14, .	2.8	0
1735	Early induction of cytokine release syndrome by rapidly generated CAR T cells in preclinical models. <i>EMBO Molecular Medicine</i> , 2024, 16, 784-804.	6.9	0
1736	Chimeric antigen receptors: CARs in the fast lane for rheumatology. <i>Current Opinion in Rheumatology</i> , 2024, 36, 176-183.	4.3	0
1737	Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2024, , .	0.4	0
1738	Critical care utilisation for patients receiving chimeric antigen receptor (CAR) T cell therapy in the UK. <i>British Journal of Anaesthesia</i> , 2024, 132, 1004-1006.	3.4	0
1739	Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3 $\alpha$ -anti-GD2 bispecific antibody armed T cells. , 2024, 12, e008744.		0
1740	The Implementation of Chimeric Antigen Receptor (CAR) T-cell Therapy in Pediatric Patients: Where Did We Come From, Where Are We Now, and Where are We Going?. <i>Clinical Hematology International</i> , 2024, 6, .	1.7	0
1741	Acute kidney injury following treatment with CD19-specific CAR T-cell therapy in children, adolescent, and young adult patients with B-cell acute lymphoblastic leukemia. <i>Pediatric Nephrology</i> , 0, , .	1.7	0